Derivatives of 4-(Imidazol[1,2-A]pyridinin-3-yl)-pyrimidine, its salt and its preparation process, and medicine.

Description

Derivatives of 4-(Imidazol[1,2-A]pyridinin-3-yl)-pyrimidine, its salt and its preparation process, and medicine. Separated from BR112022001158-0, filed on July 22, 2020. BACKGROUND OF THE INVENTION

[0001] The present invention aimed to develop new compounds with valuable properties, in particular those that can be used for the preparation of medicines.

[0002] The present invention relates to 4-(imidazo[1,2-a]pyridin-3yl)pyrimidine derivatives that inhibit c-KIT kinase in a wide range of c-KIT mutations and secondary mutations (secondary resistance mutation V654A in Exon 13) that may arise in patients with GIST (gastrointestinal stromal tumor). The compounds of this invention are therefore useful in the treatment of diseases such as cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, the compounds for use in the treatment of diseases, and methods of treating diseases using pharmaceutical compositions comprising these compounds. Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract (Gl).

[0003] c-KIT is a type III receptor tyrosine kinase and plays an important role in the occurrence of cancer. Mutated forms of the c-KIT receptor tyrosine kinase are drivers of several cancer types, such as GIST, SM (Systemic Mastocytosis), certain types of AML, and melanoma, and are therefore attractive targets for therapy. Gain-of-function mutations of KIT play an important role in the pathogenesis of gastrointestinal tumors (GISTs).

[0004] GISTs are defined as c-KIT (CD117, stem cell factor receptor) positive mesenchymal spindle cells or epithelioid neoplasms. GISTs commonly have primary activating mutations of the KIT gene (90%), leading to ligand-independent activation of c-KIT receptor tyrosine kinase, making the tumor dependent on the oncogenic activity of KIT.

[0005] Although benefits have been obtained with the use of KIT kinase activity inhibitors, such as imatinib, especially in GIST, resistance Petition 870260069920, dated 07 / 14 / 2026, page 8 / 519 Primary resistance occurs with certain oncogenic mutations. Furthermore, resistance frequently develops due to secondary mutations (LKAshman & R.Griffith (2013) Expert Opinion on Investigational Drugs, 22:1, 103-115). It has been reported that imatinib treatment of primary mutated GISTs has an initial response rate of ~70%, but acquired resistance develops in 40-50% of cases with an average of two years. The secondary mutation V654A in exon 13 is the most frequent resistance mutation after imatinib.

[0006] LL Chen et al. describe A missense mutation in domain 1 of KIT kinase correlates with imatinib resistance in gastrointestinal extremal tumors in Cancer res. 2004; 64: 5913-5919.KG Roberts et al. describe Resistance to c-KIT kinase inhibitors conferred by the V654A mutation in Mol. Cancer Ther. 2007; 6: 1159-1166.

[0007] There is a large unmet medical need for the development of a specific and safe inhibitor against the KIT V654A resistance mutation.

[0008] It has been found that the compounds according to the invention and their salts have very valuable pharmacological properties, while at the same time being well tolerated.

[0009] The present invention relates specifically to compounds of Formula I that inhibit c-KIT kinase, preferably the V654A mutant of c-KIT kinase.

[0010] Furthermore, compounds of Formula I inhibit PDGFRa (V651 D). Gain-of-function mutations of PDGFRa appear to play an important role in the development of GISTs without KIT mutations (S.Hirota et al., Gastroenterology 2003; 125: 660-667).

[0011] The host or patient may belong to any mammalian species, for example, a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for the treatment of human diseases.

[0012] The susceptibility of a given cell to treatment with the compounds according to the invention can be determined by in vitro tests. Typically, a cell culture is combined with a compound according to the invention at various concentrations for a period of time sufficient to allow Petition 870260069920, dated 07 / 14 / 2026, page 9 / 519 3 / 219 that active agents, such as anti-IgM, induce a cellular response, such as the expression of a surface marker, generally between about one hour and one week. In vitro tests can be performed with cultured blood cells or a biopsy sample. The amount of surface marker expressed is assessed by flow cytometry using specific antibodies that recognize the marker.

[0013] The dose varies depending on the specific compound used, the specific disease, the patient's condition, etc. A therapeutic dose is typically sufficient to reduce the unwanted cell population in the target tissue while maintaining patient viability. Treatment is generally continued until a considerable reduction has occurred, for example, a reduction of at least about 50% in the cell load, and may be continued until essentially no more unwanted cells are detected in the body. PREVIOUS TECHNIQUE

[0014] Document WO 2010 / 009155 describes other fused heterocyclic compounds as histone deacylase and / or cyclin-dependent kinase inhibitors.

[0015] Document WO 2011 / 076419 describes imidazopyridines as JAK kinase inhibitors. SUMMARY OF THE INVENTION

[0016] The invention relates to compounds of Formula I in what R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3', O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh or O[C(R3)2]nCyc, R2 denotes H or CH3, R3denota H or A, Petition 870260069920, dated 07 / 14 / 2026, p. 10 / 519 4 / 219 V denotes H or Hal, X denotes O or N(R3), Y denotes phenylene, pyridinyl, thiophendiyl, 1,3-thiazoldiyl or pyrazoldiyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and / or A. Z denotes CON(R3)2, phenyl, Het4ou-OA, Het1 denotes a saturated or unsaturated, aromatic, monocyclic heterocycle of 4, 5, 6, or 7 members having 1, 2, 3, or 4 N, O, and / or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =O, and where one N atom may be oxidized, or denotes a saturated or unsaturated, bicyclic or spirocyclic aromatic heterocycle of 6, 7, 8, 9, or 10 members having 1, 2, 3, or 4 N, O, and / or S atoms, which may be unsubstituted or mono-, di-, or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2,[C(R3)2]nSO2R3, Het2, oxetanyl, =NR3e / or =0, and where one N atom can be oxidized, Het2 denotes a 5- to 6-membered monocyclic aromatic or unsaturated heterocycle having 1, 2, 3, or 4 N, O, and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal; or denotes a 7-, 8-, 9-, or 10-membered aromatic bicyclic unsaturated heterocycle having 1, 2, 3, or 4 N, O, and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal. Het3 denotes a saturated monocyclic heterocycle of 4, 5, 6 or 7 members having 1, 2, 3 or 4 N and / or O atoms, which may be unsubstituted or mono- or disubstituted by A, Hal, OR3 and / or O = O. Het4 denotes a saturated or unsaturated, aromatic, monocyclic heterocycle of 4, 5, 6 or 7 members having 1, 2, 3 or 4 N and / or O atoms, which may be unsubstituted or mono, di or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3, Petition 870260069920, dated 14 / 07 / 2026, p. 11 / 519 5 / 219 N(R3)2e / ou =0, or denotes an unsaturated or saturated, bicyclic aromatic heterocycle of 6, 7, 8, 9 or 10 members showing 1, 2, 3 or 4 N and / or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3e / ou =0, A denotes branched or unbranched alkyl with 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, where 1, 2 or 3 non-adjacent CH- and / or CH2- atoms may be substituted by O or NH atoms and where 1, 2, 3, 4, 5, 6 or 7 H atoms may be substituted by R5, our denotes (ChhjnCyc, Cyc denotes cyclic alkyl showing 3, 4, 5, 6, or 7 C atoms. R5denota F, Cl, CN or OH, Ph denotes phenyl, which may be unsubstituted or mono-, di-, or trisubstituted by A, OR3e, and / or Hal. Hal denotes F, Cl, Br, or I; m denotes 0, 1, or 2; n denotes 0, 1, 2, 3, or 4; and / or pharmaceutically acceptable salt, tautomer, and / or stereoisomer thereof.

[0017] In one embodiment, the present invention relates to compounds of Formula I in what R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nPh or O[C(R3)2]nCyc, R2 denotes H or CH3, Petition 870260069920, dated 07 / 14 / 2026, p. 12 / 519 6 / 219 R3denota H or A, V denotes H or Hal, X denotes O or N(R3), Y denotes phenylene, pyridin-di-yl, thiophen-di-yl, 1,3-thiazol-di-yl or pyrazoldi-yl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and / or A. Z denotes CON(R3)2, phenyl or Het4, Het1 denotes a saturated or unsaturated, monocyclic aromatic heterocycle of 4 to 7 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =O, and in which one N atom may be oxidized, or denotes a saturated or unsaturated, bicyclic or spirocyclic aromatic heterocycle of 7 to 10 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2,[C(R3)2]nSO2R3, Het2, oxetanyl, =NR3e / or =0, and where one N atom can be oxidized, Het2 denotes an aromatic or unsaturated monocyclic heterocycle of 5 to 6 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal, or denotes an unsaturated or bicyclic aromatic heterocycle of 7 to 10 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal. Het3 denotes a saturated, monocyclic heterocycle of 4 to 7 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono- or disubstituted by A, Hal, OR3 and / or O=0. Het4 denotes a saturated or unsaturated, monocyclic aromatic heterocycle of 4 to 7 members having 1 to 4 and / or 0 atoms of O, which may be non-ionic. Petition 870260069920, dated 07 / 14 / 2026, p. 13 / 519 7 / 219 substituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]Het3e / ou =0, or denotes a saturated or unsaturated, bicyclic aromatic heterocycle of 6 to 10 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]Het3e / ou =0, A denotes branched or unbranched alkyl with 1 to 10 C atoms, where 1 to 3 non-adjacent CH- and / or CH2- groups may be substituted by O or NH atoms and where 1 to 7 H atoms may be substituted by R5, or denotes (ChhjnCyc, Cyc denotes cyclic alkyl showing 3 to 7 C atoms, R5denota F, Cl, CN or OH, Ph denotes phenyl, which may be unsubstituted or mono-, di-, or trisubstituted by A, OR3e, and / or Hal. Hal denotes F, Cl, Br, or I, m denotes 0, 1, or 2, n denotes 0, 1, 2, 3, or 4, and pharmaceutically acceptable salts, tautomers, and stereoisomers thereof, including mixtures thereof in all ratios.

[0018] The invention also encompasses optically active forms (stereoisomers), enantiomers, racemates (racemic mixtures), diastereomers, tautomers and solvates of these compounds, as well as processes for preparing them. Any reference to a compound or salt thereof should be understood as encompassing solvates thereof.

[0019] The term solvates of compounds is considered to mean additions of inert solvent molecules to the compounds that are formed due to their mutual attractive force. Solvates are, for example, hydrates, including mono- or dihydrates or alkoxides.

[0020] It is understood that the invention should also cover the solvates of salts.

[0021] The invention also relates to mixtures of compounds of Formula I, for example, mixtures of two diastereomers, for example, in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. Petition 870260069920, dated 07 / 14 / 2026, p. 14 / 519 8 / 219

[0022] These are particularly preferable mixtures of stereoisomeric compounds.

[0023] Tautomers refer to isomeric forms of a compound that are in equilibrium with each other. The concentrations of the isomeric forms will depend on the environment in which the compound is found and may be different depending, for example, on whether the compound is solid or in organic or aqueous solution.

[0024] The invention relates to compounds of Formula I and pharmaceutically acceptable salts, tautomers and stereoisomers thereof and to a process for the preparation of compounds of Formula I and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, characterized by a) for the preparation of compounds of Formula I, where X denotes N(R3), a compound of Formula II where R1 and V have the meanings indicated above and below, respectively, in any of claims 1 to 8, reacted with a compound of Formula III H2N-(CHR2)-YZ III where R2, Y and Z have the meanings indicated above and below, respectively, in any of claims 1 to 8, or b) for the preparation of compounds of Formula I, a compound of Formula IV IV where R1 and V have the meanings indicated above and below, respectively in Petition 870260069920, dated 07 / 14 / 2026, p. 15 / 519 9 / 219 Any of claims 1 to 8 is reacted with a compound of Formula V where R2, V, X, Y and Z have the meanings indicated above and below, respectively in any of claims 1 to 8, or c) for the preparation of compounds of Formula I, by converting a compound of Formula I, wherein R1 denotes F, into another compound of Formula I, wherein R1 denotes O[C(R3)2]nN(R3)2, O[C(R3)2]nN(R3) Het1 or O[C(R3)2]nHet1, wherein R3 and Het1 have the meanings indicated above and below, respectively, in any of claims 1 to 8, or d) for the preparation of compounds of Formula I, where Z denotes Het4, a compound of Formula VI where R1, R2, V, X and Y have the meanings indicated above and below, respectively in any of claims 1 to 8, is reacted with a compound of Formula VII HZ VII where Z denotes Het4, and / or the base or acid of Formula I, that is, a compound of Formula I (which can react as a base or an acid) is converted into one of its salts.

[0025] For all radicals that occur more than once, such as, for example, R3, their meanings are independent of each other. Above and below, the radicals R1, R2, V, X, Y and Z have the meanings indicated for Formula I, unless explicitly stated otherwise. The same applies to the variables nor, and to the radicals that can be designated by those already mentioned. Petition 870260069920, dated 07 / 14 / 2026, p. 16 / 519 10 / 219

[0026] Exemplary embodiments of the radicals and variables described herein in relation to the compounds of the invention are equally applicable in the above processes for preparing them.

[0027] A denotes alkyl, which is either unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 C atoms. As established above, 1 to 3 non-adjacent CHe / or CH2- groups can be replaced by O or NH atoms, and 1 to 7 H atoms can be replaced by R5, or A denotes (ChHjnCyc). A can, for example, denote methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, or tert-butyl, in addition also pentyl, 1-, 2-, or 3-methylbutyl, 1,1-, 1,2-, or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3-, or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3-, or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, more preferably trifluoromethyl.

[0028] In a preferred embodiment, A denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, which may be unsubstituted or substituted, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl. Cyc preferably denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In other preferred embodiments, A denotes CH2OCH3, CH2CH2OH, OCH2CH2OH, OCH2CH2OCH3, CH2CH2OCH3, OCH(CH2OCH3)2 or OCH2C(CH3)2OH.

[0029] In exemplary forms:

[0030] R1 preferably denotes H, F, OCH2CH2OCH3, OCH3, CF3, O[C(R3)2]nN(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, OCH(CH2OCH3)2, O[C(R3)2]nCyc, OCH2C(CH3)2OH, CH3i O[C(R3)2]nPh, NO2, Cl, OH, OCH2C (CH3)2NH2, NHCH2C(CH3)2OH, [C(R3)2]nHet1, OCH2CH2OH, OCH2CH2 CH2OH, O[C(R3)2]nS(O)mR3orOCH2CH2OCH2CH2OH.

[0031] R3 preferably denotes H or A, more preferably H or CH3.

[0032] V preferably denotes H or F, more preferably H.

[0033] X preferably denotes O or NH, more preferably NH.

[0034] Y preferably denotes 1,4-phenylene, 1,3-phenylene, pyridine-3,6-diyl, 4methyl-pyridine-3,6-diyl, 4-fluoro-pyridine-3,6-diyl, 3-fluoro-1,4-phenylene, thiophen-2,5-diyl or pyridine-2,5-diyl. Petition 870260069920, dated 07 / 14 / 2026, page 17 / 519 11 / 219

[0035] Bicyclic compounds also include spiro compounds.

[0036] Regardless of other substitutions, Het1 denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, moreover preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinIa, pyrazinyl, 1-, 2-, 3-, 4, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl,1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolinyl, 3-, 4-, 5-, 6-, 7- or 8-cinolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopiridinyl, purinyl, also preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-yl, azabicyclo[3,2,1]-octyl or dibenzofuranyl. Heterocyclic radicals can also be partially or fully hydrogenated. Regardless of other substitutions, Het1 can thus also denote, for example, 2,3-dihydro-2-,-3-,-4- or-5-furyl, 2,5-dihydro-2-,-3-,-4- or-5-furyl, tetrahydro-2- or-3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or-3-thienyl, 2,3-dihydro-1-,-2-,-3-,-4- or-5-pyrrolyl, 2,5-dihydro-1-,-2-,-3-,-4- or-5-pyrrolyl, 1-,-2- or-3-pyrrolidinyl, tetrahydro-1-,-2- or-4-imidazolyl, 2,3-dihydro-1-,-2-,-3-,-4- or-5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-,-3- or 4-pyridyl, 1,2,3,4-tetra-hydro-1-, -2-, -3-, -4-, -5-or -6-pyridyl, 1-, 2-, 3-or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetra-hydro-2-, -3- or -4-pyranyl, 1,4-dioxanil, 1,3-dioxan-2-, 4- or -5-yl, hexa-hydro-1-, -3- or -4-pyridazinyl, hexa-hydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetra-hydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8quinolyl, 1,2,3,4-tetra-hydro-1-,-2-,-3-, -4-, -5-, -6-, -7-or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7-or 8- 3,4-di-hydro-2H-benzo-1,4-oxazinyl, disso alum,e 2,3-methylenedioxyphenyl, 3,4methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-di-hydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-di-hydro-2H-1,5-benzodioxepin-6- or -7-yl, dissolved alum, 2,3-di-hydrobenzofu, Petition 870260069920, 7 / 14 / 2026, p. 18 / 5 12 / 219 ranila, 2,3-di-hydro-2-oxofuranila, 3,4-di-hydro-2-oxo-1 / - / -quinazolinila, 2,3-di-hydrobenzoxazolila, 2-oxo-2,3-di-hydrobenzoxazolila, 2,3-di-hydrobenzimidazolila, 1,3-di-hydroindole, 2-oxo-1,3-di-hydroindole ou 2-oxo-2,3-di-hydrobenzimidazolila.

[0037] Preferably, morpholin, tetra-hydro-piran-4-yl, tetra-hydrofuran-3-yl, pirrolidin, piperazin, piperidin, 6-oxa-3-azabiciclo[3,1,1]heptano-3-yl, pyridin, pyridazin, 2-oxa-6-azaespiro[3,3]heptano-6-yl, imidazoli, azetidin, 3-aza-biciclo[3,1,0]hexano-3-yl, 11ambda6-tiomorfolin, 114-tiomorfolin, 1,3-di-hidro-pirrolo[3,4-c]pirid in i la, 3,8-diaza-biciclo[3,2,1 ]octano-8-yl, 2l4-tia-5-aza-biciclo[2,2,1 ]heptano-5-ila, [1,4]oxazepanila, hexa-hidro-pirazino[2,1 -c][1,4]oxazin-8-ila, 5,6-di-hidro-8H-[1,2,4]triazolo[4,3-a]pirazin-7-ila, 5,6-di-hidro-8H-[1,2,4]triazolo[1,5a]pirazin-7-ila, 6-oxa-1-aza-espiro[3,3]heptano-1-ila, hexa-hidro-furo[3,2-b]piridina-4ila, hexa-hidro-pirano [3,4-b][1,4]oxazin-1-ila, pirazolila, 1,4-diaza-biciclo[3,2,1]octano-4-ila, 1,2,4-oxadiazolila, 6,7-di-hidro-4H-pirazolo[1,5-a]pirazin-5-ila, 6,7-di-hidro4H-[1,2,3]triazolo[ 1,5-a]pirazin-5-i la, 3,4-di-hidro-1 H-pirrolo[1,2-a]pirazin-2-ila, 1,4diazepanila,triazolyl or oxetanyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =0, and in which one N atom may be oxidized.

[0038] Regardless of other substitutions, Het2 may denote, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-,2,4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, moreover preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinIa, pyrazinyl, 1, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl,1, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl, purinyl, also preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-yl, azabicyclo[3,2,1 ]-octyl or dibenzofuranyl., Petition 870260069920, 7 / 14 / 2026, p. 19 / 5 13 / 2

[0039] Het2preferably denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, pyridazinyl, pyrazinyl, . 1,3-benzodiazolyl, 1,3-benzodioxolyl, indolyl, isoindolyl or indazolyl, each of which can be unsubstituted or mono or disubstituted by A and / or Hal.

[0040] Het3preferably denotes morpholinyl, pyrrolidinyl, piperidinyl, oxetanyl or azetidinyl,

[0041] each of which may be unsubstituted or mono or disubstituted by A, Hal, OR3 and / or =0.

[0042] Regardless of other substitutions, Het4 may denote, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-,2,4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, moreover preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinIa, pyrazinyl, 1, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl,1,3-,4-,5-,6-,7- or 8-isoquinoline, 3-,4-,5-,6-,7- or 8-cinnoline, 2-,4-,5-,6-,7- or 8-quinazolinyl, 5- or 6-quinoxalinyl, 2-,3-,5-,6-,7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopiridinyl, purinyl, also preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazole-4- or -5-yl, 2,1,3-benzoxadiazole-5-yl, azabicyclo[3,2,1]-octyl or dibenzofuranyl. Heterocyclic radicals can also be partially or fully hydrogenated. Regardless of other substitutions, Het4 can thus also denote, for example, 2,3-dihydro-2-,-3-,-4- or-5-furyl, 2,5-dihydro-2-,-3-,-4- or-5-furyl, tetrahydro-2- or-3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or-3-thienyl, 2,3-dihydro-1-,-2-,-3-,-4- or-5-pyrrolyl, 2,5-dihydro-1-,-2-,-3-,-4- or-5-pyrrolyl, 1-,-2- or 3-pyrrolidinyl, tetrahydro-1-,-2- or-4-imidazolyl, 2,3-dihydro-1-,-2-,-3-,-4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-,-3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4, Petition 870260069920, dated 07 / 14 / 2026, page 20 / 519 14 / 219 dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexa-hydro-1-, -3- or -4-pyridazinyl, hexa-hydro1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 14 / 219; 1,2,3,4-tetra-hydro-1-, -2-, -3-, -4, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetra-hydro-1-,-2-,-3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-di-hydro-2H-benzo-1,4-oxazinyl, disso alum, 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-di-hydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-di-hydro-2H-1,5-benzodioxepin-6- or -7-yl, dissolved alum, 2,3-di-hydrobenzofuranyl, 2,3-di-hydro-2-oxofuranyl, 3,4-di-hydro-2-oxo-1 / - / -quinazolinyl, 2,3-di-hydrobenzoxazolyl, 2-oxo-2,3-di-hydrobenzoxazolyl, 2,3-di-hydrobenzimidazolyl, 1,3-di-hydroindole, 2-oxo-1,3-di-hydroindole or 2-oxo-2,3-di-hydrobenzimidazolyl.

[0043] Het4 preferably denotes pyrrolidinyl, 3-aza-bicyclo[3,1,0]hexane-3-yl, pyrazolyl, pyridinyl, imidazolyl, 4,5-dihydro-1 H-imidazolyl, triazolyl, 4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl, oxadiazolyl, 1,3-benzodiazolyl, pyrimidinyl, tetrazolyl, 8-oxa3-aza-bicyclo[3,2,1]octane-3-yl, pyridazinyl, oxazolyl, isoxazolyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3, -N(R3)2 and / or =0.

[0044] As mentioned above, throughout the invention, all radicals that occur more than once can be identical or different, that is, they are independent of each other.

[0045] Compounds of Formula I may have one or more chiral centers and therefore may occur in various stereoisomeric forms. Formula I encompasses all such forms.

[0046] Thus, the invention relates, in particular, to compounds of Formula I in which at least one of said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds can be expressed by the following sub-Formulas Ia to Iw, which conform to Formula I and in which the radicals not designated in more detail have the meaning indicated for Formula I, but where in Ia R1 denotes H, F, OCH2CH2OCH3, OCH3, CF3, O[C(R3)2]nN(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, OCH(CH2OCH3)2, O[C(R3)2]nCyc, OCH2C(CH3)2OH, CH3iO[C(R3)2]nPh, NO2, Cl, OH, OCH2C(CH3)2NH2, Petition 870260069920, dated 07 / 14 / 2026, p. 21 / 519 15 / 219 NHCH2C(CH3)2OH, [C(R3)2]nHet1, OCH2CH2OH, OCH2CH2CH2OH, O[C(R3)2]nS(O)mR3or OCH2CH2OCH2CH2OH, in lb R3 denotes H or A; in IcR3 it denotes H or CH3; in Id Xdenota 0 or NH; em Ie Y denotes 1,4-phenylene, 1,3-phenylene, pyridine-3,6-di-yl, 4-methylpyridine-3,6-di-yl, 4-fluoro-pyridine-3,6-di-yl, 3-fluoro-1,4-phenylene, thiophene-2,5-di-pyridine-2, or 25-di-yl; em If Het1denota morpholinila, tetra-hidro-piran-4-ila, tetra-hidro-furan-3-ila, pyrrolidinila, piperazinila, piperidinila, 6-oxa-3-azabiciclo[3,1,1]heptano-3-ila, piridinila, piridazinila, 2-oxa-6-azaespiro[3,3]heptano-6-ila, imidazolila, azetidinila, 3-aza-bicyclo[3,1,0]hexano-3-ila, 11ambda6-thiomorpholinila, 114-thiomorpholinila, 1,3-di-hidro-pyrro lo[3,4-c] pi rid ini la, 3,8-diaza-biciclo[3,2,1 ]octano-8-ila, 2l4-tia-5-aza-biciclo[2,2,1 ] heptano-5-ila, [1,4]oxazepanila, hexa-hidro-pirazino[2,1-c][1,4]oxazin-8-ila, 5,6-di-hidro-8H-[1,2,4]triazolo[4,3-a]pirazin-7-ila, 5,6-di-hidro-8H-[1,2,4]triazolo[1,5-a]pirazin7-ila, 6-oxa-1-aza-espiro[3,3]heptano-1-ila, hexa-hidro-furo[3,2-b]piridina-4-ila, hexahidro-pirano[3,4-b][1,4]oxazin-1 -ila, pirazol i la, 1,4-diaza-biciclo[3,2,1 ]octano-4-ila, 1,2,4-oxadiazolila, 6,7-di-hidro-4H-pirazolo[1,5-a]pirazin-5-ila, 6,7-di-hidro-4H[1,2,3]triazolo[1,5-a]pirazin-5-ila, 3,4-di-hidro-1H-pirrolo[1,2-a]pirazin-2-ila, 1,4-diazepanila,triazolyl or oxetanyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN (R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =0, and in which one N atom may be oxidized; in Ig Het2denota furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, pyridazinyl, pyrazinyl, 1,3-benzodiazolyl, 1,3-benzodioxolyl, indolyl, isoindolyl or indazolyl, each of which may be unsubstituted or mono- or disubstituted by A and / or Hal; in Ih Het3denota morfolinyl, pyrrolidinyl, piperidinyl, oxetanyl or azetidinyl, each of which may be unsubstituted or mono- or disubstituted by A, Hal, OR3 and / or =0; Petition 870260069920, dated 07 / 14 / 2026, p. 22 / 519 16 / 219 in li Het4denota pyrrolidinyl, 3-aza-bicyclo[3,1,0]hexane-3-yl, pyrazolyl, pyridinyl, imidazolyl, 4,5-dihydro-1 H-imidazolyl, triazolyl, 4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl, oxadiazolyl, 1,3-benzodiazolyl, pyrimidinyl, tetrazolyl, 8-oxa-3-aza-bicyclo[3,2,1]octano-3-yl, pyridazinyl, oxazolyl, isoxazolyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3e / or =0; in Ij R1denotes H, Hal, CF3, N02, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3' °[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nPh or 0[C (R3)2]nCyc, R2 denotes H or CH3, R3denota H or A, V denotes H or Hal, X denotes 0 or N(R3), Y denotes phenylene, pyridin-di-yl, thiophen-di-yl, 1,3-thiazol-di-yl or pyrazoldi-yl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and / or A. Z denotes CON(R3)2, phenyl, Het4ou -OA, Het1denota morpholinila, tetra-hidro-piran-4-ila, tetra-hidro-furan-3-ila, pyrrolidinila, piperazinila, piperidinila, 6-oxa-3-azabiciclo[3,1,1]heptano-3-ila, piridinila, piridazinila, 2-oxa-6-azaespiro[3,3]heptano-6-ila, imidazolila, azetidinila, 3-aza-bicyclo[3,1,0]hexano-3-ila, 11ambda6-thiomorpholinila, 114-thiomorpholinila, 1,3-di-hidro-pyrrolo[3,4-c]pirid in i Ia, 3,8-diaza-biciclo[3,2,1 ]octano-8-ila, 2l4-tia-5-aza-biciclo[2,2,1 ]heptano-5-ila, [1,4]oxazepanila, hexa-hidro-pirazino[2,1 -c][1,4]oxazin-8-ila, 5,6-di-hidro-8H-[1,2,4]triazolo[4,3-a]pirazin-7-ila, 5,6-di-hidro-8H-[1,2,4]triazolo [1,5a]pirazin-7-ila, 6-oxa-1 -aza-espiro[3,3]heptano-1 -ila, hexa-hidro-furo[3,2-b]piridina-4ila, hexa-hidro-pirano[3,4-b][1,4]oxazin-1-ila, pirazolila, 1,4-diaza-biciclo[3,2,1]octano4-ila, 1,2,4-oxadiazolila, 6,7-di-hidro-4H-pirazolo[1,5-a]pirazin-5-ila, 6,7-di-hidro-4H[1,2,3]triazolo[ 1,5-a]pirazin-5-ila, 3,4-di-hidro-1 H-pirrolo[1,2-a]pirazin-2-ila, 1,4-diazepanila, triazolila ou oxetanila,each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =0, and in which one N atom may be oxidized, Petition 870260069920, dated 07 / 14 / 2026, p. 23 / 519 17 / 219 Het2denota furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, pyridazinyl, pyrazinyl, 1,3-benzodiazolyl, 1,3-benzodioxolyl, indolyl, isoindolyl or indazolyl, each of which may be unsubstituted or mono- or disubstituted by A and / or Hal, Het3denota morfolinyl, pyrrolidinyl, piperidinyl, oxetanyl or azetidinyl, each of which may be unsubstituted or mono- or disubstituted by A, Hal, OR3e / or =0, Het4denota pyrrolidinyl, 3-aza-bicyclo[3,1,0]hexane-3-yl, pyrazolyl, pyridinyl, imidazolyl, 4,5-dihydro-1H-imidazolyl, triazolyl, 4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl, oxadiazolyl, 1,3-benzodiazolyl, pyrimidinyl, tetrazolyl, 8-oxa-3-aza-bicyclo[3,2,1]octane-3-yl, pyridazinyl, oxazolyl, isoxazolyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3e / or =0, A denotes branched or unbranched alkyl with 1 to 10 C atoms, where 1 to 3 non-adjacent CH- and / or CH2- groups may be substituted by O or NH atoms and where 1 to 7 H atoms may be substituted by R5, or denotes (CH2)nCyc. Cyc denotes cyclic alkyl showing 3 to 7 C atoms, R5denota F, Cl, CN or OH, Ph denotes phenyl, which may be unsubstituted or mono-, di-, or trisubstituted by A, OR3e, and / or Hal. Hal denotes F, Cl, Br, or I. M denotes 0, 1, or 2, n denotes 0, 1, 2, 3, or 4; in IkR1 denotes H, F, OCH2CH2OCH3, OCH3, CF3, O[C (R3)2]nN(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1,OCH(CH2OCH3)2, O[C(R3)2]nCyc, OCH2C(CH3)2OH, CH3iO[C(R3)2]nPh, NO2, Cl, OH, OCH2C (CH3)2NH2, NHCH2C(CH3)2OH, [C(R3)2]nHet1, OCH2CH2OH, OCH2CH2CH2OH, O[C(R3)2]nS(O)mR3or OCH2CH2OCH2CH2OH, and Petition 870260069920, dated 07 / 14 / 2026, page 24 / 519 18 / 219 R2, R3, V, X, Y, Z, Het1, Het2, Het3, Het4, A, Cyc, R5, Ph, Hal, men presenting the meanings as in subformulas lj, in Im: R1 denotes O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, or [C(R3)2]nHet1, in In: R2 denotes H, in Io: R3 denotes H or A, in Ip: V denotes H, in Iq: X denotes NH, in Ir: Y denotes phenylene, which is unsubstituted or mono-, di-, or trisubstituted by Hal and / or A, in Is: Z denotes Het4 or -OA, in It: Het1 denotes tetrahydrofuran-3-yl, pyrrolidinyl, piperazinyl, piperidinyl, azetidinyl, imidazolyl, 6,7-dihydro-4H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl, 1,4-diazepanyl, triazolyl or oxetanyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, oxetanyl, and / or =O, and in which an N atom may be oxidized, in Iv: Het4 denotes pyrazolyl, triazolyl, or oxazolyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, and / or in Iv: R5 denotes F, Cl, or OH, in Iw: Hal denotes F or Cl, for each subformula also including salts,Pharmaceutically acceptable tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

[0047] Thus, in certain preferred modalities,

[0048] R1 denotes O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, or [C(R3)2]nHet1, and / or R2denota H, and / or R3denota H or A, and / or V denotes H, and / or X denotes NH, and / or Petition 870260069920, dated 07 / 14 / 2026, p. 25 / 519 19 / 219 Y denotes phenylene, which is unsubstituted or mono-, di-, or trisubstituted by Hal and / or A, and / or Z denotes Het4ou -OA, and / or Het1denota tetrahydrofuran-3-yl, pyrrolidinyl, piperazinyl, piperidinyl, azetidinyl, imidazolyl, 6,7-dihydro-4H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl, 1,4-diazepanyl, triazolyl or oxetanyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, oxetanyl, and / or =0, and where an N atom may be oxidized, and / or Het4denota pyrazolyl, triazolyl, or oxazolyl, each of which may be unsubstituted or mono-, di-, or trisubstituted by A, and / or A denotes branched or unbranched alkyl with 1 to 10 C atoms, where 1 to 3 non-adjacent CH- and / or CH2- groups may be substituted by O or NH atoms and where 1 to 7 H atoms may be substituted by R5, or denotes (CH2)nCyc, and / or Cyc denotes cyclic alkyl showing 3 to 7 C atoms, and / or R5denota F, Cl, or OH, and / or Hal denotes F or Cl, and / or n denotes 0, 1, 2, 3, or 4, with any other radicals and variables being defined as in Formula I or any of the subformulas above.

[0049] In certain preferred embodiments of compounds of Formula I according to the present invention, R1 denotes O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, [C(R3)2]n Het1, R2denota H, R3denota H or A, V denotes H, X denotes NH, Y denotes phenylene, which is unsubstituted or mono-, di-, or trisubstituted by Hal and / or A. Petition 870260069920, dated 07 / 14 / 2026, p. 26 / 519 20 / 219 Z denotes Het4ou -OA, Het1denota tetrahydrofuran-3-yl, pyrrolidinyl, piperazinyl, piperidinyl, azetidinyl, imidazolyl, 6,7-dihydro-4H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl, 1,4-diazepanyl, triazolyl or oxetanyl, each of which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, oxetanyl, and / or =0, and where an N atom may be oxidized, Het4denota pyrazolyl, triazolyl, or oxazolyl, each of which may be unsubstituted or mono-, di-, or trisubstituted by A, A denotes branched or unbranched alkyl with 1 to 10 C atoms, where 1 to 3 non-adjacent CH- and / or CH2- groups may be substituted by O or NH atoms and where 1 to 7 H atoms may be substituted by R5, or denotes (CH2)nCyc. Cyc denotes a cyclic alkyl group having 3 to 7 carbon atoms. R5 denotes F, Cl, or OH. Hal denotes F or Cl, n denotes 0, 1, 2, 3 or 4, this refers equally to pharmaceutically acceptable salts, tautomers and / or stereoisomers thereof.

[0050] Exemplary embodiments of compounds according to the present invention are set forth in Table 1 below and should also include pharmaceutically acceptable salts, tautomers, stereoisomers and racemic mixtures thereof, as well as solvates. Table 1 No. Name „Hi 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl] methyl}pyrimidin-4-amine „H2 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-2H-1,2,3-thnazol-4yl)phenyl]methyl}pyrimidin-4-amine H4 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-1,3-oxazol-4-yl)phenyl] methyl}pyrimidin-4-amine H6 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-( 1,3-oxazol-4yl)phenyl]methyl}pyrimidin-4-amine Petition 870260069920, dated 07 / 14 / 2026, p. 27 / 519 21 / 219 „Ai 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl] methyl}pyrimidin-4-amina A2 N-({[1,1'-biphenyl]-4-yl}methyl)-6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-amina A3 N-({[1,1'-biphenyl]-4-yl}methyl)-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amina A4 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-( 1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amina A5 6-[7-(2-methoxyethoxy)imidazo[1,2-a]21 iridin-3-yl]-N-{[4-(21 iridin-3-yl)phenyl] methyl}pyrimidin-4-amina A6 6-{7-methoxyimidazo[1,2-a]21 iridin-3-yl}-N-{[4-(21 iridin-3-yl)phenyl]methyl}pyrimidin-4-amina A7 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-( 1 -methyl-1H-pyrazol-3yl)phenyl]methyl}pyrimidin-4-amina A8 (6-lmidazo[1,2-a]21 iridin-3-yl-pyrimidin-4-yl)-(4-imidazol-1 -yl-benzyl)amina A9 (6-lmidazo[1,2-a]21 iridin-3-yl-pyrimidin-4-yl)-(4-pyrazol-1 -yl-benzyl)-amine A10 N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-[7-(trifluoromethyl)imidazo[1,2a]pyridin-3-yl]pyrimidin-4-amina A11 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[6-( 1 -methyl-1H-pyrazol-4yl)pyridin-3-yl]methyl}pyrimidin-4-amina A12 1 -(4-{[(6-{7-methoxyimidazo[1,2-a]21 iridina-3-yl}pyrimidin-4-yl)amino]methyl 1} fenil)piperidin-2-one A13 4-{[(6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)amino]methyl}-N,Ndimethylbenzamida A14 (6-lmidazo[1,2-a]21 iridina-3-yl-pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-3-yl)benzyl]-amine A15 [4-(4,5-Di-hydro-1 H-imidazol-2-yl)-benzyl]-(6-imidazo[1,2-a]pyridin-3-ylpyrimidin-4-yl)-amine A16 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-(1 H-1,2,3-triazol-1 yl)phenyl]methyl}pyrimidin-4-amine A17 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-[(4-{4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl}phenyl)methyl]pyrimidin-4-amine A18 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-( 1 H-1,2,3-triazol-1 -yl)phen yl]m ethyl}pyrimidin-4-am ina A19 {4-[1-(2-Metóxi-etil)-1 H-pyrazol-4-yl]-benzyl}-[6-(7-metóxi-imidazo[1,2a]piridin-3-il)-pirim idin-4-il]-am ina A20 [6-(7-Metóxi-imidazo[1,2-a]21 iridina-3-il)-pirim idin-4-il]-[4-(1 -metil-1 Himidazol-4-il)-benzil]-amina A21 [4-(1 -Ciclopropilmetil-1) H-pirazol-4-il)-benzil]-[6-(7-metóxi-imidazo[1,2a]piridin-3-il)-pirim idin-4-il]-am ina, Petition: 870260069920, on 07 / 14 / 2026, page. 28 / 519 22 / 219 A22 [6-(7-Metóxi-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl]-{4-[1-(2-morpholin-4yl-ethyl)-1 H -pyrazol-4-yl]-benzyl}-amine A23 [4-(1 -Ethyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-methoxy-imidazo[1,2-a]pyridolin-4-yl)-22 ina-3yl)-pirim idin-4-yl]-amina A24 [6-(7-Metóxi-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl]-{4-[1 -(2-pyrrolidin-1 yl-ethyl)-1 H-pyrazol-4-yl]-benzyl}-amina A25 H-pyrazol-4-yl)-benzyl]-[6-(7-methoxy-imidazo[1,2a]22iridin-3-yl)-pyrimidin-4-yl]-amine A26 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]methyl}pyrimidin-4-amine A27 N-{[4-(1 H-1,3-benzodiazol-1 -yl)phenyl]methyl}-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A28 [6-(7-Methoxy-imidazo[1,2-a]22iridin-3-yl)-pyrimidin-4-yl]-[3-( 1 -methyl-1 Hpyrazol-4-yl)-benzyl]-amine A29 N-{[3-fluoro-4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-{7-methoxyimidazo[1,2a]pyridin-3-yl}pyrimidin-4-amine A30 2-[4-(4-{[6-(7-Metóxi-imidazo[1,2-a]22iridin-3-yl)-pyrimidin-4-ylamino]methyl}-phenyl)-pyrazol-1-yl]-ethanol A31 [6-(7-Methoxy-imidazo[1,2-a]22iridin-3-yl)-pyrimidin-4-yl]-[4-(1 -methyl-1H- [1,2,3]triazol-4-yl)-benzyl]-amine A32 [6-(7-Methoxy-imidazo[1,2-a]22iridin-3-yl)-pyrimidin-4-yl]-[4-(2-methyl-2H- [1,2,3]triazol-4-yl)-benzyl]-amine A33 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-({4-[ 1 -(oxetan-3-yl)-1H-pyrazol-4-yl]phenyl}methyl)pyrimidin-4-amine A34 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(4-methoxypyrimidin-2yl)phenyl]methyl}pyrimidin-4-amine A35 [4-(3-Amino-1 -methyl-1H-pyrazol-4-yl)-benzyl]-[6-(7-methoxyimidazo[1,2a]22iridin-3-yl)-pyrimidin-4-yl]-amine A36 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[5-(1 -methyl-1H-pyrazol-4-yl)thiophen- 2-yl]methyl}pyrimidin-4-amine A37 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-2H-1,2,3,4-tetrazol- 5-yl)fenil]metil}pyrimidin-4-amine A38 [6-(7-Metóxi-imidazo[1,2-a]22iridina-3-yl)-pyrimidin-4-yl]-[4-(8-oxa-3-azabiciclo[3,2,1]oct-3-yl)-benzyl]-amina A39 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1 -methyl-1 H-imidazol-5-yl)phenyl]methyl}pyrimidin-4-amina A40 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(6-methylpyridazin-3-yl)phenyl]methyl}pyrimidin-4-amina A41 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methylpyrimidin-5-yl)phenyl]methyl}pyrimidin-4-amina, Petition 870260069920, de 14 / 07 / 2026, pág. 29 / 519 23 / 219 A42 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}pyrimidin-4-amina A43 5-(4-{[(6-{7-methoxyimidazo[1,2-a]23iridin-3-yl}pyrimidin-4-yl)amino]methyl}phenyl)-2-methylpyrimidin-4-amina A44 [6-(7-Methoxyimidazo[1,2-a]23iridin-3-yl)-pyrimidin-4-yl]-[5-(2-methyl-2H- [1,2,3]triazol-4-yl)-pyridin-2-ylmethyl]-amina A45 [6-(7-Methoxyimidazo[1,2-a]23iridin-3-yl)-pyrimidin-4-yl]-[6-(2-methyl-2H- [1,2,3]triazol-4-yl)-pyridin-3-ylmethyl]-amine A46 N-({4-[2-(2-methoxyethyl)-2H-1,2,3-triazol-4-yl]phenyl}methyl)-6-{7methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl A47 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methyl}pyrimidin-4-yl A48 [6-(7-Methoxyimidazo[1,2-a]23iridina-3-yl)-pyrimidin-4-yl]-[4-(2-methyloxazol-5-yl)-benzyl]-amine A49 [4-(1 -Cyclopropyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-methoxy-imidazo[1,2a]23iridin-3-yl)-pyrimidin-4-yl]-amine A50 N-{[4-(3-methoxy-1-methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A51 [6-(7-Methoxy-imidazo[1,2-a]23iridina-3-yl)-pyrimidin-4-yl]-(4-oxazol-4-ylbenzyl)-amine A52 [6-(7-Methoxy-imidazo[1,2-a]23iridina-3-yl)-pyrimidin-4-yl]-[4-(3-methylisoxazol-5-yl)-benzyl]-amine A53 [6-(7-Methoxy-imidazo[1,2-a]23iridina-3-yl)-pyrimidin-4-yl]-[4-(5-methyloxazol-2-yl)-benzyl]-amine A54 {6-[7-(2-Methoxy-1-methoxymethyl-ethyloxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin4-yl}-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A55 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(tetra-hidro-piran-4-ylóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina A56 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-morpholin-4-yl-ethóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina A57 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(tetra-hidro-furan-3-ylóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A58 6-[7-(cyclopropylmethoxy)imidazo[1,2-a]pyrid in-3-yl]-N-{[4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-am ina A59 6-{7-[2-(dimethylamino)ethoxy]imidazo[1,2-a]pyridin-3-yl}-N-(1-{-methyl-1- Hpyrazol-4-yl)phenyl]methyl}pyrimidine-4-am ina A60 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzy l]-{6-[7-(2-pyrrole id in-1 -yl-ethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-am ina A60}-am (6-{7-[2-(4-Methyl-piperazin-1-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrim idin4-yl)-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine A62 {6-[7-(1 -Methyl-piperazin-4-ylpimedin-4-yl) idazo[1,2-a]pyridin-3-yl]-pyrimidine-4i l}-[4-( 1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine, Petition 870260069920, of 14 / 07 / 2026, p. 30 / 519 24 / 219 A63 {6-[7-(1 -Methyl-piperidin-4-yloxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-[4(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine -A64-(1 -methy-( 3-4 1 H-pyrazol-4-yl)-benzylam ino]-pirim idin-4-yl}-im idazo[1,2-a]24iridine-7-yloxy)-propan-2-ol (3: Note: Alphabetical order of two prefixes ignored when selecting the origin chain-( Me115-4 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(4-oxetan-3-yl-piperazine-1 -yl)ethoxy]-imidazo[1,2-a]pindin-3-yl}-pyrimidine-4-yl)-amine A66 [6-(7-Methyl-imidazo[1,2-a]24iridine-3-yl)-pyrimidine-4-yl]-[4-(1 -methyl-1 Hpyrazol-4-yl)-benzyl]-amine A67 (6-{7-[2-(4-Methyl-piperazine-1-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}-pyrim idin4-yl)-(4-[1,2,3]triazol-1-yl-benzyl)-amine A68 {6-[7-(2-Morpholin-4-yl-ethoxy)-imidazo[1,2-a]pyridine-3-yl]-pyrimidine-4-yl}-(4[1,2,3]triazol-1 -yl-benzyl)-amine A69 [6-(6-Fluoro-7pyri-7-imi][24,24-methoxy idin-4-yl]-[4-(1 methyl-1 H-pyrazol-4-yl)-benzyl]-amine A70 {6-[7-(2-Pyrrolidin-1 -yl-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrim idin-4-yl}-(4[1,2,3]triazol-1 -yl-benzyl)-amine A71 {6-[7-(2-Methoxy-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-pinmidin-4-yl}-[4-(2-methyl2H-[1,2,3]triazol-4-yl)-benzyl]-am ina A72 6-[7-(benzyloxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine A73 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(2-pyrrolidin-1-yl-ethoxy)- imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina A74 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-morpholin-4-yl-propoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina A75 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-pyrazol-17 l-propoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina A76 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(1 -oxetan-3-yl-piperidin-4ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrim idin-4-yl}-am ina A77 6-{7-[2-(3,3-d if luropyrrol id in-1 -yl)ethoxy] im idazo[ 1,2-a]pyridin-3-yl}-N-{[4-( 1 metil-1 H-pyrazol-4-yl)fenil]metil}pyrimidin-4-amine A78 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzi l]-{6-[7-( 1 -oxetan-3-yl-piperidin-4ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine idin-4-yl}-amine A79 {6-[7-(1-Methyl-piperidin-4-ylmetóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4yl}-[4-(2-metil-2H-[1,2,3]triazol-4-yl)-benzyl]-amine A80 {6-[7-(1-Methyl-piperidin-4-ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4yl}-(4-[1,2,3]triazol-1 -yl-benzyl)-amine A81 N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-{7-nitroimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A82 6-{7-chloroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine, Petition 870260069920, de 14 / 07 / 2026, pág. 31 / 519 25 / 219 A83 {6-[7-(1-Oxetan-3-yl-piperidin-4-ylmethoxy)-imidazo[1,2-a]pyridine-3-yl]pyrimidine-4-yl}-(4-[1,2,3]triazol-1 -yl-benzyl)-am ina A84 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1 -yl-propoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-am ina Ά85 2-Methyl-1-(3-{6-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzylamino]-pyrimidine-4yl}-imidazo[1,2-a]25iridine-7-yloxy)-propan-2-ol (3: Obxobeteca: ignorados dosdei predem alfa origem) Ά86 7-[2-(4-Methyl-piperazine-1 -yl)-ethoxy]-3-{6-[4-( 1 -methyl-1 H-pyrazol-4-yl)benzyloxy]-pyrim idin-4-yl}-im idazo[1,2-[a-8]Methyl4-γ H-pyrazol-4-yl)-benzy loxi]-pyrim id in-4-yl}-7-(2-pyrrol id in-1 il-ethoxy)-imidazo[1,2-a]pyridine Ά88 4-[3-({3-[6-({[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidine-4yl]imidazo[1,2-a]pyridine-7-yl}oxy)propyl]morpholin-3-one Ά89 6-{7-[2-(3-f fluoropyrrole id in-1 -yl)ethoxy[1,]imide2-a]pyrid in-3-yl}-N-{[4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine Ά90 7-[2-(3,3-D fluoro-pyrrolide in-1 -yl)-ethoxy-[methyl-3-(6 H-pyrazol-4-i I)benzyloxy]-pyrim idin-4-yl}-im idazo[1,2-a]pyridine Ά91 {6-[7-(2,2-Dimethyl-3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]ylpyridine-methyl-3-4-yl] H-pyrazol-4-yl)-benzyl]-amine Ά92 4-[2-({3-[6-({[[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidine-4yl]imidazo[1,2-a]pyridin-73-ylonate]ylmoroxylin 1-methyl-4-[2-({3-[6-({[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}am ino)pyrim idin4-yl]imidazo[1,2-a]pyridine-7-yl}oxy)ethyl]piperazine-2-ona -[methyl-1(1-N- H-pyrazol-4-yl)phenyl]methyl}-6-{7-[3-(4-methylpiperazine-1 il)propoxi]imidazo[1,2-a]pyridine-3-yl}pinmidine-4-amine Ά95 1 -[2-({3-[6-({[methyl-(1 -1 H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidine-4yl]imidazo[1,2-a]pyridine-7-yl}oxy)ethyl]-4-(oxetan-3-yl)piperazine-2-one Ά96 N-{[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}-6-{7-[3-(4-methylpiperazine-1 il)propoxy]imidazo[1,2-a]pyridine-3-yl}pinmidine-4-amine Ά97 5-fluoro-6-{7-methoxyimidazo[4-azo]-[1,2-din -methyl-1 H-pyrazol4-yl)phenyl]methyl}pyrim idin-4-amine Ά98 (6-{7-[2-(1 -Methyl-1 H-imidazol-2-yl)-ethoxy]-imidazo[1,2-a]pyrid in-3-yl}-pyrim idin-4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά99 6-{7-[2-(azetidin-1 -yl)ethoxy]imidazo[1,2-a]pyridine-3-yl}-(1-{[4-methyl H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine, Petition 870260069920, dated 07 / 14 / 2026, p. 32 / 519 26 / 219 A100 6-{7-[2-(azetidine-1-yl)ethoxy]imidazo[1,2-a]pyridine-3-yl}-N-{[4-(2-methyl-2H1,2,3-triazol-4-yl)phenyl]methyl}pyrim idin-4-amine Ά101 6-{7-[3-(3,3-difluoropyrrolidin-1 -yl)propoxy]im idazo[1,2-a]pyridine-3-yl}-N-{[4(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine A102 {6-[7-(3-Azetidine-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-[4(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά103 [4-(1-Methyl-Methyl H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(6-oxa-3-aza- bicyclo[3,1,1 ]hept-3-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrim idin-4-yl)amine Ά104 {6-[7-(2-Amino-2-methyl-propoxy)-imidazo[1,2-a]pyridine-3-yl]-pinmidine-4-yl}[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine Dilidine Ά105 (6-{gold-1-3-pyroflu3-( -yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}pyrimidine-4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά106 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(pyridin-2-ylmethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-am ina Ά107 {6-[7-(2-Methyl-2-morpholin-4-yl-propoxy)-imidase[1,2-a]pyridin-3-yl]-pyrimidin4-yl}-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά108 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-(6-{7-[2-(2-(2-6-a-aza-6) espiro[3,3]hept-6-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrim idin-4-yl)-am ina Ά109 {6-[7-(2-Methyl-2-morpholin-4-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin4-yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά110 {6-[Methyl-(1-7-7) H-imidazol-2-ylmethoxy)-imidazo[1,2-a]pyride in-3-yl]-pyrim id in4-yl}-[4-(1-methyl-1 H-[1,2,3]triazol-4-yl)-benzyl]-am ina Ά111 (6-{7-[2-(1 -Methyl-1 H-imidazol-2-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-[4-( 1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά112 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(pyridin-3-ylmethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina Ά113 {6-[7-(1 -Methyl-1 H-imidazol-2-ylmethoxy)-imidazo[1,2-a]pyride in-3-yl]-pyrim id in4-yl}-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά114 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(2-oxa-6-aza-espiro[3,3]hept6-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrimidine-4-yl)-amine Ά115 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzi l]-(6-{7-[2-( 1 -pyrro ethy l in-3-yl)-ethoxy]imidazo[1,2-a]pyridin-3-yl}-pyrimidine-4-yl)-amine Ά116 (6-{7-[2-(1 -Methyl-pyrrolidin-3-yl)-ethoxy]-im idazo[1,2-a]pyridin-m3-yl} idin4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά117 {6-[7-(®-4-Methyl-morpholin-2-ylmethoxy)-imidazo[1,2-a]pyridin-methyl-3-1-yl-1-yl-}-pyridine H-pyrazol-4-yl)-benzyl]-amine Ά118 {6-[7-((S)-4-Methyl-morpholin-2-ylmethoxy)-imidazo[1,2-a]26iridine-3-yl]-pyrimidine-4-yl}-[4-( 1 -methyl-methyl)-benzy-1-1 Ά119 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-(6-{7-[2-(1-oxetan-3-yl-pyrrolidin- 3-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-amine}-ylpymi Petition 870260069920, dated 07 / 14 / 2026, p. 33 / 519 27 / 219 A120 {6-[7-(3-Azetidin-1-yl-propóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-[4(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά121 {6-[7-(®-4-Methyl-morpholin-2-ylmethóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin4-yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά122 {6-[7-((S)-4-Methyl-morpholin-2-ylmethoxy)-imidazo[1,2-a]27iridina-3-yl]-pyrimidin-4-yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά123 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-( 1 -oxetan-3-yl l-pyrrol id in-3-i I)etoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A124 N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-(7-{[(3R)-4-methylmorpholine-3yl]metóxi}imidazo[1,2-a]pyridin-3-yl)pyrimidin-4-am ina Ά125 N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-(7-{[(3S)-4-methylmorpholine-3yl]metóxi}imidazo[1,2-a]pyridin-3-yl)pyrimidin-4-am ina Ά126 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(2-pyridin-3-yl-ethoxy)- imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-am ina Ά127 (6-{7-[2-(3-Aza-bicyclo[3,1,0]hex-3-yl)-etóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά128 (6-{7-[2-(3-Aza-bicyclo[3,1,0]hex-3-yl)-etóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(2-methyl-2H-[1,2,3]triazol~4-yl)-benzyl]-amine Ά129 (6-{7-[2-(1 -Methyl-piperidin-4-yl)-etóxi]-im idazo[1,2-a]pyridin-3-yl}-pyrim idin4-yl)-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά130 (6-{7-[2-(1 -Methyl-piperidin-4-yl)-ethóxi]-im idazo[1,2-a]pyridin-3-yl}-pyrim idin4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine Ά131 3-(3-{6-[4-(1 -Methyl-1 H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyrid in-7-ylóxi)-propan-1 -ol Ά132 {6-[7-(3-Dimethylamino-propóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine Ά133 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(3-morpholin-4-yl-propóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine Ά134 3-(3-{6-[4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzylam ino]-pyrimidin-4-yl}imidazo[1,2-a]pirid in-7-ilóxi)-propan-1-ol Ά135 {6-[7-(3-Dimetilamino-propóxi)-imidazo[1,2-a]27iridina-3-il]-pirimidin-4il}-[4-(2-methyl-2H-[1,2,3]triazol-4-il)-benzil]-am ina Ά136 6-{7-[2-(3,3-d if luoropiperid in-1-il)etóxi] im idazo[1,2-a]pirid in-3-il}-N-{[4-( 1 metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina Ά137 6-{7-[3-(dietilamino)propóxi]imidazo[1,2-a]piridin-3-il}-N-{[4-(1 -metil-1 Hpirazol-4-il)fenil]metil}pirimidin-4-am ina Ά138 4-[2-({3-[6-({[4-(1 -metil-1) H-pirazol-4-il)fenil]metil}amino)pirimidin-4i I]im idazo[1,2-a]piridin-7-il}óxi )eti l]-1 Iambda6-tiomorfolina-1,1 -diona Ά139 6-{7-[2-(3,3-difluoroazetidin-1 -il)etóxi]im idazo[1,2-a]pirid in-3-il}-N-{[4-( 1 metil-1 H-pirazol-4-il)fenil]metil}pyrimidin-4-amina, Petition: 870260069920, on 07 / 14 / 2026, page. 34 / 519 28 / 219 Α140 6-{7-[2-(3-fluoroazetidin-1 -yl)ethoxy]imidazo[1,2-a]pyridin-3-yl}-N-{[4-( 1 -metil-1 H-pyrazol-4-yl)fenil]metil}pyrimidin-4-amine Α141 4-metil-1-[2-({3-[6-({[4-(1-methyl-1-pyrazol-4-yl))]) H-pyrazol-4-yl)fenil]metil}amino)pyrimidin- 4-yl]imidazo[1,2-a]pyridin-7-yl}óxi)ethyl]piperazin-2-one Α142 6-{7-[3-(3,3-difluoroazetidin-1-yl)propóxi]imidazo[1,2-a]pyridin-3-yl}-N-{[4(1-methyl-1-yl)] H-pyrazol-4-yl)fenil]metil}pyrimidin-4-amine A143 {6-[7-(3-Methanossulfonyl-propóxi)-imidazo[1,2-a]pyridin-3-yl]-pirim idin-4i l}-[4-( 1 -metil-1 H-pyrazol-4-yl)-benzil]-amina A144 N-{[4-(1 -metil-1 H-pyrazol-4-yl)phenyl]methyl}-6-{7-[(1 -metilazetidin-3-yl)metóxi]imidazo[1,2-a]pyridin-3-yl}pyrim idin-4-amina А145 1 -[3-({3-[6-({[4-(1 -metil-1 H-pyrazol-4-yl)fenil]metil}amino)pyrimidin-4yl]imidazo[1,2-a]pyridin-7-yl}oxy)propyl]pyrrolidin-2-one А146 6-{imidazo[1,2-a]pyridin-3-yl}-N-({6-[(3R)-3-methoxypyrrolidin-1-yl]pyridin-3yl}metil)pyrimidin-4-amine A147 (6-imidazo[1,2-a]28iridina-3-yl-pinmidin-4-yl)-(6-pyrrolidin-1 -yl-pyridin-3-ylmethyl)-amine A148 N-({6-[(3S)-3-fluoropyrrolidin-1 -yl]pyridin-3-yl}methyl)-6-{im idazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A149 [6-(3-Aza-bicyclo[3,1,0]hex-3-yl)-pyridin-3-ylmethyl]-(6-imidazo[1,2-a]pyridin3-yl-pyridin-4-yl)-amine Ά150 [6-(3,3-Difluoro-pyrrolidin-1 -yl)-pyridin-3-ylmethyl]-(6-im idazo[1,2-a]pyridin-3yl-pyrimidin-4-yl)-amine Ά151 6-{imidazo[1,2-a]28iridina-3-yl}-N-({6-[(3S)-3-methoxypyrrolidin-1 -yl]28iridina-3-yl}methyl)pyrimidin-4-amine Ά152 (4-Fluoro-6-pyrrolidin-1 -yl-pyridin-3-ylmethyl)-(6-imidazo[1,2-a]pyridin-3-ylpyrimidin-4-yl)-amine Ά153 N-({6-[(3R)-3-fluoropyrrolidin-1 -yl]pyridin-3-yl}methyl)-6-{imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine Ά154 (6-lmidazo[1,2-a]28iridina-3-yl-pyrimidin-4-yl)-(4-methyl-6-pyrrolidin-1 -ylpyridin-3-ylmethyl)-amine Ά155 [6-((S)-3-Fluoro-pyrrolidin-1-yl)-4-methyl-pyridin-3-ylmethyl]-(6-imidazo[1,2a]28iridine-3-yl-pyrimidin-4-yl)-am ina Ά156 [6-(®-3-Fluoro-pyrrolidin-1 -yl)-4-methyl-pyridin-3-ylmethyl]-(6-im idazo[1,2a]pyridin-3-yl-pyrimidin-4-yl)-amine Ά157 (6-lmidazo[1,2-a]28iridine-3-yl-pyrimidin-4-yl)-[4-(1 H-imidazol-2-yl)-benzyl]amine Ά158 7-Metóxi-3-{6-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzylóxi]-pyrimidin-4-yl}-im idazo[1,2-a]pyridine Ά159 N-[(4-{1-[(azetidin-3-yl)methyl]-1 H-pyrazol-4-yl}phenyl)methyl]-6-{7methoxiimidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine, Petition 870260069920, 14 / 07 / 2026, pág. 35 / 519 29 / 219 A160 3-[6-({[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-7-ol A161 [4-(4-{[6-(7-Methoxy-imidazo[1,2-a]29iridin-3-yl)-pyrimidin-4-ylamino]-methyl}-phenyl)-2-methyl-2H-pyrazol-3-yl]-methanol A162 6-{7-aminoimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine A163 2-Methyl-2-(3-{6-[4-(1 -methyl-1H-pyrazol-4-yl)-benzylamino]-pyrim idin-4-yl}-imidazo[1,2-a]29iridin-7-ylamino)-propan-1 -ol A164 N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-[7-(piperidin-4-yloxy)imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-yl}-amine A165 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(piperidin-4-ylmethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A166 [4-(1-Methyl-1H-pyrazol-4-yl)-benzyl]-{6-[7-(piperidin-4-ylmethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A167 6-{7-[(azetidin-3-yl)methoxy]imidazo[1,2-a]pyrid in-3-yl}-N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine A168 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-pyrrolidin-1 -yl-ethyl)-imidazo[1,2a]pyridin-3-yl]-pyrimidin-4-yl}-amine A169 (6-{7-[2-(3,3-Difluoro-pyrrolidin-1 -yl)-ethyl]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A170 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(4-oxetan-3-yl-piperazin-1 -yl)ethyl]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A171 7-Metóxi-3-(6-{1-[4-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-ethóxi}-pyrimidin-4-yl)imidazo[1,2-a]pyridine A172 2-({3-[6-({[4-(1-methyl-1 H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyrid in-7-yl}óxi )ethane-1 -ol A173 2-({3-[6-({[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}amino)pyrim idin-4yl]imidazo[1,2-a]pyridin-7-yl}óxi)ethan-1 -ol A174 [5-(4-{[6-(7-Metóxi-imidazo[1,2-a]pyridine-3-yl)-pyrimidine-4-ylam ino]-methyl}phenyl)-1-methyl-1 H-imidazol-2-yl]-methanol A175 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-pyrrolidin-3-yl-ethoxy)imidazo[1,2-a]pyridine-3-yl]-pyrimidine-4-yl}-am ina A176 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(2-pyrrolidin-3-yl-ethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-am ina A177 [-1-(1-Methyl H-pyrazol-4-yl)-benzyl]-[6-(7-pyrrolidin-1 -yl-im idazo[1,2a]pyridin-3-yl)-pyrim idin-4-yl]-am ina A178 2-[1-(3-{6-[4-(1 -methyl-1m4myr-noyl])-pyrazol idin-4-yl}imidazo[1,2-a]pyridine-7-yl)-pyrrolidin-3-yl]-ethanol, Petition 870260069920, dated 07 / 14 / 2026, p. 36 / 519 30 / 219 A179 2-[1-(3-{6-[4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzylam ino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yl)-pyrrolidin-3-yl]-ethanol A180 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-morpholin-4-yl-imidazo[1,2a]30iridine-3-yl)-pyrimidin-4-yl]-amine A181 {6-[7-(4-Methyl-piperazin-1-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-[4(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A182 N-{[4-(1 -methyl-1 H-pyrazol-4-yl)pheni l]methyl}-6-(7-{[1 -(oxetan-3-yl)piperidin-4yl]óxi}imidazo[1,2-a]pyridin-3-yl)pyrim idin-4-amine A183 N-{[4-(1 -methyl-1 H-pyrazol-4-yl)pheni l]methy l}-6-(7-{[1 -(oxetan-3-yl)azetidin-3yl]metóxi}imidazo[1,2-a]pyridin-3-yl)pyrimidin-4-am ina A184 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[3-(4-oxetan-3-yl-piperazin-1 -yl)propóxi]-imidazo[1,2-a]pyridin-3-yl}-pirim idin-4-yl)-am ina A185 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-(6-{7-[3-(4-oxetan-3-yl-piperazin1-yl)-propóxi]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A186 {6-[7-(1-Cyclopropyl-piperidin-4-ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine A187 {6-[7-(1-Cyclopropyl-piperidin-4-ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-yl}-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine A188 [4-(3-{6-[4-(1-Methyl-1 H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxymethyl)-piperidin-1 -yl]-acetonitrila A189 [4-(3-{6-[4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxymethyl)-piperidin-1 -yl]-acetonitrila A190 (6-{7-[1-(2-Metóxi-ethyl)-piperidin-4-ylmethóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A191 (6-{7-[1-(2-Metóxi-ethyl)-piperidin-4-ylmethóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine A192 (6-{7-[1-(2,2-Difluoro-ethyl)-piperidin-4-ylmethoxy]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A193 (6-{7-[1-(2,2-Difluoro-ethyl)-piperidin-4-ylmethoxy]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine A194 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(1 -oxo-114-thiom orfol in-4-yl)etoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A195 (6-{7-[2-(1,3-Di-hydro-pyrrolo[3,4-c]pyridin-2-yl)-ethoxy]-imidazo[1,2- a]pyridin-3-yl}-pyrimidin-4-yl)-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-amine A196 (6-{7-[2-(4-Fluoro-4-methyl-piperidin-1-yl)-ethoxy]-imidazo[1,2- a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A197 (6-{7-[2-(4-Cyclopropyl-piperazin-1-yl)-ethóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine, Petition 870260069920, 14 / 07 / 2026, pág. 37 / 519 31 / 219 A198 (6-{7-[2-(3-Methyl-3,8-diaza-bicyclo[3,2,1]oct-8-yl)-ethoxy]-imidazo[1,2a]pyridin-3-yl}-pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A199 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(2-oxo-2l4-thia-5-azabicyclo[2,2,1 ]hept-5-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)amine A200 (6-{7-[2-(6,6-Difluoro-[1,4]oxazepan-4-yl)-ethóxi]-imidazo[1,2-a]pyridin-3yl}-pyrim idin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A201 (6-{7-[2-(Hexa-hidro-pyrazino[2,1-c][1,4]oxazin-8-yl)-ethóxi]-imidazo[1,2a]pyridin-3-yl}-pirim idin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A202 (6-{7-[2-(4,4-Difluoro-piperidin-1-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A203 (6-{7-[2-(5,6-Di-hidro-8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl)-ethoxy]imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-[4-(1-methyl-1 H-pyrazol-4-yl)benzyl]-amine A204 (6-{7-[2-(2-Methyl-5,6-di-hidro-8H-[1,2,4]triazolo[1,5-a]pyrazin-7-yl)-ethóxi]imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-[4-(1-methyl-1H-pyrazol-4-yl)benzyl]-amine A205 {Methyl-[2-(3-{6-[4-(1 -methyl-1H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxy)-ethyl]-amino}-acetonitrile A206 3-Methyl-1 -[2-(3-{6-[4-(1 -methyl-1H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxy)-ethyl]-azetidina-3-carbonitrile A207 [4-(1 -methyl-1H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(6-oxa-1 -aza-espiro[3,3]hept1 -yl)-ethoxy]-im idazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A208 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-{2-[metil-(2,2,2-trifluoro-ethyl)amino]-ethoxy}-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl]-amine A209 (6-{7-[2-((3S,4R)-3,4-Difluoro-pyrrolidin-1-yl)-ethoxy]-imidazo[1,2-a]pyridin3-yl}-pyrimidin-4-yl)-[4-(1 -metil-1 H-pyrazol-4-yl)-benzyl]-amine A210 (6-{7-[(3aS,7aS)-2-(Hexa-hidro-furo[3,2-b]pyridin-4-yl)-ethóxi]-imidazo[1,2a]pyridin-3-yl}-pyrim idin-4-yl)-[4-(1 -metil-1 H-pyrazol-4-yl)-benzyl]-amine A211 (6-{7-[(4aS,7aS)8aS)-2-(Hexa-hydro-pyrano[3,4-b][1,4]oxazine-1-yl)-ethoxy]imidazo[1,2-a]pyridine-3-yl}-pyrimidine-4-yl)-[4-(1-methyl-1 H-pyrazol-4-yl)benzyl] (6-{7-[2-(1,4-Diaza-bicyclo[3,2,1 ]oct-4-yl)-ethoxy]-imidazo[1,2-a]pyrid in-3-i I}pyrimidine-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-amine A21] [6-(7-{2-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-azetidin-1 -yl]-ethoxy}-im idazo[1,2a]pyridin-3-yl)-pyrim idin-4-yl]-[4-(1 -methyl-1 A21 H-4-pyrazol)mine (6-{7-[2-(2,2-Difluoro-morpholin-4-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}pyrimidine-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine, Petition 870260069920, dated 07 / 14 / 2026, p. 38 / 519 32 / 219 A215 (6-{7-[2-(3-Methanosulfonyl-azetidine-1-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}pyrimidine-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A216 (6-{7-[2-(6,7-Di-hydro-4H-pyrazolo[1,5-a]pyrazin-5-yl)-ethoxy]-imidazo[1,2a]pyridin-3-yl}-pyrim idin-4-yl)-[4-(1 -methyl-1 H-pyrazol-amine-41-yl) (6-{7-[2-(6,7-Di-hydro-4H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl)-ethoxy]imidazo[1,2-a]pyridin-3-yl}-pyrimidine-4-yl)-[4-(1-methyl-21 H-8-aminazol) (6-{7-[2-(3,4-Di-hydro-1 H-pyrrol[1,2-a]pyrazine-2-yl)-ethoxy]-imidazo[1,2a]pyridine-3-yl}-pyrim idin-4-yl)-[4-(1 -methyl-1 H-a-4benzyl-1-Methyl-4-yl) -[2-(3-{6-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzylam ino]-pyrim idin-4-i I}imidazo[1,2-a]pyridin-7-yloxy)-ethyl]-[1,4]diazepan-5-ona A220 (6-{7-[7-[2-(4-Methoxy-4-methyl-piperidin-1-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}pyrimidine-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A221 (6-{7-[2-(3-Methyl-5,6-di-hydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-yl)-ethoxy]imidase[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-[4-(1-methyl-1H-pyrazol-4-yl)benzyl]-amine A222 4-Methyl-1-[2-(3-{6-[4-(1 -methyl-1H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxy)-ethyl]-piperidine-4-carbonitrile A223 {6-[7-(3-Amino-3-methyl-butoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-[4(1 -methyl-1H-pyrazol-4-yl)-benzyl]-amine A224 {6-[7-(2-Methanossulfonyl-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}[4-(1-metil-1 H-pyrazol-4-yl)-benzyl]-amine A225 {6-[7-(4-Azetidin-1-yl-butóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-[4(1 -metil-1 H-pyrazol-4-yl)-benzyl]-amine A226 6-[7-(1 -metil-1 H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-N-{[4-(1 -metil-1 Hpyrazol-4-yl)fenil]metil}pyrimidin-4-amine A227 {6-[7-(2-Methyl-3-pyrrolidin-1 -yl-propóxi)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin4-yl}-[4-(2-metil-2H-[1,2,3]triazol-4-yl)-benzil]-amina A228 1 -[3-({3-[6-({[4-(1 -metil-1 H-pyrazol-4-yl)fenil]amino)pyrimidin-4-yl]imidazo[1,2-a]2-a]pyridine-7-yl}oxy)propyl]pyrrolidin-1 -io-1 -olate A229 1-[3-Amino-4-(4-{[6-(7-methoxy-imidazo[1,2-a]32iridine-3-yl)-pyrimidine-4-ylamino]-methyl}-phenyl)-pyrazol-1-yl]-2-methyl-propan-2-ol (3: Obxoservecete ignorado adés al origem) A230 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(4-oxetan-3-yl-piperazine-1 -yl)imidazo[1,2-a]pyridine-3-yl]-pyrimidine-4-yl}-am ina A231 {6-[7-(3-Methanosulfonyl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrim idin-4yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine A232 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-[6-(7-pyrrolidin-1 -yl-im idazo[1,2a]pyridin-3-yl)-prim idin-4-yl]-am ina, Petition 870260069920, dated 07 / 14 / 2026, p. 39 / 519 33 / 219 A233 (6-{7-[2-(3-Amino-oxetan-3-yl)-ethóxi]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A234 2-[2-(3-{6-[4-(1 -Methyl-1) H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-ylóxi)-ethóxi]-etanol A235 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzi l]-{6-[7-(2-m ethyl-3-pyrrol id in-1 -il-propóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A236 2-(3-{6-[4-(2-Methyl-oxazol-4-yl)-benzylamino]-pyrimidin-4-yl}-imidazo[1,2a]pyridin-7-ylóxi)-ethanol A237 N-{[4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-{7-[3-(piperid in-1 -yl)propóxi]imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A238 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[3-(2-oxa-6-aza-espiro[3,3]hept-6-yl)-propóxi]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A239 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-(6-{7-[3-(2-oxa-6-azaespiro[3,3]hept-6-yl)-propóxi]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)amine A240 (6-{7-[3-(3-Fluoro-azetidin-1-yl)-propóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A241 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[3-(1 -oxo-114-thiom orfol in-4-yl)propóxi]-imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amine A242 [4-(2-Methyl-oxazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1 -yl-propóxi)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A243 (6-{7-[3-(4-Cyclopropyl-piperazin-1-yl)-propóxi]-imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine A244 [4-(2-Methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(4-oxetan-3-yl-piperazin-1yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A245 1 -(3-{6-[4-(1 -Methyl-1 H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yl)-pyrrolidin-3-ol A246 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-oxa-6-aza-espiro[3,3]hept-6yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A247 [4-(1-Methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-oxa-6-aza-espiro[3,4]oct-6-yl)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A248 7-Methyl-2-[2-(3-{6-[4-(1-methyl-1 H-pyrazol-4-yl)-benzylamino]-pyrimidin-4-yl}imidazo[1,2-a]pyridin-7-yloxy)-ethyl]-5-oxa-2,7-diaza-espirio[3,4]octan-6-one A249 {6-[7-(3-Azetidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-{1 [4-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-ethyl}-amine A250 {1 -[4-(1 -Methyl-1 H-pyrazol-4-yl)-phenyl]-ethyl}-{6-[7-(3-pyrrolidin-1-yl-propoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine A251 2-{3-[6-(4-Oxazol-4-yl-benzylamino)-pyrimidin-4-yl]-imidazo[1,2-a]pyridin-7yloxy}-ethanol A252 (4-Oxazol-4-yl-benzyl)-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2a]pyridin-3-yl]-pyrimidin-4-yl}-amine, Petition 870260069920, 14 / 07 / 2026, pág. 40 / 519 34 / 219 A254 H-pyrazol-4-yl)fenil]metil}-6-(7-{[1 -(2,2,2trifluoroethyl)azetidin-3-yl]metóxi}imidazo[1,2-a]pyridin-3-yl)pyrim idin-4amina A255 N-{[4-(1 -metil-1 H-pyrazol-4-yl)fenil]methi l}-6-{7-[2-(1 H-pyrazol-1-yl)ethoxy} idazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine A256 6-{7-[(3-fluoro-1-methylazetidin-3-yl)methoxy]imidazo[1,2-a]pyridin-3-yl}-N-{[4(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-yl A257 N-{[4-(1 -methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-{7-[3-( 1H-pyrazol-1-yl)propoxy]imidazo[1,2-a]pyridin-3-yl}pyrimidin-4-yl)-amina „A258 [4-(1 -Methyl-1H-pyrazol-4-yl)-benzyl]-(6-{7-[3-(oxetan-3-ylamino)-propoxy]imidazo[1,2-a]pyridin-3-yl}-pyrimidin-4-yl)-amina „A259 N-{[4-(2-metil-2H-1,2,3-triazol-4-yl)fenil]metil}-6-(7-{3-[(oxetan-3yl)amino]propoxy}imidazo[1,2-a]pyridin-3-yl)pyrimidin-4-amine „A260 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-{3-[®-(tetra-hidro-furan-3yl)amino]-propóxy}-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl]-amine „A261 4-Methyl-1-[2-({3-[6-({[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}amino)pyrimidin4-yl]imidazo[1,2-a]pyridin-7-yl}óxy)ethyl]-1,4-diazepan-5-one „A262 (6-{7-[3-(4-Fluoro-4-methyl-piperidin-1-yl)-propóxi]-imidazo[1,2-a]pindin-3yl}-pirim idin-4-yl)-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine „A263 6-{7-[3-(4-fluoro-4-methylpiperidin-1-yl)propóxi]imidazo[1,2-a]pyridin-3-yl}-N{[4-(1,3-oxazol-4-yl)phenyl]methyl}pinmidin-4-amine „A264 N-{[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}-6-[7-(2-{4H,5H,6H,7H- [1,2,3]triazolo[1,5-a]pyrazin-5-yl}ethoxy)imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-amine „A265 6-[7-(2-{4H,5H,6H,7H-[1,2,3]triazolo[1,5-a]pyrazin-5-yl}ethoxy)imidazo[1,2a]pindin-3-yl]-N-{[4-(tnfluoromethoxy)phenyl]methyl}pyrimidin-4-amine „A266 [4-(1 -Methyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-[1,2,4]triazol-1 -yl-imidazo[1,2a]pyridin-3-yl)-pyrimidin-4-yl]-amine „A267 {6-[7-(4-Methyl-imidazol-1-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-[4-(1methyl-1H-pyrazol-4-yl)-benzyl]-amine „A268 {6-[7-(3-Methylamino-azetidin-1-yl)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}[4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-amine, Petition 870260069920, dated 07 / 14 / 2026, page 41 / 519 35 / 219

[0051] Examples A75, A185, A217 and A258 to 268 are particularly preferred. Compounds that have been found to have good solubility, as described below and those listed in Table 3, are also preferred.

[0052] The preparation and properties of those exemplary varieties will be described further below.

[0053] The compounds of Formula I and also the starting materials for their preparation are, additionally, prepared by methods known per se, as described in the literature (for example in standard works, such as Houben-Weila, Metoden der organischen Chemie [Methods of Organic Chemistry], Georg-Tieme-Verlag, Stuttgart), to be precise, under reaction conditions that are known and suitable for the said reactions. Use may also be made of variants known per se that are not mentioned in this document in greater detail.

[0054] Compounds of Formula I wherein X denotes N(R3) may preferably be obtained by reacting a compound of Formula II with a compound of Formula III.

[0055] The starting compounds of Formula II and III are generally known. If they are new, however, they can be prepared by methods known per se. The reaction is generally carried out in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, sodium, calcium or cesium, or in the presence of an organic base, such as diisopropylamine (DIPEA). Preferably the reaction is carried out in the presence of compounds such as K2CO3 and / or KI.

[0056] Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between 60° and 130°, in particular between about 80° and about 110°. Examples of suitable inert solvents are carbonates, such as hexane, petroleum ether, benzene, toluene or xylene; colored carbonates, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanolic, n-propanolic, n-butanolic or ferc-butanolic; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglymide); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, 1-methylpyrrolidin-2-one or dimethylformamide (DMF); nitriles, such as Petition 870260069920, dated 07 / 14 / 2026, page 42 / 519 36 / 219 acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of said solvents. Particular preference is given to DMSO.

[0057] Compounds of Formula IV can preferably be obtained by reacting a compound of Formula IV with a compound of Formula V. The starting compounds of Formula IV and V are generally known. If they are novel, however, they can be prepared by methods known per se. Preferably, the reaction is carried out in the presence of compounds such as N-bromosuccinimide (NBS). Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 120°, normally between -10° and 80°, in particular between about -5° and about 70°.Examples of suitable inert solvents are carbonates, such as hexane, petroleum ether, benzene, toluene or xylene; colored carbonates, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanolic, n-propanolic, n-butanolic or tert-butanolic; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglymethane); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; Sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of said solvents. Particular preference is given to 1,4-dioxane and / or water.

[0058] Compounds of Formula I can preferably be obtained by converting a compound of Formula I, where R1 denotes F, into another compound of Formula I, where R1 denotes O[C(R3)2]nN(R3)2 or O[C(R3)2]nHet1.

[0059] A compound of Formula I, where R1 denotes F, is reacted with an alcohol HO[C(R3)2]nN(R3)2, where R3 and n have the meanings as indicated above, or in any of claims 1 to 8, or with an alcohol HO[C(R3)2]nHet1, where R3, Het1 and n have the meanings as indicated above, or in any of claims 1 to 8. Petition 870260069920, dated 07 / 14 / 2026, p. 43 / 519 37 / 219

[0060] Preferably the reaction is carried out in the presence of compounds such as potassium tert-butanolate (KO'Bu). Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -10° and 140°, normally between 0° and 120°, in particular between about 20° and about 110°.Examples of suitable inert solvents are carbonates, such as hexane, petroleum ether, benzene, toluene or xylene; colored carbonates, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanolic, n-propanolic, n-butanolic or tert-butanolic; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglymethane); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; Sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of said solvents. Particular preference is given to 1,4-dioxane.

[0061] Compounds of Formula I wherein Z denotes Het4 may preferably be obtained by the reaction of a compound of Formula VI with a compound of Formula VII. The starting compounds of Formulas VI and VII are generally known. If they are novel, however, they may be prepared by methods known per se. The reaction is generally carried out in the presence of an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, sodium, calcium or cesium. Preferably the reaction is carried out in the presence of compounds such as K2CO3. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between 60° and 130°, in particular between about 80° and about 110°.Examples of suitable inert solvents are carbonates, such as hexane, petroleum ether, benzene, toluene or xylene; colored carbonates, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanolic, n-propanolic, n-butanolic or tert-butanolic; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglymethane); ketones, etc. Petition 870260069920, dated 07 / 14 / 2026, page 44 / 519 38 / 219 such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of said solvents. Particular preference is given to acetonitrile. Pharmaceutical salts and other forms

[0062] The compounds according to the invention can be used in their final non-salt form, i.e., free form. On the other hand, the present invention also encompasses the use of compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. The pharmaceutically acceptable salt forms of the compounds of Formula I are mostly prepared by conventional methods. If the compound of Formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to produce the corresponding base addition salt.Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide, and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine, and N-methylglutamine. Aluminum salts of the compounds of Formula I are also included.In the case of certain compounds of Formula I, acid addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example, hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl sulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Consequently, the pharmaceutically acceptable acid addition salts of the compounds of Formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, bu. Petition 870260069920, dated 07 / 14 / 2026, page 45 / 519 39 / 219 tyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanopropionate, digluconate, dihydrogen phosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, formate, galacterate (of mucic acid), galacturonate, glucoeptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, chlorohydrate, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogen phosphate, 2naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

[0063] In addition, the base salts of the compounds according to the invention include salts of aluminum, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc, but are not intended to be a restriction. Of the aforementioned salts, preference is given to ammonium, to the alkali metal salts sodium and potassium and to the alkaline earth metal salts calcium and magnesium.Salts of compounds of Formula I that are derived from pharmaceutically acceptable non-toxic organic bases include salts of primary, secondary, and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic tensile exchange resins, for example, arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropilamine and tris(hydroxymethyl)methylamine (tromethamine), but this should not represent a restriction.

[0064] Compounds of the present invention containing basic nitrogen-containing groups can be quaternized using agents such as (C1-C4)alkyl halides, for example, methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C1-C4)alkyl sulfates, for example, dimethyl, diethyl and diamyl sulfate; (C10-C11)alkyl halides, for example, decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(C1-C4)alkyl halides, for example, benzyl chloride and bromide Petition 870260069920, dated 07 / 14 / 2026, page 46 / 519 40 / 219 of phenethyl. The water- and oil-soluble compounds according to the invention can be prepared using such salts.

[0065] The pharmaceutical salts mentioned above that are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this should not represent a restriction.

[0066] Particular preference is given to hydrochloride, dihydrochloride, hydrobromide, maleate, mesylate, phosphate, sulfate and succinate.

[0067] The acid addition salts of the basic compounds of Formula I are prepared by bringing the free base form into contact with a sufficient quantity of the desired acid, causing the formation of the salt in a conventional manner. The free base forms can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in certain respects from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

[0068] As mentioned, the pharmaceutically acceptable base addition salts of the compounds of Formula I are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Preferred metals are sodium, potassium, magnesium, and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine, and procaine.

[0069] The base addition salts of acidic compounds according to the invention are prepared by contacting the free acid form with a sufficient quantity of the desired base, causing the formation of the salt in a conventional manner. The free acid can be regenerated by contacting the salt form with an acid and isolating the free acid in a conventional manner. The free acid forms differ in certain respects from the corresponding salt forms of the same with respect to certain physical properties, such as solubility in solvents. Petition 870260069920, dated 07 / 14 / 2026, page 47 / 519 41 / 219 lares; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

[0070] If a compound according to the invention contains more than one group capable of forming pharmaceutically acceptable salts of this type, the invention also covers multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium, and trichloride, but this should not represent a restriction.

[0071] With respect to the foregoing, it may be observed that the expression "pharmaceutically acceptable salt" in the present connection is intended to mean an active ingredient comprising a compound of Formula I in the form of one of its salts, in particular if this salt form confers improved pharmacokinetic properties to the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used previously. The pharmaceutically acceptable salt form of the active ingredient may also provide this active ingredient with a desired pharmacokinetic property that it did not previously possess and may also have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body. Isotopes

[0072] It is further understood that a compound of Formula I includes isotope-labeled forms thereof. An isotope-labeled form of a compound of Formula I is identical to that compound except that one or more atoms of the compound have been replaced by an atom or atoms having an atomic mass or mass number that differs from the atomic mass or mass number of the atom that generally occurs naturally. Examples of isotopes that are readily available commercially and that can be incorporated into a compound of Formula I by well-known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, for example 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. A compound of Formula I, a prodrug thereof, or a pharmaceutically acceptable salt thereof containing one or more of the aforementioned isotopes and / or other isotopes of other atoms is intended to be part of the present invention.A compound of Formula I labeled. Petition 870260069920, dated 07 / 14 / 2026, p. 48 / 519 42 / 219 with an isotope can be used in several beneficial ways. For example, a compound of Formula I labeled with an isotope to which, for example, a radioisotope such as 3H or 14C has been incorporated is suitable for drug and / or substrate tissue distribution assays. These radioisotopes, namely tritium (3H) and carbon-14 (14C), are particularly preferred due to their simple preparation and excellent detectability. The incorporation of heavier isotopes, for example deuterium (2H), into a compound of Formula I has therapeutic advantages due to the greater metabolic stability of this isotope-labeled compound. Higher metabolic stability translates directly into an increased in vivo half-life or lower dosages, which in most circumstances would represent a preferred embodiment of the present invention.A compound of Formula I labeled with an isotope can generally be prepared by carrying out the procedures disclosed in the synthesis schemes and related description, in the example and preparation sections of this text, replacing an unlabeled reagent with a readily available isotope-labeled reagent.

[0073] Deuterium (2H) can also be incorporated into a compound of Formula I for the purpose of manipulating the oxidative metabolism of the compound through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction that results from the exchange of isotopic nuclei, which in turn is caused by a change in the ground-state energies required for covalent bond formation after this isotopic exchange. The exchange of a heavier isotope generally results in a reduction of the ground-state energy for a chemical bond and therefore causes a reduction in the rate of breaking of the rate-limiting bond. If bond breaking occurs in or near a saddle-point region along the coordinate of a multi-product reaction, the product distribution relationships can be substantially altered.For explanation: if deuterium is bonded to a carbon atom in a non-interchangeable position, Km / ko rate differences of 2-7 are typical. If this rate difference is successfully applied to a Formula I compound that is susceptible to oxidation, the in vivo profile of this compound can be drastically modified and result in improved pharmacokinetic properties.

[0074] In finding and developing therapeutic agents, the expert in the technique Petition 870260069920, dated 07 / 14 / 2026, p. 49 / 519 43 / 219 attempts to optimize pharmacokinetic parameters while retaining desirable in vitro properties. It is reasonable to assume that many compounds with weak pharmacokinetic profiles are susceptible to oxidative metabolism. Currently available in vitro liver microsomal assays provide valuable information on the course of this type of oxidative metabolism, which in turn allows for the rational design of deuterated compounds of Formula I with improved stability through resistance to such oxidative metabolism. Significant improvements in the pharmacokinetic profiles of the compounds of Formula I are thus obtained, and can be expressed quantitatively in terms of increases in in vivo half-life (t1 / 2), concentration at maximum therapeutic effect (Cmax), area under the dose-response curve (AUC) and F; and in terms of reduced clearance, dose and material costs.

[0075] The following is intended to illustrate the above: a compound of Formula I possessing multiple potential attack sites for oxidative metabolism, for example benzylic hydrogen atoms and hydrogen atoms bonded to a nitrogen atom, is prepared as a series of analogues in which various combinations of hydrogen atoms are replaced by deuterium atoms, such that some, most, or all of these hydrogen atoms have been replaced by deuterium atoms. Half-life determinations allow for the favorable and precise determination of the extent to which the improvement in resistance to oxidative metabolism has increased. Thus, it is determined that the half-life of the parent compound can be extended by up to 100% as a result of this type of deuterium-hydrogen exchange.

[0076] Deuterium-hydrogen exchange in a compound of Formula I can also be used to obtain a favorable modification of the metabolite spectrum of the starting compound in order to decrease or eliminate unwanted toxic metabolites. For example, if a toxic metabolite arises through oxidative carbon-hydrogen (CH) bond cleavage, it can reasonably be assumed that the deuterated analog will greatly decrease or eliminate the production of the unwanted metabolite, even if the particular oxidation is not a rate-determining step. Further state-of-the-art information regarding deuterium-hydrogen exchange can be found, for example, in Hanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J. Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985, Gillette et al, Biochemistry 33(10) 2927-2937, 1994, and Jarman et al. Carcinogenesis 16(4), 683688, 1993. Petition 870260069920, dated 07 / 14 / 2026, page 50 / 519 44 / 219

[0077] The invention further relates to medicaments containing at least one compound of Formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants. Obviously, this should be understood as including solvates of the compounds and salts.

[0078] Pharmaceutical formulations may be administered in the form of dosage units comprising a predetermined amount of active ingredient per dosage unit. Such a unit may comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations may be administered in the form of dosage units comprising a predetermined amount of active ingredient per dosage unit. Preferred unit dosage formulations are those comprising a daily dose or partial dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type may be prepared using a process that is generally known in the pharmaceutical art.

[0079] Pharmaceutical formulations may be adapted for administration by any suitable method desired, for example, by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral methods (including subcutaneous, intramuscular, intravenous or intradermal). Such formulations may be prepared using all processes known in the pharmaceutical art, for example, by combining the active ingredient with the excipient(s) or adjuvant(s).

[0080] Pharmaceutical formulations adapted for oral administration may be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foamed foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

[0081] Thus, for example, in the case of oral administration in tablet form Petition 870260069920, dated 07 / 14 / 2026, pp. 51 / 519 45 / 219 powder or capsule, the active ingredient component may be combined with an orally inert, non-toxic and pharmaceutically acceptable excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by grinding the compound to a suitable fine size and mixing it with a similarly ground pharmaceutical excipient, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavoring, preservative, dispersant and coloring agent may also be present.

[0082] The capsules are produced by preparing a powder mixture as described above and filling molded gelatin shells with it. Glidants and lubricants, such as, for example, highly dispersed silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, may be added to the powder mixture before filling. Similarly, a disintegrant or solubilizer such as, for example, agar-agar, calcium carbonate or sodium carbonate, may be added to improve the bioavailability of the drug after ingestion of the capsule.

[0083] In addition, if desired or necessary, suitable binders, lubricants and disintegrants, as well as colorants, may also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as, for example, glucose or beta-lactose, sweeteners made from corn, natural and synthetic rubber such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to form the tablets.A powdered mixture is prepared by mixing the suitably ground compound with a diluent or base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatin or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and / or an absorbent, such as, for example, bentonite, kaolin or dicalcium phosphate. The powdered mixture may be granulated. Petition 870260069920, dated 07 / 14 / 2026, page 52 / 519 46 / 219 moistening it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymeric materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be passed through a tablet machine, resulting in non-uniformly shaped lumps, which fragment to form granules. The granules can be lubricated by adding stearic acid, a stearate salt, talc or mineral oil to prevent them from sticking to the tablet casting molds. The lubricated mixture is then pressed to form tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to form tablets, without performing the granulation or dry pressing steps.A transparent or opaque protective layer may be present, consisting of a sealant layer of shellac, a layer of sugar or polymeric material, and a glossy layer of wax. Colorants may be added to these coatings in order to differentiate between different dosage units.

[0084] Oral liquids, such as solutions, syrups, and elixirs, can be prepared in the form of dosage units so that a given quantity consists of a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavor, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers, such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives, such as peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, may also be added.

[0085] Dosage unit formulations for oral administration may, if desired, be encapsulated in microcapsules. The formulation may also be prepared in such a way that release is prolonged or delayed, such as by coating or incorporating particulate material into polymers, waxes and the like.

[0086] The compounds of Formula I and pharmaceutically available salts, tautomers and stereoisomers thereof may also be administered in the form of systems Petition 870260069920, dated 07 / 14 / 2026, page 53 / 519 47 / 219 of liposome release, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

[0087] The compounds of Formula I and their salts, tautomers, and stereoisomers can also be released using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted drug carriers. Such polymers may include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamidophenol, polyhydroxyethyl spartamidophenol, or polyethylene oxide polylysine, via palmitoyl radicals. The compounds can further be coupled to a class of biodegradable polymers that are suitable for achieving controlled drug release, for example, polylactic acid, polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates, and crosslinked or antipathic block copolymers of hydrogels.

[0088] Pharmaceutical formulations adapted for transdermal administration can be administered as stand-alone patches for prolonged and close contact with the recipient's epidermis. Thus, for example, the active ingredient can be administered from the patch by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318(1986).

[0089] Pharmaceutical compounds adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols, or oils.

[0090] For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream. In the case of a formulation to provide an ointment, the active ingredient may be used either with a paraffin base or a water-miscible cream. Alternatively, the active ingredient may be formulated to provide a cream with an oil-in-water cream base or a water-in-oil base.

[0091] Pharmaceutical formulations adapted for topical application in the eye Petition 870260069920, dated 07 / 14 / 2026, page 54 / 519 48 / 219 include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent. Pharmaceutical formulations adapted for topical application in the mouth include lozenges, lozenges and mouthwashes.

[0092] Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

[0093] Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder with a particle size, for example, in the range of 20 to 500 microns, which is administered in the manner in which snuff is administered, i.e., by rapid inhalation through the nasal passages, from a container containing the powder held close to the nose.

[0094] Formulations suitable for administration as nasal sprays or nasal drops with a liquid as the carrier substance include solutions of the active ingredient in water or oil.

[0095] Pharmaceutical formulations adapted for administration by inhalation include powders or mists of fine particles, which can be generated by various types of pressurized aerosol dispensers, nebulizers, or insufflators. Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams, or spray formulations.

[0096] Pharmaceutical formulations adapted for parenteral administration include sterile aqueous and non-aqueous injectable solutions comprising antioxidants, buffers, bacteriostatics, and solutes, by means of which the formulation is made isotonic with the blood of the recipient to be treated; and sterile aqueous and non-aqueous suspensions, which may comprise suspension media and thickeners. The formulations may be administered in single-dose or multi-dose containers, for example, sealed ampoules and vials, and stored in a freeze-dried (lyophilized) state, so that only the addition of the sterile carrier fluid, for example, water for injection purposes, immediately before use is necessary. Injectable solutions and suspensions prepared according to prescription may be prepared from sterile powders, granules, and tablets.

[0097] It is essential to say that, in addition to the constituents in particular Petition 870260069920, dated 07 / 14 / 2026, page 55 / 519 49 / 219 mentioned above, the formulations may also include other agents commonly used in the art with respect to the particular type of formulation; thus, for example, formulations that are suitable for oral administration may include flavorings.

[0098] A therapeutically effective amount of a compound of Formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition requiring treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the attending physician or veterinarian. However, an effective amount of a compound according to the invention is generally in the range of 0.1 to 100 mg / kg of body weight of the recipient (mammal) per day and particularly typically in the range of 1 to 10 mg / kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is generally between 70 and 700 mg, where this amount can be administered as a single dose per day or generally in a series of partial doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.An effective amount of a salt or solvate, or of a physiologically functional derivative thereof, can be determined as the fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are adequate for the treatment of the other conditions mentioned above.

[0099] A combined treatment of this type can be achieved with the aid of simultaneous, consecutive or separate release of the individual components of the treatment. Combination products of this type utilize the compounds according to the invention.

[00100] The invention further relates to a medicament comprising at least one compound of Formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and at least one other pharmaceutically active ingredient (being synonymous with medicament active ingredient).

[00101] The invention also relates to a kit consisting of separate packages of

[00102] an effective quantity of a compound of Formula I and / or salt, tautomer Petition 870260069920, dated 07 / 14 / 2026, p. 56 / 519 50 / 219 and stereoisomer thereof, including mixtures thereof in all ratios, and

[00103] an effective amount of another pharmaceutically active ingredient.

[00104] The kit comprises suitable containers, such as boxes, individual vials, bags or ampoules. The kit may, for example, comprise separate ampoules, each containing an effective amount of a compound of Formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all proportions, and an effective amount of another active ingredient of the medicinal product in dissolved or lyophilized form.

[00105] To treat, as used in this document, means relief, in whole or in part, of the symptoms associated with a disorder or disease, or slowing or halting the progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder in an individual at risk of developing the disease or disorder.

[00106] The term effective amount in connection with a compound of Formula I may mean an amount capable of relieving, in whole or in part, the symptoms associated with a disorder or disease, or slowing or halting the progression or worsening of those symptoms, or preventing or providing prophylaxis for the disease or disorder in an individual at risk of developing a disease described herein, such as inflammatory conditions, immunological conditions, cancer, or metabolic conditions.

[00107] The term effective quantity denotes the amount of a drug or active pharmaceutical ingredient that causes a biological or medical response in a tissue, system, animal, or human that is being researched or desired, for example, by a researcher or physician. Furthermore, the term therapeutically effective quantity denotes an amount that, compared to a corresponding individual who did not receive it, has the following consequence: improved treatment, cure, prevention, or elimination of a disease, syndrome, condition, complaint, disorder, or side effects, or also the reduction of the progression of a disease, complaint, or disorder. The term therapeutically effective quantity also encompasses amounts that are effective in enhancing normal physiological function.

[00108] In one embodiment, an effective amount of a compound of Formula I is an amount that inhibits c-KIT kinase in a cell, such as, for example, Petition 870260069920, dated 07 / 14 / 2026, page 57 / 519 51 / 219 in vitro or in vivo. In some embodiments, the effective amount of the compound of Formula I inhibits c-Kit in a cell by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 99%, compared to the c-KIT kinase activity in an untreated cell. The effective amount of the compound of Formula I, for example in a pharmaceutical composition, may be at a level that will exert the desired effect; for example, from about 0.005 mg / kg of an individual's body weight to about 10 mg / kg of an individual's body weight in unit dosage for oral and parenteral administration. USE

[00109] The present compounds are suitable as active pharmaceutical ingredients for mammals, especially humans, in the treatment of cancer, such as gastrointestinal stromal tumors.

[00110] The present invention encompasses the use of the compounds of Formula I and / or pharmaceutically acceptable salts, tautomers and stereoisomers thereof for the preparation of a medicament for the treatment or prevention of cancer, preferably for the treatment of gastrointestinal stromal tumors.

[00111] Preferably, the present invention relates to a method of treating a disease, wherein the disease is cancer, preferably a gastrointestinal stromal tumor.

[00112] Particularly preferable, the present invention relates to a method wherein the disease is cancer, in which administration is simultaneous, sequential or alternating with the administration of at least one other active drug.

[00113] The compounds of Formula I described may be administered in combination with other known therapeutic agents, including anticancer agents. As used in this document, the term anticancer agent refers to any agent that is administered to a cancer patient for the purpose of treating the cancer.

[00114] The anticancer treatment defined above may be applied as monotherapy or may involve, in addition to the compounds of Formula I described herein, conventional surgery or radiotherapy or medical therapy. Such medical therapy, for example, chemotherapy or targeted therapy, may include one or more, but preferably one, of the following antitumor agents: Petition 870260069920, dated 07 / 14 / 2026, page 58 / 519 52 / 219 Alkylating Agents

[00115] such as altretamine, bendamustine, busulfan, carmustine, chlorambucil, chlormethine, cyclophosphamide, dacarbazine, ifosfamide, improsulfan, tosylate, lomustine, melphalan, mitobronitol, mitolactol, nimustine, ranimustine, temozolomide, thiotepa, treosulfan, mechlorethamine, carboquone, apaziquone, fotemustine, glufosfamide, palifosfamide, pipobroman, trofosfamide, uramustine, TH-3024, VAL-0834; Platinum Compounds

[00116] such as carboplatin, cisplatin, eptaplatin, miriplatin hydrate, oxaliplatin, lobaplatin, nedaplatin, picoplatin, satraplatin;

[00117] lobaplatin, nedaplatin, picoplatin, satraplatin; DNA-altering agents

[00118] such as amrubicin, bisantrene, decitabine, mitoxantrone, procarbazine, trabectedin, clofarabine;

[00119] amsacrine, brostallicin, pixantrone, laromustine13; Topoisomerase inhibitors

[00120] such as etoposide, irinotecan, razoxane, sobuzoxane, teniposide, topotecan; amonafide, belotecan, elliptinium acetate, voreloxin; Microtubule modifiers

[00121] such as cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel, vinblastine, vincristine, vinorelbine, vindesine, vinflunine;

[00122] fosbretabulin,thesistaxel; Antimetabolites

[00123] such as asparaginase3, azacitidine, calcium levofolinate, capecitabine,

[00124] cladribine, cytarabine, enocitabine, floxuridine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, Nelarabine, pemetrexed, pralatrexate, azathioprine, thioguanine, carmofur;

[00125] doxifluridine, elacitarabine, raltitrexed, sapacitabine, tegafur23, trimetrexate; Anticancer antibiotics Petition 870260069920, dated 07 / 14 / 2026, page 59 / 519 53 / 219

[00126] such as bleomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, levamisole, miltefosine, mitomycin C, romidepsin, streptozocin, valrubicin, zinostatin, zorubicin, daunurobicin, plicamycin;

[00127] aclarubicin, peplomycin, pyrarubicin; Hormones / Antagonists

[00128] such as abarelix, abiraterone, bicalutamide, buserelin, calusterone, chlorotrianisene, degarelix, dexamethasone, estradiol, fluocortolone

[00129] fluoxymesterone, flutamide, fulvestrant, goserelin, histrelin, leuprorelin, megestrol, mitotane, nafarelin, nandrolone, nilutamide, octreotide, prednisolone, raloxifene, tamoxifen, thyrotropin alfa, toremifene, trilostane, triptorelin; diethylstilbestrol;

[00130] acolbifen, danazol, deslorelin, epithiostanol, orteronel, enzalutamide13; Aromatase inhibitors

[00131] such as aminoglutethimide, anastrozole, exemestane, fadrozole, letrozole, testolactone;

[00132] formestano; Small molecule kinase inhibitors

[00133] such as crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, Pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, vandetanib, vemurafenib, bosutinib, gefitinib, axitinib;

[00134] afatinib, alisertib, dabrafenib, dacomitinib, dinaciclib, dovitinib, enzastaurin, nintedanib, lenvatinib, linifanib, linsitinib, masitinib, midostaurin, motesanib, neratinib, orantinib, perifosine, ponatinib, radotinib, rigosertib, tipifarnib, tivantinib, Tivozanib, trametinib, pimasertib, brivanibalaninate, cediranib, apatinib4, S-malate13de cabozantinib, ibrutinib13, icotinib4, buparlisib2, cipatinib4, cobimetinib1'3, idelalisib13fedratinib1, XL-6474; Photosensitizers

[00135] such as methoxsalen3; sodium porfimer, talaporfin, temoporfin; Antibodies Petition 870260069920, 7 / 14 / 2026, p. 60 / 5 54 / 2

[00136] such as alemtuzumabe, besilesomabe, brentuximabe vedotina, cetuximabe, denosumabe, ipilimumabe, ofatumumabe, panitumumabe, rituximabe, tositumomabe,

[00137] trastuzumabe, bevacizumabe, pertuzumabe23;

[00138] Catumaxomabe, elotuzumabe, epratuzumabe, farletuzumabe, mogamulizumabe, necitumumabe, nimotuzumabe, obinutuzumabe, ocaratuzumabe, oregovomabe, ramucirumabe, rilotumumabe, siltuximabe, tocilizumabe, zalatumumabe, zalumabebe, zalonmimumabe, ears of us, dalotuzumabe1'23, onartuzumabe13, racotumomabe1, earsofusuzumabe1'23, onartuzumabe13, racotumomabe1,

[00139] tablebad1'3, EMD-5257974, levelbad13; Cytokines

[00140] tais such as aldesleucine, interferon alpha2, interferon alpha2a3, interferon alpha2b23; celmoleucine, tasonermine, teceleucine, oprelvecin13, recombinant interferon beta-1 a4; Drug Conjugates

[00141] such as denileucindiftitox, ibritumomab tiuxetan, iobenguane 1123, prednimustine, trastuzumab emtansine, estramustine, gentuzumab, ozogamicin, aflibercept;

[00142] cintredecinbesudotox, edotreotide, inotuzumab ozogamicin, naptumomabestafenatox, oportuzumabmonatox, technetium (99mTc) arcitumomab13, vintafolide1'3; Vaccines

[00143] such as sipuleucel3; vitespen3, emepepimut-S3, oncoVAX4, risopepimut3, troVax4, MGN-16014, MGN-17034; Several

[00144] alitretinoin, bexarotene, bortezomib, everolimus, ibandronic acid, imiquimod, lenalidomide, lentinan, metirosin, mifamurtide, pamidronic acid, pegaspargase, pentostatin, sipuleucel3, sizofiran, tamibarotene, temsirolimus, thalidomide, tretinoin, vismodegib, zoledronic acid, vorinostat;

[00145] celecoxib, cilengitide, entinostat, etanidazole, ganetespib, idronoxyl, Petition 870260069920, dated 07 / 14 / 2026, page 61 / 519 55 / 219 iniparib, ixazomib, lonidamine, nimorazole, panobinostat, peretinoin, plitidepsin, pomalidomide, procodazole, ridaforolimus, tasquinimod, telotristat, thymalfasin, tirapazamine, tosedostat, trabedersen, ubenimex, valspodar, gendicin4, picibanial4, reolysin4, retaspimycin hydrochloride1'3, trebananib23, virulizin4, carfilzomib13, endostatin4, imucotel4, belinostat3, MGN-17034;

[00146] 1Prop. INN (Proposed International Nonproprietary Name)

[00147] 2Rec. INN (Recommended International Nonproprietary Names)

[00148] 3USAN (United States Adopted Name)

[00149] 4none INN.

[00150] In addition, the invention relates to selected intermediates of:

[00151] 6-chloro-N-{[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-methyl}-pyrimidin-4-amine ci

[00152] 6-[1-2-ethoxyethenyl]-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4amine

[00153] 4-chloro-6-[(E)-2-ethoxythenyl]pyrimidine

[00154] 4-chloro-6-{7-fluoroimidazo[1,255i rid inad in-3-yl}pyrimidine Petition 870260069920, dated 07 / 14 / 2026, p. 62 / 519 56 / 219

[00155] The following abbreviations are used throughout this document:

[00156] aq (aqueous), h (hour), g (gram), L (liter), mg (milligram), MHz (Megahertz), min. (minute), mm (millimeter), mmol (millimol), mM (millimolar), mp (melting point), eq (equivalent), mL (milliliter), pl (microliter), ACN (acetonitrile), AcOH (acetic acid), CDCh (deuterated chloroform), CD3OD (deuterated methanol), CH3CN (acetonitrile), c-hex (cyclohexane), DCC (dicyclohexylcarbodiimide), DCM (dichloromethane), DIC (diisopropylcarbodiimide), DIPEA (diisopropylethylamine), DMF (dimethylformamide), DMSO (dimethyl sulfoxide), DMSO-de (deuterated dimethyl sulfoxide); EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide), ESI (electrospray ionization), EtOAc (ethyl acetate), Et2O (diethyl ether), EtOH (ethanol), HATU (dimethylamino-([1,2,3]triazolo[4,5-b]pindin-3-yloxy)methylene]dimethylammonium hexafluorophosphate), HPLC (High Performance Liquid Chromatography), i-PrOH (2-propanol), K2COs (potassium carbonate), LC (Liquid Chromatography), MeOH (methanol), MgSO4 (magnesium sulfate),MS (mass spectrometry), MTBE (methyl tert-butyl ether), NaHCO3 (sodium bicarbonate), NaBFk (sodium borohydride), NMM (N-methylmorpholine), NMR (Nuclear Magnetic Resonance), PyBOP (benzotriazol-1-yl-oxy-tris-pyrrolidinephosphonium hexafluorophosphate), RT (room temperature), Rt (retention time), SPE (solid phase extraction), TBTU (2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate), TEA (triethylamine), TFA (trifluoroacetic acid), THF (tetrahydrofuran), TLC (thin layer chromatography), UPLC (ultra-performance liquid chromatography), UV (ultraviolet).

[00157] Above and below, all temperatures are indicated in °C.

[00158] 1H NMR was recorded on Bruker DPX-300, DRX-400, AVII-400 or on a 500 MHz spectrometer, using residual deuterated solvent signal as internal reference. Chemical shifts (ε) are reported in ppm relative to the residual solvent signal (ε = 2.49 ppm for 1H NMR in DMSO-de). 1H NMR data are reported as follows: chemical shift (multiplicity, coupling constants, and number of hydrogens). Multiplicity is abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), bs Petition 870260069920, dated 07 / 14 / 2026, page 63 / 519 57 / 219 (wide singlet), p (pentet). HPLC / MS Conditions A:

[00159] HPLC / MS: Agilent 1200 / 6100

[00160] Eluent A: water + 0.05% formic acid

[00161] eluent B: acetonitrile + 0.04% formic acid

[00162] column: Chromolith HR RP-18e; 50-4.6mm

[00163] flow rate: 3.3 mL / min

[00164] gradient: 0% -> 100% of B: 0.0 ->2.0 min | 100% B: 2.0 -> 2.5 min

[00165] UV detection: 220 nm

[00166] MS detection: 65-800 amu positive HPLC / MS conditions B:

[00167] HPLC / MS: Agilent 1200 / 6100

[00168] Eluent A: water + 0.05% formic acid

[00169] eluent B: acetonitrile + 0.04% formic acid + 1% H2O

[00170] column: Kinetex XB-C18; 2.6 pm; 50-4.6 mm

[00171] flow rate: 3.3 mL / min

[00172] column temperature: 40° C

[00173] gradient: 1% ->99% B: 0.0 -> 0.8 min | 99% B: 0.8 ->1.1 min

[00174] UV detection: 220 nm

[00175] MS detection: 65-800 positive conditions amu UPLC / MS:

[00176] UPLC / MS: Waters Acquity / SQD

[00177] Eluent A: water + 0.05% formic acid

[00178] eluent B: acetonitrile + 0.04% formic acid + 1% H2O

[00179] column: Kinetex XB-C18; 1.7 pm; 50-2.1 mm

[00180] flow rate: 0.9 mL / min Petition 870260069920, dated 07 / 14 / 2026, p. 64 / 519 58 / 219

[00181] gradient: 1% -> 99% of B: 0.0 -> 1.0 min | 99% B: 1.0 -> 1.3 min

[00182] column temperature: 40° C

[00183] UV detection: 220 nm

[00184] MS detection: 61-800 amu positive + 46-1000 amu negative Tests and Measurements c-Kit test (V654A):

[00185] c-Kit (V654A) (recombinant human c-Kit, N-terminal GST-labeled, amino acid end 544 containing the V654A mutation) is incubated with 8 mM MOPS, pH 7.0, 0.2 mM EDTA, 250 pM GGMEDIYEFMGGKKK, 10 mM Mg Acetate, and [gamma-33P-ATP] (specific activity of approximately 500 cpm / pmol, concentration 200 μM). The reaction is initiated by the addition of the MgATP mixture. After incubation for 40 minutes at room temperature, the reaction is stopped by the addition of 3% phosphoric acid solution. 10 pL of the reaction are then applied to a P30 filter and washed three times for 5 minutes in 75 mM phosphoric acid and once in methanol before drying and scintillation counting. Assay principle for cell testing of cKIT mutant inhibitors

[00186] The GIST430 cell line expressing the constitutively active cKIT receptor tyrosine kinase (Δ560-576 deletion) and the imatinib-resistant GIST430 / 654 cell line expressing the mutated constitutively active cKIT receptor tyrosine kinase (Δ60-576 deletion and V654A point mutation) were used to evaluate the cellular potency of the compounds. The cellular activity of the mutant cKIT was determined by the degree of cKIT autophosphorylation at tyrosine 307 using a Luminex-based bead assay. GIST430 cells were seeded at a rate of 22,000 cells per well in a 96-well plate in 100 µl of medium (85% IMDM / 15% FCS), and GIST430 / 654 cells were seeded at a rate of 25,000 cells per well in a 96-well plate in 100 µl of medium (85% IMDM / 15% FCS supplemented with 100 nM Imatinib). The following day, the compounds were added in a serial dilution over 45 min.Next, the cells were lysed with 90 µl of lysis buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 1.5 mM MgCb x 6H2O, 0.4 mM EDTA, 1% Triton-X-100, 1% Phosphatase Inhibitor II, 20 mM β-Glycerol Phosphate, 0.1% Protease Inhibitor Cocktail III, 0.01% Benzonase) and lysed. Petition 870260069920, dated 07 / 14 / 2026, page 65 / 519 59 / 219 were cleaned by centrifugation through a 96-well filter plate (0.65 µm). Samples were incubated with Luminex beads coupled with a total anti-cKIT antibody overnight at 4°C under gentle shaking. For the detection of phospho-Y307-cKIT, a phospho-specific antibody and a species-specific PE-labeled secondary antibody were added. The amount of phospho-Y307cKIT was determined on a Luminex 200 instrument measuring 100 events per well in 60 seconds.

[00187] Counts of samples treated with compounds were calculated as a percentage of control samples treated with solvent (0.3% DMSO). Dose-response curves were fitted and IC50 values ​​were determined using Genedata Screener software. Determination of the efflux ratio (ER) in Caco-2 cells

[00188] The efflux ratio of the test compounds was determined in the human epithelial colorectal adenocarcinoma cell line Caco-2 (clone TC7) using evident permeability calculation (Papp). Cell monolayers were differentiated in vitro for 14 days prior to the experiment. Subsequently, the test compound (in HBSS pH 7.4 at a final concentration of 1 pM) was applied to the donor side while HBSS buffer (pH 7.4) was added to the recipient wells. The final DMSO concentration at incubation did not exceed 1%. The plate was then incubated in a 5% CO2 incubator (37°C, 100% humidity). At the end of the 2-hour incubation period, a 50 pL sample was removed from the donor and recipient wells and diluted 1:1 with equal volumes of acetonitrile for LC-MS / MS analysis. The LC-MS / MS analysis used a one-point calibration method from a 1 pM standard solution diluted 1:1 with an equal volume of acetonitrile (consistent with the test samples).

[00189] The data were used to calculate the evident permeabilities of the compounds in the apical-to-basolateral (Papp, AB) and basolateral-to-apical (Papp, BA) directions at a concentration of 1 pM in duplicate. The Papp values ​​were calculated from the concentrations in the donor and acceptor compartments using the following formula: _ ACrccVrec6appAt A-Co Petition 870260069920, dated 07 / 14 / 2026, p. 66 / 519 60 / 219

[00190] The outflow rate was calculated according to the following formula: ER =Papp,BAPapp,AB

[00191] Papp = obvious permeability through the cell monolayer (10⁻⁶ cm / s)

[00192] ACrec / At = Change in receptor concentration over time (nM / s)

[00193] Vdon, Vrec = Donor / recipient cavity volume = 0.25 mL (apical) or 0.75 mL (basolateral)

[00194] Odon, Cacc—Concentration in donor cavity I recipient at the end of the experiment (nM)

[00195] cto.don = Concentration in the donor at the very beginning of the experiment (nM)

[00196] A = Surface area of ​​the cavity membrane = 0.33 cm2 Solubility determination

[00197] In a 96-well filtration plate, 2 pL of a 10 mM solution of the test compound in DMSO are added to 98 pL of 20 mM Sorensen phosphate buffer at pH 7.4. The mixture is incubated at room temperature for 120 min while being stirred at 250 rpm followed by centrifugation at 2500 rpm for 3 min. After dilution by a factor of 2, the concentration of the test compound is determined by HPLC / UPLC with detection at a suitable wavelength and by comparison with a corresponding compound standard. EXAMPLES

[00198] As represented and described in the examples below, in certain exemplary embodiments, the compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods represent the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one skilled in the art, can be applied to all compounds and subclasses and species of each compound, as described herein. Petition 870260069920, dated 07 / 14 / 2026, p. 67 / 519 61 / 219

[00199] The following data, determined by the assays described above and presented in Tables 2 and 3 below, illustrate the potency of the embodiments of the present invention in terms of cKit (V654A), respectively, of the inhibition of GIST 430 / 654. As evident from the Tables, the compounds have excellent ICso values, many in the low nanomolar range. Furthermore, the compounds are selective, particularly compared to the closely related FLT3 kinase (fms as tyrosine kinase 3). The embodiments that were tested against a broader panel of kinases, including JAK, showed very good selectivity on these kinases as well.

[00200] In addition to excellent inhibitory potencies, certain preferred embodiments of the present invention have been found to have a balance of promising pharmacokinetic properties, including bioavailability, as determined experimentally by solubility and efflux, and acceptable to excellent values ​​relative to unwanted blockade of the hERG potassium channel. The results of the experimental efflux measurements are given in Table 4 below.

[00201] Exemplary modalities A8, A12, A15, A60, A73, A75, A83, A84, A99, A100, A102, A120, A149, A153, A154, A156, A168, A170, A212, A242 and A252 were determined to have a favorable solubility of at least 25 μM. Petition 870260069920, dated 07 / 14 / 2026, page 68 / 519 CM CM CO ω oo '5 oo ro E ω oo 05 Q Table 2. Inhibition (IC50) of c-KIT (V654A) and GIST 430 / 654 of Compounds of Formula 1 GIST 430 / 654 IC50 [M] 2.1E-07 0 LLJ in Έ— with 0 LLEJ-0 CO8,0 2.6E-08 CO O LLJ m co' 6.5E-08 OR LLJ CO CO 6.1E-08 2.5E-07 3.4E-07 4.3E-07 2.2E-07 2.7E-07 0 LLJ — 3.0E-07 CM5 OR c-4KIT) co 0 LLJ O Έ— CD O LLJ CO in 6,9E-09 CD O LLJ CO cd' co 0 LLJ Έ— Έ— CO O LLJ m Έ— CD O LLJ CO 2.1E-08 CD O LLJ Έ— in co 0 LLJ LLJ Έ CM O— CD O LLJ CO CD O LLJ CD with 0 LLJ m — Compound No.IO CO — co co — CO — co co — CD CO — 0 — Έ— — CM — co — — m — CO — — CO — CD — O m — — m — GIST 430 / 654 IC50 [M] 2,4E-07 5,5E-08 0 LLJ CO Έ— 2,6E-06 co 0 LLJ CO 0 LLJ Έ— 0 LLJ m co 0 LLJ O CO 0 LLJ O in 0 LLJ CD Έ— co 0 LLJ O Έ— 0 LLJ Έ— co 0 LLJ Έ— Έ— 2,3E-06 2,0E-07 0 LLJ CO — c-KIT (V654A) IC50 [M] co 0 LLJ CM Έ— 8,6E-09 CD O LLJ CO CD O LLJ m in CD O LLJ CO CD O LLJ CM co' CD 0 LLJ CO CD O LLJ 2,3E-08 CD O LLJ CM cm' co 0 LLJ CO Έ— co 0 LLJ m Έ— co 0 LLJ co' 0 LLJ O — CD O LLJ m in 0 LLJ CM CO CD O LLJ CO CO Composto No. Έ— T — CM co CO CO co CD 0 — Έ— — CM — co — — m — CO —. Petição 870260069920, de 14 / 07 / 2026, pág. 69 / 519 63 / 219 GIST 430 / 654 IC50 [M] 3.7E-07 ο LLI CXI Ε— ΙΟ Ο LLI Ο CO CO Ο LLI Ο Ο LLI Ο Ο LLI ΧΓ Ε— 1.0E-06 O LLJ CO Ε— O LLJ CO Ε— CO O LLJ CD Ε— 2.6E-07 CO O LLJ Ο Ο O LLJ CXI Ε— 5.0E-07 6.3E-07 3.0E-07 3.3E-07 CO O LLJ Ο Ο co o LLJ Ο ο Ο Ο c-KIT (V654A) cd ο LLI co co CD Ο LLI χτ ω ο LLI 00 Ε— co ο LLJ CXI cd' Ο LLI 00 Ε— co ο LLI CO co' co ο LLI CO Ε— CO O LLJ CO co' co o LLJ CO co' co o LLJ CXI CXÍ CD O LLJ XT co o LLJ LO co' CD o LLJ O cd' CD O LLJ O CXÍ CD O LLJ O XT CD O LLJ LO co o LLJ CXÍ co o LLJ CXI co' co o LLJ CO co' CO O LLJ CO IO CD O LLJ CO co' CD O LLJ co' Composto No.CXI ιό — co ΙΌ — χΓ ΙΌ — ΙΌ ΙΌ — co ΙΌ — LO — co ΙΌ — CD LO — O CO — Έ— co — CXI CO — CO CO — xr co — LO CO — CO CO CO — CO — CO CO — CD CO — O — — — CXI — CO — IC50 [Μ] GIST 430 / 654 ο LLI Έ— Έ— ο LLI Ο CXÍ CO ο LLI Έ— ο LLI ΙΌ co' co ο LLI CO ΙΌ co ο LLI CO co' o LLJ Έ— cxi o LLJ CO Έ— CO o LLJ XT Έ— o LLJ CXI Έ— o LLJ CO Έ— o LLJ Έ— co' co o LLJ CO o LLJ CXI — o LLJ XT o LLJ CD co' o LLJ LLJ ΙΌ ΙΌ CD Ο LLI 00 o LLJ CD XT CD O LLJ XT XT co o LLJ CO — CO O LLJ CXI ΙΌ CO O LLJ — CD O LLJ CXI XT CO O LLJ ΙΌ — co o LLJ LO ΙΌ Composto No. — co — CD — Ο 04 Έ— 04 04 04 CO 04 xr 04 LO 04 CO 04 04 CO 04 CD 04 O CO Έ— CO CXI CO co co XT co ΙΌ co CO co co CO <. Petição 870260069920, de 14 / 07 / 2026, pág. 70 / 519 64 / 219 GIST 430 / 654 IC50 [M] o LLI 00 xG OO o LLI xG 00 3.4E-08 OO o LLJ xt 2.4E-08 OO O LLI O LLI Ε— Ε— 9.2E-08 2.7E-08 CO O LLJ CO 5.9E-08 CO O LLJ O co' O LLJ CO co' O LLJ CD Ε— O LLJ CO — o LLJ — CO O LLJ CD co' 6.7E-08 2.6E-08 9.2E-08 CO O LLJ CM o ΙΌ Ο c-KIT (V654A) o LLJ co cT cd o LLI co CD CD Ο LLI CXI CO co ο LLI Ε— OO Ο LLI CD Ε— CD Ο LLJ Ε— co CD Ο LLI 00 ΟΟ o LLI ΙΌ Ε— co o LLJ Ε— Ε— CD O LLJ CO O LLJ O 04 CD O LLJ co' CD O LLJ O CD O LLJ IΕ CD O LLJ CO cd' CD O LLJ CO cd' CD O LLJ CO co' CD O LLJ CM CN co o LLJ CO CN co o LLJ CD — CD O LLJ — co' CD O LLJ cd' Composto No.— ΙΌ — CO — — ΟΟ — CD — Ο ΟΟ — Έ— ΟΟ — CM CO — CO CO — xT CO — CO CO — CO CO — CO — CO CO — CD CO — O CD — — CD — CM CD — co CD — xr CD — CO CD — IC50 [Μ] GIST 430 / 654 ο LLI χΓ (D co ο LLI Έ— Έ— co ο LLI CO Έ— ΟΟ ο LLI CD ΙΌ ο LLJ Έ— ΙΌ ΟΟ ο LLI ΙΌ cd o LLJ CD Έ— o LLJ xT CO o LLJ CD co' o LLJ CD xT co o LLJ CO ΙΌ o LLJ ΙΌ Έ— o LLJ xT co' o LLJ CO co' co o LLJ O ΙΌ o LLJ CN o LLJ ΙΌ — co o LLJ CM co' co o LLJ O ο ΙΌ Ο c-KIT (V654A) 00 Ο LLJ ΟΝ ΟΟ ο LLI co CO ΟΟ ο LLI CO xT CD Ο LLI 00 Έ— ο LLI CO CN ΟΟ Ο LLJ Cxi ο LLI 00 Έ— CD Ο LLJ LLJ CM - WHAT ABOUT LLJ CM CN CD O LLJ CO CO O LLJ — — co o LLJ CD — CO O LLJ — — CD O LLJ O co' Composto No. cd co ο Έ— CXI CO χτ ΙΌ CO CO CD O CO Έ— CO 04 CO CO CO xr CO ΙΌ CO CO CO ΙΌ co CO CD CO O <. Petição 870260069920, de 14 / 07 / 2026, pág. 71 / 519 65 / 219 GIST 430 / 654 IC50 [Μ] ο LLI χΓ Έ— ο LLJ ΙΌ Έ— ο LLI CXI Έ— o LLJ O Έ— o LLJ CD Έ— 9,9E-08 2,0E-LL o CXJ o LL Έ— Έ— or LLJ O Έ— 2,3E-07 with LLJ CO or LLJ O Έ— with LLJ LO with 2.1E-07 or LLJ CO Έ— or LLJ CO CD co co CD CD co CD CD co CD co co co CD CD ο ο ο O ooo O oo OO o OO o O ooo OO LLI LLI LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ [x””. [x””. CO [x””. CO CXI OR Έ— [X””. CO CO LO O CO CO Έ— O CXI CO ο Έ— Έ— Έ— CD CXI Έ— Έ— CD Έ— Έ— [x- co CD co Έ— fx- Έ— CXI Έ— co fx-. ο ω ο CL with co CD or Έ— CXI CO xr CO with [X·^. with CD or Έ— CXI with xr LO with [X·^.cd cd cd CD ooo O o O ooo O Έ— Έ— Έ— Έ— Έ— Έ— — — ο ο — — — — CXI CXI CXI CXI CXI CXI CXI CXI CXI CXI CXI 130 / 654 IC50 [Μ] co co co co co co co co co co co co co co co co co co >1 ο ο oooooooooo O oooooooo / Λ LLI LLI LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ χΓ ΟΙ χΓ XT CO CD CO xr CO XT CO CD CXI OR CD CO CO [X»». [X””. 0 co co co co xr Έ— co co CXI CXI xr CO CD xr CO CD xr LO LO xr b- CXI co CD CXI V654A) IC50 [Μ] cd cd co CD co CD CD CD co CD CO CD CD CD co CD CD CO CD ο ο ο OJ OOOOJ LO ooo LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ ιό Έ— CXI [x»». Έ— CO CO [X»». CO Έ— with CXI O with LO CO xr Έ— LO XT [X»». CXI 1 ο co xr Έ— co Έ— b- xr CO Έ— CXI xr b- xr xr co b- Έ— CD Έ— co CXI CD ο ω ο CL Έ— οι co xr CO co X·^. CO CD or Έ— CXI with xr LO with [X·^. CO CD o — CXI Ο ο co co co co CO co co co CO [x-. [x«— [x--. [x--. [X·-. [x·-.[x·-. [x·-. [x·-. [x·-. co co CO ο ζ. Petition 870260069920, dated 07 / 14 / 2026, page 72 / 519 66 / 219 GIST 430 / 654 IC50 [Μ] 2,0Ε-07 O LLJ O Έ— o LLJ Έ— o LLJ O co o LLJ CO cd' o LLJ CD Έ— co o LLJ CD cd' co o LLJ in CO O LLJ Έ— in CO O LLJ CO CO O LLJ O LLJ CO CO 6,3E-08 O LLJ CO cm' O LLJ Έ— O LLJ CO Έ— CO O LLJ O CO O LLJ co' co o LLJ co o LLJ ΙΌ CO 6,2E-08 9,4E-08 V654A) IC50 [Μ] co co co CO CO CO CD co CD CD CO CO co co co CD CD CD CD CD CD CD ο oo OO o O o o OOOO ooo OOOOOOO LLI LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ Έ— Έ— Έ— CO CO CM CO Έ— CO CO CO CO CO CO CM ο Έ— Έ— Έ— Έ— Έ— co Έ— co Έ— co CM Έ— CM co co Έ— co co ο ω ο CL co CD o Έ— CM co CO co co CD O Έ— CM co CO co co CD r Έ— Έ— CM CM CM CM CM CM CM CM CM CM CO co CO co CO co co co CO ο ο CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CM CN Ο Ζ 130 / 654 IC50 [Μ] CO CO CO CO CO CO CO CO CO CO CO CO >1 Ο OOOOOOOOOOOOOO o OOOOOO / Λ LLI LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ Έ— ΙΌ ΙΌ Έ— O CDCM CO CO Έ— Έ— Έ— CO CO CM CO CO CO CM 0 co co Έ— CO co co CM b- co Έ— co CM co CM CD co co Έ— Έ— — V654A) IC50 [Μ] co CD CD CD CO co CD CO CD CD CD CD CD CD CD co CD CD CD ο OOO oo OOOO o OOOOOOO o OOO LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ LLJ ΙΌ CO ΙΌ O Έ— CM CO O CO CM CO CO CO CD CO CO CM CM CO CO O 1 ο CM CM co CO Έ— Έ— co Έ— co co Έ— co CD CM co co co CD CM CD CD b- ο ω ο CL O Έ— CO CO CO CO co CD o Έ— CM co CO CO co CD O o CN O o Ο ο CO CO co co co co CO CD CD CD CD CD CD CD CD CD — — O — — — ο ζ <£ Petição 870260069920, de 14 / 07 / 2026, pág. 73 / 519 67 / 219 GIST 430 / 654 IC50 [M] ΙΌ Ο LLI Ο Έ— co ο LLI Ο Ύ co o LLJ co' co o LLJ CO CO co o LLJ CM CO o LLJ CO Έ— o LLJ o LLJ Έ— co o LLJ co o LLJ o LLJ O — o LLJ CO — co o LLJ CO ΙΌ CO o LLJ CO CO CO o LLJ CO co o LLJ ΙΌ ο ΙΌ Ο c-KIT (V654A) cd ο LLI co CD Ο LLI ΙΌ Φ CD Ο LLI Έ— Έ— CD Ο LLJ CO co o LLJ Έ— CM CO O LLJ CO Έ— CD O LLJ O co' CD O LLJ CO co o LLJ Έ— cm' CO O LLJ co' o LLJ Έ— Έ— CD O LLJ O cm' CD O LLJ CM cm' CD O LLJ CO CO co o LLJ cm' co o LLJ ΙΌ — co o LLJ CM — co o LLJ CO — CD O LLJ — ΙΌ CD O LLJ CO CO CD O LLJ O CO CD O LLJ — cm' Composto No.ο < Έ— C4 cm C4 CO CM CM ΙΌ CM CO CM CM co CM CD CM o ΙΌ CM Έ— ΙΌ CM CM ΙΌ CM CO ΙΌ CM ΙΌ CM ΙΌ ΙΌ CM co ΙΌ CM ΙΌ < CO ΙΌ < CD ΙΌ < O CO < — co < ​​IC50 [Μ] GIST 430 / 654 ο LLJ CM Έ— Ο LLJ CO Ο LLJ CM Έ— CO Ο LLJ Ο Ύ CO O LLJ CD CO O LLJ CO CO O LLJ CO cm' O LLJ CM CO CO O LLJ CO co' CO O LLJ CD CO O LLJ CO CO O LLJ O CO CO O LLJ O CO O LLJ CM CO CO O LLJ CM ΙΌ CO O LLJ CO O LLJ CO cm' CO O LLJ CO ΙΌ CO O LLJ CO ΙΌ O LLJ — cm' o LLJ — ο ΙΌ Ο c-KIT (V654A) cd ο LLI ΙΌ CD CD Ο LLJ ΙΌ cd' co ο LLI CO Έ— CD Ο LLJ CO CO CD O LLJ ΙΌ O LLJ Έ— Έ— CD O LLJ CD CO O LLJ O CO O LLJ Έ— CD O LLJ cd' CD O LLJ CO CD O LLJ CO Έ— CD O LLJ O CO CD O LLJ CD O LLJ CO CD O LLJ CD cm' CD O LLJ CO CO CO O LLJ CO cm' CD O LLJ CO ΙΌ CD O LLJ co o LLJ CO cm' co o LLJ CO — Composto No. ΙΌ Ο — CO Ο — ο — CO O — CD O — o Έ— — Έ— Έ— — CM Έ— — co Έ— — — — CO Έ— — co Έ— — Έ— — CO Έ— — CD — — O CM — — CM — CM CM — CO CM — CM — CO CM — co CM —. Petição 870260069920, de 14 / 07 / 2026, pág. 74 / 519 68 / 219 GIST 430 / 654 IC50 [Μ] CO o LLJ CO 6,6E-08 co o LLJ CO CO co co o LLJ CO o LLJ CO Έ— 6,3E-08 o LLJ xT — c-KIT (V654A) IC50 [Μ] CD O LLJ O in CD O LLJ CO CN CD O LLJ CO Έ— CD O LLJ CO CO CD O LLJ CD CD O LLJ xT xT co o LLJ — — Composto No. CM co < ​​CO CO < xr co < ​​m co < ​​CO CO < CO < co co < ​​GIST 430 / 654 IC50 [M] o LLJ O Έ— O LLJ CO Έ— co o LLJ CM CO co o LLJ O xT CO O LLJ CD CO CO O LLJ CO xT co o LLJ O CO CO o LLJ CM in c-KIT (V654A) IC50 [M] CD O LLJ CO CD O LLJ CD cd' CD O LLJ Έ— co CD O LLJ m co CD O LLJ m CD O LLJ O in CD O LLJ CO CN CD O LLJ CO xT Composto No. CN — CO CM — CD CM — o co — Έ— co — CM CO — CO CO — xT CO — Petição 870260069920, de 14 / 07 / 2026, pág. 75 / 519 Table 3. Inibição (IC50) de GIST 430 de compostos da Fórmula I GIST 430 IC50 [M] CD o LLJ CD O LLJ CN CD O LLJ 00 Έ— CD O LLJ CD Έ— CD O LLJ Έ— CD O LLJ 'T CD O LLJ CO 'T CD O LLJ Έ— Έ— CD O LLJ CO CO CD O LLJ Έ— LO CD O LLJ Έ— CO O LLJ O Έ— ó zo Composi Έ— CM CO LO CM CD LO CM o CO CM Έ— CO CM CM CO CM CO CO CM ^r CO CM ib CO CM cb CO CM CO CM CO CO CM Φ Ό Çü Ό c <φ b CL '05 o LO O CO o CD O CD O CO O CD O CD O CO O CD o CO O CO o CD O CD O o 70 Cü ω o LLJ CO LLJ CO LLJ CO LLJ CM LLJ CD LLJ LLJ Έ— LLJ LLJ CM LLJ LO LLJ CO LLJ CO Φ Φ 0 y M- Έ— CD CO LO CM CM Έ— CO Έ— cn P ω o CL E r> r> CO Έ— Έ— CO Έ— o LO Έ— Έ— LO Έ— CO LO — ib LO Έ— ÕM Έ— CO Έ— — CO Έ— LO CO Έ— Φ N Φ > N Φ 70 Cü OZ Ó 'c CD ω O LO O CD O CD O CD O CD O CD O CD O CD O CD O CD O CD O CD O CD O o 70 o E ω o — co LLJ CD LLJ LLJ CD LLJ Έ— LLJ CO LLJ Έ— LLJ LLJ CO LLJ CO LLJ O LLJ LO LLJ CO ω ω o $ CO CM CM CO CM CO CO CO Έ— CM Ό o LU Composi No O CO CM CO LO cb CO CD ^r oo ib CO OT CM O — 00 o — O CM — to ' ό — X τ— CÜ ο Έ CD o LO O CD O CD O CD O CD O CO O CD O CD o CD O CD O CD OCD O CD O ω co ο ω o — CO LLJ CM LLJ LLJ CO LLJ CO LLJ O LLJ Έ— LLJ LLJ O LLJ CM LLJ CM LLJ CO LLJ CD LLJ sj· o CO M- LO CM CO CM M- Έ— CO o Õ >Φ ω o CL E oo — CM LO CO CD Έ— — CO — 00 — CM CO LO Φ C Φ CL O z 11 1 Petition 870260069920, dated 07 / 14 / 2026, page 76 / 519 Table 4 Efflux ratio m co O oo O o LO CO o Έ— co co Ol co LO CO co CD o — Ol LO Ol OI CO co co co co LO LO LO LO LO d Ol Ol Ol Ol Ol Ol Ol Ol Ol Ol Ol Ol Ol Ol CN CN CN CN CN z Efflux ratio O m OO m LO CO CD Ol LO CO co CD O Έ— Ol co LO CO CO CO CO CO CO CD CD CD CD CD CD CD CD O o O oo OOO d — — — — — — — — — — — Ol Ol Ol Ol Ol Ol Ol CN z Efflux ratio mmmm OO LO Έ— cd oo Ol o „80 14 20 Έ— co co co O Έ— 44 46 „Ztz 48 50 — LO d CO cd cd — Έ— — — — — — — — — — — — — — — z <£ Efflux ratio co co CD Έ— co Ol co Ol co — co o — Ol d — Ol 'CT co — — — — Ol Ol co co LO LO co co co z Petition 870260069920, dated 07 / 14 / 2026, page 77 / 519 71 / 219 Efflux ratio mm No. A258 A259 A260 A261 A262 A263 A264 A265 A266 A267 A268 Efflux ratio OO mm OO CQ No. A211 A212 A213 A214 A215 A216 A217 A218 A219 A220 A221 OI OI OI A223 A224 Efflux ratio OOOOOO No. A153 A158 A165 A166 A167 A168 A172 A173 A175 A176 A177 A178 A179 CO CO — Efflux ratio OO >15-50; C >50 No. A63 A64 A65 A67 A71 A73 A74 A75 A76 A77 A78 A79 o 00 A84 A: < 15; B: Petition 870260069920, dated 07 / 14 / 2026, page 78 / 519 72 / 219 Synthesis of Intermediates Arylmethylamines Synthesis of 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-methanamine (D1)

[00202] To a solution of N-Boc-4-bromobenzylamine (29.4 g, 103 mmol) in 1,2-dimethoxyethane (275 mL) are added 1-methyl-1H-pyrazol-4-pinacol boronic acid ester (25.5 g, 122.6 mmol), water (105 mL) and sodium carbonate (16.3 g, 154 mmol) and the resulting suspension is flooded with argon. Under argon, bis(triphenylphosphine)palladium(II) chloride (2.9 g, 4.13 mmol) is added. The mixture is heated to 80°C and stirred at this temperature for 2 days. The reaction mixture is allowed to reach room temperature and treated with water and ethyl acetate. The organic phase is separated and the aqueous phase is extracted twice with ethyl acetate. The combined organic phases are dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with cyclohexane / ethyl acetate as eluent to give tert-butyl N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}carbamate as a pale yellow crystalline solid; UPLC / MS 0.709 min, [M+H]+288.

[00203] 1H NMR (400 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.81 (s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.33 (t, J = 6.3 Hz, 1H), 7.20 (d, J = 8.1 Hz, 2H), 4.09 (d, J = 6.2 Hz, 2H), 3.85 (s, 3H), 1.39 (s, 9H).

[00204] To a solution of tert-butyl N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}carbamate (24.7 g, 85.6 mmol) in 1,4-dioxane (170 mL) a solution is added to 4 N hydrogen chloride in dioxane and the mixture is stirred for 18 hours at temp Petition 870260069920, dated 07 / 14 / 2026, p. 79 / 519 73 / 219 ambient temperature. The resulting precipitate is filtered, washed with tert-butyl-methyl ether and dried under vacuum to give 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-methanamine dihydrochloride as a pale yellow powder; UPLC / MS 0.286 min, [M-NH2Γ 171.

[00205] To a solution of 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-methanamine dihydrochloride (22.4 g, 86.0 mmol) in water (500 mL) 2 N aqueous sodium hydroxide (129 mL) is added dropwise under stirring. The resulting precipitate is filtered, washed with water and dried for 3 days at 50°C under vacuum to give 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine as a pale brown powder; UPLC / MS 0.286 min, [M-NH2]4· 171.

[00206] 1H NMR (400 MHz, DMSO-d6) δ 8.08 (d, J = 0.8 Hz, 1H), 7.82 (d, J = 0.8 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 3.85 (s, 3H), 3.68 (s, 2H), 1.76 (s, 2H). Synthesis of 1-[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenylmethanamine (D2)

[00207] To a solution of 4-bromo-2-methyl-2H-1,2,3-triazole (3.23 g, 19.9 mmol) in 1,4-dioxane (40 mL) are added 4-N-(Boc)aminomethylphenylboronic acid (5.24 g, 20.9 mmol), water (4.0 mL) and potassium hydrogen carbonate (4.0 g, 40.0 mmol) and the resulting suspension is flooded with argon. Under argon, bis(triphenylphosphine)palladium(II) chloride (710 mg, 1.01 mmol) is added. The mixture is heated to 80°C and stirred at this temperature for 18 hours. The reaction mixture is allowed to reach room temperature and treated with water and dichloromethane. The organic phase is separated and the aqueous phase is extracted twice with dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with cyclohexane / ethyl acetate as eluent to give tert-butyl N-{[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}carbamate as a white crystalline solid; UPLC / MS 0.739 min, [M-BocNH2]+172. Petition 870260069920, dated 07 / 14 / 2026, page 80 / 519 74 / 219

[00208] 1H NMR (400 MHz, DMSO-d6) δ 8.17 (s, 1H), 7.77 (d, J = 8.1 Hz, 2H), 7.38 (t, J = 6.2 Hz, 1H), 7.31 (d, J = 8.0 Hz, 2H), 4.18 (s, 3H), 4.15 (d, J = 6.2 Hz, 2H), 1.40 (s, 9H).

[00209] tert-Butyl N-{[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}carbamate (3.2 g, 11.1 mmol) is dissolved in a 4 N solution of hydrogen chloride in dioxane (75 mL) and the mixture is stirred for 18 hours at room temperature. The resulting precipitate is filtered and washed with dichloromethane. The residue is treated with 1 N aqueous sodium hydroxide until a basic pH value of 14 is reached. The solids are filtered and washed with water. The residue is captured in acetonitrile and filtered. The filtrate is evaporated and dried under vacuum to give 1-[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methanamine as a white crystalline solid; UPLC / MS 0.302 min, [M-NH2]+172.

[00210] 1H NMR (500 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.75 (d, J = 8.2 Hz, 2H), 7.51 - 7.02 (m, 2H), 4.18 (s, 3H), 3.72 (s, 2H), NH2 peak not visible. [00211 ] 4-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-benzylamine (D3)

[00212] This compound is prepared similarly to D1; whitish solid; HPLC / MS (A) 0.93 min, [M+H]+214.

[00213] 1 -{4-[1 -(2-methoxyethyl)-1 H-pyrazol-4-yl]phenyl}methanamine (D4)

[00214] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+215.

[00215] 1 -[4-(1-methyl-1 H-imidazol-4-yl)phenyl]methanamine (D5)

[00216] This compound is prepared similarly to D2; yellow solid; HPLC / MS Petition 870260069920, dated 07 / 14 / 2026, p. 81 / 519 75 / 219 [M+H]+188.

[00217] 1 -{4-[1 -(cyclopropylmethi 1)-1 H-pyrazol-4-yl]phenyl}methanamine (D6)

[00218] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+228.

[00219] 1 -(4-{1 -[2-(morphoIin-4-yl)ethyl]-1H-pyrazol-4-yl}phenyl)methanamine (D7)

[00220] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+287.

[00221] 1-(4-{1-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrazol-4-yl}phenyl)methanamine (D8)

[00222] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+271.

[00223] 1 -[3-(1-methyl-1 H-pyrazol-4-yl)phenyl]methanamine (D9)

[00224] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+188.

[00225] 1-[3-fluoro-4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine (D10)

[00226] This compound is prepared similarly to D1; whitish solid; Petition 870260069920, dated 07 / 14 / 2026, p. 82 / 519 76 / 219 UPLC / MS 0.315 min, [M-NH2]+189.

[00227] 2-{4-[4-(aminomethyl)phenyl]-1H-pyrazol-1-yl}etan-1-ol (D11)

[00228] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M-NH2]+201.

[00229] 1-[4-(1-methyl-1 H-1,2,3-triazol-4-yl)phenyl]methanamine (D12) n=n

[00230] This compound is prepared similarly to D2; yellow solid; HPLC / MS [M+H]+189.

[00231] Synthesis of 1-{4-[1-(oxetan-3-yl)-1 H-pyrazol-4-yl]phenyl}methanamine (D13)

[00232] To a solution of tert-butyl N-({4-[1-(oxetan-3-yl)-1H-pyrazol-4-yl]phenyl}methyl)carbamate (168 mg, 0.51 mmol), which is prepared similarly to the first reaction step for intermediate D1, in dichloromethane (5 mL) is added trifluoroacetic acid (393 pl, 5.1 mmol) and the mixture is stirred for 3 hours at room temperature. The reaction mixture is treated with saturated aqueous sodium carbonate solution. The organic phase is separated and evaporated to give 1-{4-[1-(oxetan-3-yl)1H-pyrazol-4-yl]phenyl}methanamine as a pale yellow solid; UPLC / MS 0.307 min, [M-NH2]+213.

[00233] 1-[4-(4-methoxypyrimidin-2-yl)phenyl]methanamine (D14) Petition 870260069920, dated 07 / 14 / 2026, p. 83 / 519 77 / 219

[00234] This compound is prepared similarly to D2; whitish crystalline solid; HPLC / MS (A) 0.89 min, [M+H]+216.

[00235] 1H RMN (500 MHz, DMSO-d6) δ 8.63 (d, J = 5.2 Hz, 1H), 8.14 (d, J = 8.3 Hz, 2H), 7.68 (d, J = 5.2 Hz, 1H), 7.50 (d, J = 8.1 Hz, 2H), 3.99 (s, 3H), 3.79 (s, 2H), 1.90 (bs, 2H).

[00236] 4-[4-(aminometil)fenil]-1-metil-1 H-pirazol-3-amina (D15)

[00237] This comes with a similar input to D2; solid amarelo; HPLC / MS [M+H]+203.

[00238] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[5-( 1 -metil-1 H-pirazol-4-il)tiofen2-il]metil}pirimidin-4-amina (D16)

[00239] This comes with a similar input to D1; Solido esbranquiçado; HPLC / MS(A) 0.84 min, [M-NH2]+177.

[00240] 1H RMN (400 MHz, DMSO-d6) δ 7.92 (d, J = 0.7 Hz, 1H), 7.62 (d, J = 0.8 Hz, 1H), 6.94 (d, J = 3.5 Hz, 1H), 6.80 (dt, J = 3.5, 1.0 Hz, 1H), 3.84 (d, J = 1.1 Hz, 2H), 3.83 (s, 3H), 1.89 (bs, 2H).

[00241] 1-[4-(2-methyl-2H-1,2,3,4-tetrazol-5-il)fenil]metanamina (D17) N=n,

[00242] This compound is prepared similarly to D2; yellow solid; UPLC / MS Petition 870260069920, dated 07 / 14 / 2026, p. 84 / 519 78 / 219 0.294 min, [M-NH2 -N2]+ 145.

[00243] Synthesis of 1-(4-{8-oxa-3-azabicyclo[3,2,1]octan-3-yl}phenyl)methanamine (D18)

[00244] To a stirred solution of 4-fluorobenzonitrile (474 ​​mg, 3.92 mmol) and 8oxa-3-azabicyclo[3,2,1]octane (443 mg, 3.92 mmol) in DMF (8 mL) is added cesium carbonate (2.55 g, 7.84 mmol). The resulting mixture is stirred for 16 hours at 80°C. The resulting mixture is filtered, the filter mass is washed with methanol, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography, eluted with PE / EtOAc (1:1) to give 4-[8-oxa-3-azabicyclo[3,2,1]octan-3-yl]benzonitrile as a white solid; HPLC / MS [M+H]+215.

[00245] To a stirred solution of 4-[8-oxa-3-azabicyclo[3,2,1]octan-3-yl]benzonitrile (165 mg, 0.77 mmol) in THF (8 mL) is added lithium aluminum hydride (116 mg, 3.06 mmol) at 0°C under a nitrogen atmosphere. The resulting mixture is stirred for 3 hours at 25°C under a nitrogen atmosphere. The reaction is abruptly stopped by the addition of water (10 mL) at 0°C. The aqueous layer is extracted with ethyl acetate (3 x 10 mL). The organic phase is evaporated under reduced pressure to give 1-(4-[8-oxa-3-azabicyclo[3,2,1]octan-3-yl]phenyl)methanamine as a white solid; HPLC / MS [M-NH2]+202.

[00246] 1 -[4-(1-methyl-1 H-imidazol-5-yl)phenyl]methanamine (D19)

[00247] This compound is prepared similarly to D1; orange-red resin; UPLC / MS 0.113 min, [M+H]+188. Petition 870260069920, dated 07 / 14 / 2026, page 85 / 519 79 / 219

[00248] 1H NMR (400 MHz, DMSO-d6) δ 7.67 (d, J = 1.3 Hz, 1H), 7.41 (s, 4H), 7.00 (d, J = 1.2 Hz, 1H), 3.75 (s, 2H), 3.66 (s, 3H), NH2 peak not visible.

[00249] 1-[4-(6-methylpyridazin-3-yl)phenyl]methanamine (D20)

[00250] This compound is prepared similarly to D2; whitish solid; UPLC / MS 0.288 min, [M+H]+200.

[00251] 1-[4-(6-methylpyridazin-3-yl)phenyl]methanamine (D21)

[00252] This compound is prepared similarly to D2; whitish powder; UPLC / MS 0.299 min, [M-NH2]+183.

[00253] Synthesis of 1 -[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methanamine (D22)

[00254] A 20% ammonia solution in methanol (15 mL) and wet Raney nickel (300 mg) are added to a solution of 4-(2-methyl-1,3-oxazol-4-yl)benzonitrile (369 mg, 2.00 mmol) in methanol (15 mL). The mixture is hydrogenated at a pressure of 5 bar and 60°C. The catalyst is filtered off and the filtrate is evaporated. The residue is triturated with tert-butyl methyl ether to give 1-[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methanamine as a whitish powder; UPLC / MS 0.319 min, [M-NH2]+202.

[00255] 5-[4-(aminomethyl)phenyl]-2-methylpyrimidin-4-amine (D23) Petition 870260069920, dated 07 / 14 / 2026, page 86 / 519 80 / 219

[00256] This compound is prepared similarly to D2; whitish solid; UPLC / MS 0.118 min, [M+H]+215.

[00257] Synthesis of 1-[5-(2-methyl-2H-1,2,3-triazol-4-yl)pindin-2-yl]methanamine (D24)

[00258] Yellow solid; HPLC / MS [M+H]+186.

[00259] 1 -[6-(2-methyl-2H-1,2,3-triazol-4-yl)pindin-3-yl]methanamine (D25)

[00260] This compound is prepared similarly to D24; white solid; HPLC / MS [M+H]+190.

[00261] 1-{4-[2-(2-methoxyethyl)-2H-1,2,3-triazol-4-yl]phenyl}methanamine (D26)

[00262] This compound is prepared similarly to D2; white solid; UPLC / MS Petition 870260069920, dated 07 / 14 / 2026, p. 87 / 519 81 / 219 0.311 min, [M+H]+233.

[00263] Synthesis of 1-[4-(1-cyclopropyl-1H-pyrazol-4-yl)phenyl]methanamine (D27)

[00264] Light yellow oil; HPLC / MS [M+H]+214.

[00265] 1-[4-(3-methoxy-1-methyl-1H-pyrazol-4-yl)phenyl]methanamine (D28)

[00266] This compound is prepared similarly to D2; pale yellow oil; HPLC / MS(B) 0.601 min, [M+H]+218.

[00267] 1H NMR (400 MHz, DMSO-d6) δ 7.92 (s, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.31 - 7.18 (m, 2H), 3.88 (s, 3H), 3.71 (s, 3H), 3.67 (s, 2H), 2.00 (bs, 2H).

[00268] Synthesis of 1-[4-(1,3-oxazol-4-yl)phenyl]methanamine (D29)

[00269] Yellow solid; HPLC / MS [M+H]+171.

[00270] Synthesis of 1 -[4-(3-methyl-1,2-oxazol-5-yl)phenyl]methanamine(D30) Petition 870260069920, dated 07 / 14 / 2026, p. 88 / 519 82 / 219 [00271 ] Yellow solid; HPLC / MS [M+H]+189.

[00272] Synthesis of 1-[4-(5-methyl-1,3-oxazol-2-yl)phenyl]methanamine (D31)

[00273] yellow solid; HPLC / MS [M+H]+189.

[00274] Synthesis of 1 -[4-(1-methyl-1 H-pyrazol-4-yl)phenyl]ethan-1-amine (D32) pd(pph3)4 K2CO3dioxane / water 1000C

[00275] solid brown; HPLC / MS [M+H]+185. Alkoxypyridylamines

[00276] Synthesis of 4-(2-methoxy-ethoxy)-pyridin-2-ylamine (E1) NaH diglima / 160°C Petition 870260069920, dated 07 / 14 / 2026, p. 89 / 519 83 / 219

[00277] Under nitrogen, a reaction flask is charged with diethylene glycol dimethyl ether (20 mL) and sodium hydride (60% suspension in paraffin oil, 915 mg, 23.0 mmol). A solution of ethylene glycol monomethyl ether (1.16 g, 15.3 mmol) in diethylene glycol dimethyl ether (10 mL) is added slowly at room temperature. The mixture is heated to 40°C and stirred at this temperature for 1 hour. 2-Amino-4-chloropyridine (980 mg, 7.62 mmol) is added. The mixture is heated to 160°C and stirred at this temperature for 20 hours. The reaction mixture is allowed to reach room temperature and reduced in volume under vacuum. The residue is treated with water and dichloromethane. The organic phase is separated and the aqueous phase is extracted several times with dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated.The residue is chromatographed on a silica gel column with ethyl acetate / methanol as eluent to give 4-(2-methoxy-ethoxy)pyridin-2-ylamine as a brown solid; HPLC / MS (A) 0.79 min, [M+H]+261.

[00278] 4-[(1,3-dimethoxypropan-2-yl)oxy]pyridin-2-amine (E2)

[00279] The compound is prepared similarly to E1; brown oil; HPLC / MS [M+H]+213

[00280] 4-(oxan-4-yloxy)pyridin-2-amine (E3)ΙΧ^Οχ^ί?ΐ\ΐΗ2

[00281] The compound is prepared similarly to E1; brown oil; HPLC / MS [M+H]+195

[00282] 4-[2-(morpholin-4-yl)ethoxy]pyridin-2-amine (E4)

[00283] The compound is prepared similarly to E1; whitish crystals; HPLC / MS (A) 0.273 min, [M+H]+224. Petition 870260069920, dated 07 / 14 / 2026, page 90 / 519 84 / 219

[00284] 1H NMR (500 MHz, DMSO-d6) δ 7.70 (d, J = 5.8 Hz, 1H), 6.12 (dd, J = 5.8, 2.3 Hz, 1H), 5.95 (d, J = 2.3 Hz, 1H), 5.75 (s, 2H), 4.03 (t, J = 5.8 Hz, 2H), 3.60 3.53 (m, 4H), 2.66 (t, J = 5.8 Hz, 2H), 2.48 - 2.40 (m, 4H).

[00285] 4-(oxolan-3-yloxy)pyridin-2-amine (E5)

[00286] The compound is prepared similarly to E1; brown oil; HPLC / MS [M+H]+181

[00287] 4-(cyclopropylmethoxy)pyridin-2-amine (E6)

[00288] The compound is prepared similarly to E1; white solid; HPLC / MS [M+H]+165

[00289] 4-[2-(dimethylamino)ethoxy]pyridin-2-amine (E7)

[00290] The compound is prepared similarly to E1; yellow solid; HPLC / MS [M+H]+182

[00291] 4-[2-(pyrrolidin-1-yl)ethoxy]pyridin-2-amine (E8)

[00292] The compound is prepared similarly to E1; pale orange solid; UPLC / MS0.113 min, [M+H]+208.

[00293] 1H NMR (400 MHz, DMSO-Ó6) δ 7.70 (d, J = 5.8 Hz, 1H), 6.11 (dd, J = 5.8, 2.3 Hz, 1H), 5.94 (d, J = 2.3 Hz, 1H), 5.76 (s, 2H), 4.00 (t, J = 5.9Hz, 2H), 2.74 Petition 870260069920, dated 07 / 14 / 2026, p. 91 / 519 85 / 219 (t, J = 5.9 Hz, 2H), 2.48 (m, 4H), 1.73 -1.61 (m, 4H).

[00294] 4-[2-(4-methylpiperazin-1-yl)ethoxy]pyridin-2-amine (E9)

[00295] The compound is prepared similarly to E1; pale brown solid; HPLC / MS[M+H]+237.

[00296] 4-[(1-methylpiperidin-4-yl)methoxy]pindin-2-amine (E10)

[00297] The compound is prepared similarly to E1; white solid; HPLC / MS[M+H]+222.

[00298] 4-[(1-methylpiperidin-4-yl)oxy]pindin-2-amine (E11) k^0^^NH2

[00299] The compound is prepared similarly to E1; white solid; HPLC / MS[M+H]+208. Synthesis of 1-[(2-aminopyridin-4-yl)oxy]-2-methylpropan-2-ol (E12) CS2CO3 DMF

[00300] To a solution of 2-aminopyridin-4-ol (200 mg, 1.73 mmol) in DMF (5 mL) are added 2,2-dimethyloxirane (393 mg, 5.18 mmol) and cesium carbonate (1.13 g, 3.46 mmol) and the resulting suspension is stirred for 18 hours at 40°C. The Petition 870260069920, dated 07 / 14 / 2026, page 92 / 519 86 / 219 solids are filtered and washed with dichloromethane. The filtrate is evaporated and chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 1-[(2-aminopyridin-4-yl)oxy]-2-methylpropan-2-ol as a white solid; HPLC / MS [M+H]+183. Synthesis of 2-[4-(oxetan-3-yl)piperazin-1-yl]ethan-1-ol (E13) NaH / diglyma / 150°C

[00301] To a solution of 1-(oxetan-3-yl)piperazine (284 mg, 1.73 mmol) in ethanol (5 mL) are added potassium carbonate (554 mg, 3.98 mmol) and 2-bromoetan-1-ol (524 mg, 3.98 mmol) and the resulting suspension is stirred for 18 hours at 40°C. The solids are filtered and washed with dichloromethane. The filtrate is evaporated to give 2-[4-(oxetan-3-yl)piperazin-1-yl]etan-1-ol as a white solid; HPLC / MS [M+H]+187.

[00302] The subsequent synthesis step is performed similarly to the E1 synthesis to provide 4-{2-[4-(oxetan-3-yl)piperazin-1-yl]ethoxy}pyridin-2-amine as a yellow oil; HPLC / MS [M+H]+279.

[00303] 4-[3-(morpholin-4-yl)propoxy]pyridin-2-amine (E14)

[00304] The compound is prepared similarly to E1; yellow solid; HPLC / MS [M+H]+238. Synthesis of 4-[3-(pyrrolidin-1-yl)propoxy]pyridin-2-amine (E15) Petition 870260069920, dated 07 / 14 / 2026, page 93 / 519 87 / 219 NaH diglima / 100°C

[00305] Under nitrogen, a reaction flask is charged with diethylene glycol dimethyl ether (75 mL) and sodium hydride (60% suspension in paraffin oil, 6.15 g, 154 mmol). 3-(Pyrrolidin-1-yl)propan-1-ol (10.2 g, 79.1 mmol) is added slowly and the mixture is stirred for one hour at room temperature. A solution of 2-amino-4-fluoropyridine (8.87 g, 79.1 mmol) in diethylene glycol dimethyl ether (60 mL) is added dropwise. The mixture is heated to 100°C and stirred at this temperature for 18 hours. The reaction mixture is allowed to cool to room temperature and reduced in volume under vacuum. The residue is captured in acetonitrile. The solids are filtered and the filtrate is evaporated. The residue is captured in ethyl acetate and dried over sodium sulfate. The sodium sulfate is filtered out and the filtrate is cooled to 0°C.The crystalline solid that is subsequently formed is filtered, washed with cold ethyl acetate, and dried under vacuum to give 4-[3-(pyrrolidin-1-yl)propoxy]pyridin-2-amine as a beige solid; UPLC / MS 0.116 min, [M+H]+222.

[00306] 1H NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 5.8 Hz, 1H), 6.10 (dd, J = 5.9, 2.3 Hz, 1H), 5.95 (d, J = 2.2 Hz, 1H), 5.72 (s, 2H), 3.96 (t, J = 6.5 Hz, 2H), 2.54 2.46 (m, 3H), 2.48 - 2.36 (m, 4H), 1.85 (p, J = 6.8 Hz, 2H), 1.75 -1.61 (m, 4H). tert-Butyl 4-{[(2-aminopyridin-4-yl)oxylmethyl}piperidine-1-carboxylate (E16)

[00307] The compound is prepared similarly to E15; pale yellow solid; HPLC / MS(A) 1.24 min, [M+H]+308.

[00308] 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 5.8 Hz, 1H), 6.10 (dd, J = 5.8, 2.2 Hz, 1H), 5.93 (d, J = 2.2 Hz, 1H), 5.76 (s, 2H), 4.10 - 3.92 (m, 4H), 3.78 (d, J = 6.4 Hz, 2H), 2.72 (bs, 4H), 2.00 -1.81 (m, 1H), 1.71 (dd, J = 13.4, 3.4 Hz, 4H), 1.12 Petition 870260069920, dated 07 / 14 / 2026, page 94 / 519 88 / 219 (qd, J = 12.5, 4.3 Hz, 4H). Synthesis of 4-{[1-(oxetan-3-yl)piperidin-4-yl1methoxy}pyridin-2-amine (E17) 1,2-dichloroethane

[00309] tert-Butyl 4-{[(2-aminopyridin-4-yl)oxy]methyl}piperidine-1-carboxylate (E16) (1.80 g, 4.98 mmol) is dissolved in a 4 N hydrogen chloride solution in dioxane (15 mL) and stirred for 2 hours at room temperature. Water and saturated sodium hydrogen carbonate solution are added to achieve a neutral pH value. The mixture is extracted with ethyl acetate. The organic phase is evaporated to give 4-[(piperidin-4-yl)methoxy]pindin-2-amine as a yellow solid; HPLC / MS [M+H]+208.

[00310] A solution of 4-[(piperidin-4-yl)methoxy]pindin-2-amine (1.00 g, 4.68 mmol) and oxetan-3-one (355 mg, 4.68 mmol) in 1,2-dichloroethane (5 mL) is stirred for 2 hours at room temperature. 3.96 g (18.7 mmol) of sodium triacetoxyborohydride are added and the resulting mixture is stirred for 16 hours at room temperature. The reaction mixture is treated with water and dichloromethane. The organic phase is separated and evaporated. The residue is chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 4-{[1-(oxetan-3-yl)piperidin-4-yl]methoxy}pindin-2-amine as a yellow solid; HPLC / MS [M+H]+264.

[00311] 4-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]pyridin-2-amine (E18)

[00312] The compound is prepared similarly to E1; orange resin; UPLC / MS0, 164 min, [M+H]+244.

[00313] 1H NMR (500 MHz, DMSO-d6) δ 7.71 (d, J = 5.9 Hz, 1H), 6.12 (dd, J = Petition 870260069920, dated 07 / 14 / 2026, p. 95 / 519 89 / 219 5.9, 2.3 Hz, 1H), 5.95 (d, J = 2.3 Hz, 1H), 5.74 (s, 2H), 4.02 (t, J = 5.6 Hz, 2H), 2.96 (t, J = 13.5 Hz, 2H), 2.87-2.72 (m, 4H), 2.22 (tt, J = 15.3, 7.0 Hz, 2H).

[00314] 4-[(1-methylpiperidin-4-yl)methoxy]pyridin-2-amine (E19)

[00315] The compound is prepared similarly to E15; yellow solid; HPLC / MS[M+H]+222.

[00316] 4-{3-[(2-aminopyridin-4-yl)oxy]propyl}morpholin-3-one (E20)

[00317] The compound is prepared similarly to E15; colorless resin; UPLC / MS0, 288 min, [M+H]+252.

[00318] 1H NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 5.9 Hz, 1H), 6.10 (dd, J = 5.9, 2.3 Hz, 1H), 5.92 (d, J = 2.3 Hz, 1H), 5.78 (s, 2H), 4.01 (s, 2H), 3.93 (t, J = 6.3 Hz, 2H), 3.82 (dd, J = 5.9, 4.3 Hz, 2H), 3.44 (t, J = 7.0 Hz, 2H), 3.38 - 3.34 (m, 2H), 1.93 (p, J = 6.6 Hz, 2H).

[00319] 4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]pyridin-2-amine (E21)

[00320] The compound is prepared similarly to E15; colorless resin; UPLC / MS0, 112 min, [M+H]+226.

[00321] 1H NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 5.9 Hz, 1H), 6.12 (dd, J = 5.9, 2.2 Hz, 1H), 5.94 (d, J = 2.2 Hz, 1H), 5.77 (s, 2H), 5.18 (dt, J = 56.1,6.3 Hz, 1H), 4.02 (t, J = 5.8 Hz, 2H), 2.97 - 2.80 (m, 2H), 2.78 (t, J = 5.8 Hz, 2H), 2.65 (ddd, J = 31.7, 11.6, 5.1 Hz, 1H), 2.37 (q, J = 8.0 Hz, 1H), 2.11 (ddq, J = 27.8, 14.0, 7.0 Hz, 1H), 1.85 (ddt, J = 29.4, 14.3, 7.2 Hz, 1H). Petition 870260069920, dated 07 / 14 / 2026, p. 96 / 519 90 / 219

[00322] 4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]pyridin-2-amine (E22)

[00323] The compound is prepared similarly to E15; yellow solid; HPLC / MS [M+H]+250.

[00324] tert-Butyl 4-[(2-aminopyridin-4-yl)oxy]pipendine-1-carboxylate (E23)

[00325] The compound is prepared similarly to E15; whitish solid; HPLC / MS(A) 1.17 min, [M+H]+294.

[00326] 1H NMR (500 MHz, DMSO-d6) δ 7.71 (d, J = 5.9 Hz, 1H), 6.14 (dd, J = 5.9, 2.3 Hz, 1H), 5.98 (d, J = 2.2 Hz, 1H), 5.71 (s, 2H), 4.51 (tt, J = 7.9, 3.7 Hz, 1H), 3.64 (ddd, J = 13.4, 6.6, 4.3 Hz, 2H), 3.23 - 3.01 (m, 2H), 1.95 - 1.83 (m, 1H), 1.50 (ddt, J = 17.1, 8.6, 3.9 Hz, 2H), 1.40 (s, 9H).

[00327] 4-{2-[(2-aminopyridin-4-yl)oxy]ethyl}morpholin-3-one (E24)

[00328] The compound is prepared similarly to E15; whitish solid; HPLC / MS(A) 0.76 min, [M+H]+238.

[00329] 1H NMR (500 MHz, DMSO-d6) δ 7.72 (d, J = 5.9 Hz, 1H), 6.13 (dd, J = 5.8, 2.3 Hz, 1H), 5.96 (d, J = 2.3 Hz, 1H), 5.75 (s, 2H), 4.09 (t, J = 5.6 Hz, 2H), 4.03 (s, 2H), 3.87 - 3.74 (m, 2H), 3.66 (t, J = 5.6 Hz, 2H), 3.50 - 3.41 (m, 2H).

[00330] 4-[2-(oxan-2-yloxy)ethoxy]pyridin-2-amine (E25) Petition 870260069920, dated 07 / 14 / 2026, p. 97 / 519 91 / 219

[00331] The compound is prepared similarly to E1; brown oil; HPLC / MS(A) 1.82 min, [M+H]+239.

[00332] 1H NMR (500 MHz, DMSO-d6) δ 7.71 (d, J = 5.9 Hz, 1H), 6.12 (dd, J = 5.9, 2.3 Hz, 1H), 5.95 (d, J = 2.3 Hz, 1H), 5.72 (s, 2H), 4.63 (dd, J = 4.4, 3.1 Hz, 1H), 4.07 (td, J = 4.1, 1.9 Hz, 1H), 3.93 - 3.83 (m, 1H), 3.80 - 3.73 (m, 1H), 3.73 - 3.66 (m, 1H), 3.48 - 3.38 (m, 1H), 1.81-1.66 (m, 1H), 1.62 (tdd, J = 9.9, 4.8, 2.7 Hz, 1H), 1.53 -1.38 (m, 5H).

[00333] 4-{2-[(2-aminopyridin-4-yl)oxy]ethyl}-1-methylpiperazin-2-one (E26) THE

[00334] The compound is prepared similarly to E15; brown resin; UPLC / MS 0.196 min, [M+H]+251.

[00335] 4-[3-(4-methylpiperazin-1-yl)propoxy]pyridin-2-amine (E27)

[00336] The compound is prepared similarly to E15; white solid; UPLC / MS 0.115 min, [M+H]+251. Synthesis of 1-{2-[(2-aminopyridin-4-yl)oxy]ethyl}-4-(oxetan-3-yl)piperazin-2-one (E28) NaH / deglima / 120°C

[00337] Pale orange wax; HPLC / MS(A) 0.772 min, [M+H]+293.

[00338] 1H NMR (500 MHz, DMSO-d6) δ 7.72 (d, J = 5.8 Hz, 1H), 6.13 (dd, J = Petition 870260069920, of 14 / 07 / 2026, p. 98 / 519 92 / 219 5.8, 2.2 Hz, 1H), 5.95 (d, J = 2.3 Hz, 1H), 5.73 (s, 2H), 4.53 (t, J = 6.6 Hz, 2H), 4.44 (t, J = 6.1 Hz, 2H), 4.07 (t, J = 6.6 Hz, 2H), (t, J = 5.6 Hz, 2H), 3.56 to 3.47 (m, 1H), 3.44 to 3.40 (m, 2H), 2.95 (s, 2H), 2.65 to 2.53 (m, 2H).

[00339] tert-Butyl 3-{[(2-aminopyridin-4-yl)oxy]methyl}azetidine-1-carboxylate (E29)

[00340] The compound is prepared similarly to E15; bleached powder; UPLC / MS 0.407 min, [M+H]+280.

[00341] 4-[2-(1 -methyl-1 H-imidazol-2-yl)ethoxy]pyridine-2-amine (E30)

[00342] The compound is prepared similarly to E15; yellow oil; HPLC / MS [M+H]+219.

[00343] 4-[2-(azetidin-1-yl)ethoxy]pyridin-2-amine (E31)

[00344] The compound is prepared similarly to E15; yellow powder; UPLC / S 0.109 min, [M+2H]++ / 297.5.

[00345] 1H NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 5.8 Hz, 1H), 6.08 (dd, J = 5.9, 2.3 Hz, 1H), 5.92 (d, J = 2.2 Hz, 1H), 5.72 (s, 2H), 3.85 (t, J = 5.7 Hz, 2H), 3.16 (t, J = 6.9 Hz, 4H), 2.66 (t, J = 5.7 Hz, 2H), 1.96 (p, J = 6.9 Hz, 2H).

[00346] 4-[3-(3,3-difluoropyrrolidin-1-yl)propoxy]pyridin-2-amine (E32)

[00347] The compound is prepared similarly to E15; beige solid; HPLC / MS(B) Petition 870260069920, dated 07 / 14 / 2026, p. 99 / 519 93 / 219 0.165 min, [M+H]+258.

[00348] 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 5.8 Hz, 1H), 6.09 (dd, J = 5.9, 2.2 Hz, 1H), 5.94 (d, J9 = 2.5, 3 Hz, 1H2), J = 6.4 Hz, 2H), 2.87 (t, J = 13.5 Hz, 2H), 2.69 (t, J = 7.0 Hz, 2H), 2.53 (t, J = 7.1 Hz, 2H), 2.22 (tt, J = 15,71, J, = 7.04 Hz, 2H). Chloro-imidazopyridinyl-pyrimidinase Synthesis of 3-(6-chloro-pyrimidine-4-yl)-7-methoxy-imidase[1,2-al pyridine (F1)

[00349] To a solution of 7-methoxyimidazo[1,2-a]pyridine (3.70 g, 25 mmol) and 4-chloro-6-methylthiopyrimidine (6.02 g, 37.5 mmol) in a mixture of 1,4-dioxane (34 mL) and ethanol (17 mL) are added potassium carbonate (6.91 g, 50.0 mmol) and triphenylphosphine (2.1 g, 8.0 mmol). The suspension is flooded with argon and palladium(II) acetate (898 mg, 4.00 mmol) is added. The mixture is stirred in a closed flask at 100°C for 18 hours. The reaction mixture is allowed to reach room temperature and 150 mL of water are added. The resulting precipitate is filtered, washed with water, and dried. The residue is chromatographed on a silica gel column with methanol / dichloromethane as eluent to give 7-methoxy-3-(6-methylsulfanyl-pyrimidin-4-yl)-imidazo[1,2-a]pyridine as a pale brown solid; HPLC / MS (A) 1.17 min, [M+H]+273.

[00350] To a suspension of 7-methoxy-3-(6-methylsulfanyl-pyrimidin-4-yl)-imidazo[1,2-a]pyridine (3.23 g, 11.9 mmol) in acetonitrile (31 mL) is added 37% hydrochloric acid, immediately followed by the addition of sulfuryl chloride (4.33 mL, 53.4 mmol). The reaction mixture is stirred for 20 minutes at temperature Petition 870260069920, dated 07 / 14 / 2026, page 100 / 519 94 / 219 ambient and then poured into ice-cold water (150 mL). The mixture is stirred for 45 minutes at room temperature. Saturated sodium hydrogen carbonate solution is added until a pH value of 10-11 is reached. The resulting precipitate is filtered and washed with water. The residue is crystallized from methanol to give 3-(6-chloro-pyrimidin-4-yl)-7-methoxy-imidazo[1,2-a]pyridine as a whitish solid; HPLC / MS (A) 1.13 min, [M+H]+261.

[00351] 1H NMR (500 MHz, DMSO-d6) δ 9.74 (dd, J = 7.7, 0.7 Hz, 1H), 8.97 (d, J = 1.1 Hz, 1H), 8.67 (s, 1H), 8.20 (d, J = 1.1 Hz, 1H), 7.21 (dd, J = 2.7, 0.6 Hz, 1H), 6.95 (dd, J = 7.7, 2.7 Hz, 1H), 3.91 (s, 3H). Synthesis of 3-(6-chloro-pyrimidin-4-yl)-7-methoxy-imidazo[1,2-alloiridine (F2) .

[00352] Chloroacetaldehyde (approximately 50% solution in water, 903 mg, 5.75 mmol) is added to a solution of 4-(2-methoxy-ethoxy)-pyridin-2-ylamine (879 mg, 5.23 mmol) in ethanol (20 mL). The mixture is heated to 80°C and stirred at this temperature for 18 hours. The reaction mixture is reduced in volume under vacuum and the residue is treated with water and sodium hydrogen carbonate solution. The organic phase is separated and the aqueous phase is extracted twice with dichloromethane. The organic phase is dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 7-(2-methoxy-ethoxy)-imidazo[1,2-a]pyridine as a brown solid;

[00353] UPLC-MS System: Petition 870260069920, dated 07 / 14 / 2026, page 101 / 519 95 / 219

[00354] Waters Acquity H Class -SQD

[00355] method: polar MS pos; polar MS neg.

[00356] column: column: BEH C-18 2.1-50 1.7 pm; column temperature: 40°C

[00357] Eluent A: water + 0.1% HCOOH

[00358] eluent B: acetonitrile + 0.08% HCOOH

[00359] flow rate: 0.9 mL / min

[00360] gradient: 0 min 4% B, in 1 min up to 100% B

[00361] up to 1.3 min 100% of B

[00362] up to 1.4 min at 4% B

[00363] up to 2 min 4% of B

[00364] Rt = 0.556 min, [M+H]+193.

[00365] The remaining steps are performed analogously to the synthesis of 3-(6-chloropyrimidin-4-yl)-7-methoxyimidazo[1,2-a]pyridine (F1); pale brown solid; HPLC / MS (A) 1.14 min, [M+H]+305.

[00366] 1HRMN (500 MHz, DMSO-d6) δ 9.75 (d, J = 7.7 Hz, 1H), 8.98 (s, 1H), 8.67 (s, 1H), 8.21 (s, 1H), 7.22 (d, J = 2.6 Hz, 1H), 6.97 (dd, J = 7.6, 2.7 Hz, 1H), 4.36 -4.16 (m, 2H), 3.83 - 3.55 (m, 2H), 3.33 (s, 3H). Synthesis of 4-chloro-6-{imidazo[1 ^-alpyridin-S-yljpyrimidine (F3) NÇyci Pd(PPh3)4 Cl THF

[00367] Under nitrogen, tetracis(triphenylphosphane)palladium (1.64 g, 1.42 mmol) is added to a solution of 3-(tributylstannyl)imidazo[1,2-a]pyridine (11.0 g, 20.3 mmol) and 4,6-dichloropyrimidine (4.80 g, 30.6 mmol) in DMF (25 mL). The reaction mixture is stirred for 16 hours at 110°C. The reaction mixture is allowed to reach room temperature and concentrated under vacuum. The residue is chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 4-chloro-6-{imidazo[1,2-a]pyridin3-yl}pyrimidine as a whitish solid; HPLC / MS [M+H]+231. Petition 870260069920, dated 07 / 14 / 2026, page 102 / 519 96 / 219

[00368] 3-(6-Methylsulfanyl-pyrimidin-4-yl)-7-trifluoromethyl-imidazo[1,2-a] pyridine (F4)

[00369] This compound is prepared similarly to F1; whitish solid; HPLC / MS (A) 1.66 min, [M+H]+299. Ethoxy-ethenyl-pyrimidines 6-[(E)-2-ethoxyethenyl1-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl1methyl}pyrimidin-4-amine (G1)

[00370] To a suspension of 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine (10.8 g, 54.6 mmol) (D1) and 4,6-dichloropyrimidine (8.95 g, 60.1 mmol) in DMF (80 mL) is added trimethylamine (9.09 mL, 65.6 mmol) and the reaction mixture is stirred for 2 hours at 30°C. The solids are filtered and washed with DMF. The filtrate is evaporated under vacuum and the residue is treated with water and stirred for 15 minutes at room temperature. The precipitate is filtered, washed with water and dried under vacuum. The residue is suspended in tert-butyl methyl ether and stirred for 10 minutes. The solids are filtered, washed with tert-butyl methyl ether and dried under vacuum to give 6chloro-N-{[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-methyl}-pyrimidin-4-amine as a beige solid; HPLC / MS (B) 0.682 min, [M+H]+300.

[00371] 1H NMR (500 MHz, DMSO-d6) δ 8.28 (s, 1H), 8.15 (s, 1H), 8.08 (d, J = 0.8 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 6.58 (s, 1H), 4.52 (s, 2H), 3.85 (s, 3H).

[00372] A suspension of 6-chloro-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]-methyl}-pyrimidin-4-amine (5.15 g, 17.2 mmol), (E)-1-ethoxyethene-2-pinacol boronic acid ester (5.11 g, 25.8 mmol) and tripotassium triphosphate (7.30 g, 34.4 mmol) in DMF is flooded with argon. Tetracis(triphenylphosphine)-palladium (994 mg, 0.86 mmol) is added. The reaction mixture is heated to 100°C and stirred at this temperature for 16 hours. Petition 870260069920, dated 07 / 14 / 2026, p. 103 / 519 97 / 219 The reaction mixture is allowed to reach room temperature and treated with water. The precipitate is filtered and dried. The filtrate is extracted several times with dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated. The residue is combined with the previously obtained precipitate and chromatographed on a silica gel column with dichloromethane / methanol as eluent. The product containing fractions is combined and evaporated. The residue is triturated with tert-butyl methyl ether to give 6-[(E)-2-ethoxythenyl]-N-{[4-(1-methyl-1H-pyrazol~4-yl)phenyl]methyl}pyrimidin-4-amine as a beige crystalline solid; HPLC / MS (B) 0.696 min, [M+H]+336.

[00373] 1H NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 1.0 Hz, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.72 (d, J = 0.8 Hz, 1H), 7.72, - m (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 6.19 (d, J = 1.2 Hz, 1H), 5.65 (d, J = 12.4 Hz, 1H), 4.46 (d, J = 5.9 Hz, 2H), J 2H), 3.85 (s, 3H), 1.25 (t, J = 7.0 Hz, 3H).

[00374] 6-[(E)-2-ethoxyethenyl]-N-{[4-(1 H-1,2,3-triazol-1 -yl)phen based l}pyrim id in-4amine (G2)

[00375] The compound is prepared similarly to G1; yellow solid; HPLC / MS [M+H]+323.

[00376] 6-[(E)-2-ethoxyethenyl]-N-{[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl] methyl}pyrimin-4-amine (G3)

[00377] The compound is prepared similarly to G1; branched crystalline solid; HPLC / MS (B) 0.708 min, [M+H]+337.

[00378] 1H NMR (400 MHz, DMSO-d6) δ 8.21 (s, 1H), 8.16 (s, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.69 (t, J = 6.2 Hz, 1H, 7.64), 7.4, J 1H), 7.37 (d, J = 8.2 Hz, 2H), 6.20 (s, 1H), 5.66 (d, J = 12.4 Hz, 1H), 4.51 (d, J = 6.0 Hz, 2H), 4.18 (s, 3H), 3.93 (q, Petition 870260069920, of 14 / 07 / 2026, p. 104 / 519 98 / 219 J = 7.0 Hz, 2H), 1.25 (t, J = 7.0 Hz, 3H).

[00379] 4-[(E)-2-ethoxyethenyl]-6-{[4-(1-methyl-1 H-pyrazol-4-yl)phenyl]methoxy} pyrimidine (G4) er Pd(PPh3)4 K2CO3dioxa and / HaO YOUR WO'C brown solid; HPLC / MS [M+H]+337.

[00380] 6-[(E)-2-Ethoxyethenyl]-5-fluoro-N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phene derived l}pyrimidine-4-amine (G5)

[00381] The compound is prepared similarly to G1; bleached powder; UPLC / MS0.635 min, [M+H]+354.

[00382] 6-[(E)-2-ethoxyethenyl]-N-{1-[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]ethyl}pyrim idyne-4amine (G6) Petition 870260069920, of 14 / 07 / 2026, p. 105 / 519 99 / 219

[00383] The compound is prepared from D32 similarly to G1; brown oil; HPLC / MS [M+H]+350. Fluoroimidazopyridinas e-fy-fluoroimidazone^-alpyridin-S-ylj-Nf^-yl-methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine4-amine (H1)

[00384] A suspension of 6-[(E)-2-ethoxythenyl]-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine (G1) (335 mg, 1.00 mmol) in a mixture of 1,4-dioxane (4.5 mL) and water (1.5 mL) is cooled to 0°C and N-bromosuccinimide (196 mg, 1.10 mmol) is added in portions over a period of 15 minutes. After the last addition, the reaction mixture is stirred for 20 minutes at 0°C. 2-Amino-4-fluoropyridine (118 mg, 1.00 mmol) is added. The reaction solution is heated to 60°C and stirred at this temperature for 2 hours. The reaction mixture is allowed to reach temperature and poured into a 1 N aqueous NaOH solution (25 mL). The resulting mixture is stirred for several hours.The resulting solid material is filtered, washed with water, dried, and chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine as a pale yellow crystalline solid; HPLC / MS(B) 0.794 min, [M+H]+400.

[00385] 1H NMR (500 MHz, DMSO-d6) δ 9.94 - 9.85 (m, 1H), 8.55 (s, 1H), 8.28 (s, 1H), 8.07 (s, 1H), 7.91 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.9 Hz, 1H), 7.57 (dd, J = 9.8, 2.7 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.15 (td, J = 7.6, 2.8 Hz, 1H), 6.96 (d, J = 1.2 Hz, 1H), 4.55 (d, J = 5.8 Hz, 2H), 3.84 (s, 3H). Petition 870260069920, dated 07 / 14 / 2026, p. 106 / 519 100 / 219

[00386] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}pyrimidin-4-amine (H2)

[00387] The compound is prepared similarly to H1; whitish powder; UPLC / MS 0.574 min, [M+H]+401.

[00388] 1H NMR (700 MHz, DMSO-d6) δ 9.90 (t, J = 6.9 Hz, 1H), 8.55 (s, 1H), 8.29 (s, 1H), 8.16 (s, 1H), 7.95 (t, J = 6.2 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.56 (dd, J = 9.8, 2.7 Hz, 1H), 7.44 (d, J = 7.8 Hz, 2H), 7.15 (td, J = 7.6, 2.7 Hz, 1H), 6.97 (d, J = 1.2 Hz, 1H), 4.61 (d, J = 6.0Hz, 2H), 4.17 (s, 3H).

[00389] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1-methyl-1H-1,2,3-triazol-4-yl)phenyl]methyl}pyrimidin-4-amine (H3)

[00390] The compound is prepared analogously to H1; brown solid; HPLC / MS [M+H]+401.

[00391] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}pyrimidin-4-amine (H4)

[00392] The compound is prepared from intermediate D22 analogously to the synthesis Petition 870260069920, dated 07 / 14 / 2026, page 107 / 519 101 / 219 alternative of H1; yellow solid; HPLC / MS [M+H]+401.

[00393] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]ethyl}pyrimidin-4-amine (H5)

[00394] The compound is prepared from G6 analogously to H1; brown oil; HPLC / MS [M+H]+414.

[00395] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1,3-oxazol-4-yl)phenyl]methyl}pyrimidin-4-amine (H6)

[00396] The compound is prepared from intermediate D29 analogously to the alternative synthesis of H1; brown solid; HPLC / MS [M+H]+387.

[00397] 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(trifluoromethoxy)phenyl]methyl}pinmidin-4-amine (H7)

[00398] The compound is prepared from [4-(trifluoromethoxy)phenyl]methanamine analogously to the alternative synthesis of H1; brown solid; HPLC / MS [M+H]+404. Alternative synthesis of fluoroimidazopyridines 6-{7-fluoroimidazo[1,2-alpyridin-3-yl}-N-{[4-(1-methyl-1 H-pyrazol-4-yl)phenyl1 methylpyrimidine4-amine (H1) Petition 870260069920, of 14 / 07 / 2026, p. 108 / 519 102 / 219 there h2n

[00399] To a solution of 4,6-dichloropyrimidine (9.87 g, 66.3 mmol) and 2-[(E)-2-ethoxythenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (12.5 g, 63.1 mmol) in dioxane (90 mL) are added water (10 mL) and tripotassium phosphate (26.8 g, 126 mmol). Argon is bubbled through the mixture and tetracis(triphenylphosphine)-palladium (3.65 g, 3.16 mmol) is added. The mixture is heated to 80°C and stirred at this temperature under an argon atmosphere for three hours. The reaction mixture is allowed to reach room temperature and concentrated under vacuum. The residue is divided between water and dichloromethane. The combined organic phases are dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with cyclohexane / ethyl acetate as eluent to give 4-chloro-6-[(E)-2-ethoxythenyl]pyrimidine as a whitish crystalline solid; UPLC / MS 0.645 min, [M+H]+185.

[00400] 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 1.0 Hz, 1H), 7.97 (d, J = 12.5 Hz, 1H), 7.48 (d, J = 1.0 Hz, 1H), 5.89 (d, J = 12.5 Hz, 1H), 4.05 (q, J = 7.0 Hz, 3H), 1.29 (t, J = 7.0 Hz, 4H).

[00401] To a solution of 4-chloro-6-[(E)-2-ethoxythenyl]pyrimidine (9.70 g, 52.5 mmol) in dioxane (375 mL) are added water (125 mL) and N-bromosuccinimide (8.88 g, 49.9 mmol). The mixture is stirred for 1 hour at room temperature. Then, 4-fluoropyridin-2-amine (7.07 g, 63.1 mmol) is added. The reaction mixture is heated to 60°C and stirred at this temperature for 2 hours. The reaction mixture is allowed to reach room temperature and saturated sodium carbonate solution is added to achieve a pH value of 9. The mixture is concentrated under vacuum. The solids are filtered, washed with water, and dried under vacuum. The residue is triturated with a small amount of acetonitrile and a small amount of Petition 870260069920, dated 07 / 14 / 2026, p. 109 / 519 103 / 219 tert-butyl methyl ether to provide 4-chloro-6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}pyrimidine as a brown powder; UPLC / MS 0.577 min, [M+H]+249.

[00402] 1H NMR (400 MHz, DMSO-d6) δ 9.96 (ddd, J = 7.8, 6.0, 0.8 Hz, 1H), 9.05 (d, J = 1.1 Hz, 1H), 8.81 (s, 1H), 8.32 (d, J = 1.2 Hz, 1H), 7.73 (ddd, J = 9.7, 2.8, 0.7 Hz, 1H), 7.32 (td, J = 7.6, 2.8 Hz, 1H).

[00403] To a solution of 4-chloro-6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}pyrimidine (497 mg, 2.00 mmol) and 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine (D1, 497 mg, 2.00 mmol) in N,N-dimethylacetamide (4 mL) is added potassium carbonate (553 mg, 4.00 mmol) and the resulting mixture is heated for 16 hours at 80°C. The reaction mixture is allowed to reach room temperature and water is added. The resulting precipitate is filtered, washed with water and dried under vacuum. The residue is chromatographed on a silica gel column with dichlormethane / methanol as eluent to give 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine as a pale yellow crystalline solid; HPLC / MS(B) 0.794 min, [M+H]+400. Example 1 Synthesis of [6-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl1-[4-(1-methyl-1H-pyrazol4-yl)-benzyl]-amine (A1)

[00404] To a solution of 4-chloro-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidine (F1) (75.6 mg, 0.29 mmol) and 1-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methanamine (D1) (56 mg, 0.30 mmol) in dimethyl sulfoxide (1.3 mL) are added potassium carbonate (81 mg, 0.59 mmol) and potassium iodide (5.0 mg, 30 pmol). The mixture is heated to 100°C and stirred at this temperature for 18 hours; the reaction mixture is left Petition 870260069920, dated 07 / 14 / 2026, page 110 / 519 104 / 219 reach room temperature and treated with excess water. The resulting precipitate is filtered and washed with water. The residue is chromatographed on a silica gel column with methanol / dichloromethane as eluent to give [6-(7-methoxy-imidazo[1,2-a]pyrid in-3-yl)-pyrim idi n-4-yl]-[4-( 1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine as a pale yellow powder; HPLC / MS(A) 1.23 min, [M+H]+412.

[00405] 1H RMN (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.84 (t, J = 6.4 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.54 (d, J = 6.1 Hz, 2H), 3.87 (s, 3H), 3.84 (s, 3H).

[00406] Used other similar options:

[00407] N-({[1,1'-bifenil]-4-il}metil)-6-[7-(2-metoxietoxi)imidazo[1,2-a]piridin-3-il]pirimidin-4-amina (A2) de F2; pó marrom palido; HPLC / MS (A) 1.99 min, [M+H]+452.

[00408] 1H RMN (500 MHz, DMSO-d6) δ 9.71 (d, J = 7.7 Hz, 1H), 8.53 (s, 1H), 8.17 (s, 1H), 7.94 (t, J = 6.2 Hz, 1H), 7.69-7.56 (m, 4H), 7.45 (t, J = 7.7 Hz, 4H), 7.40 - 7.31 (m, 1H), 7.10 (d, J = 2.6 Hz, 1H), 6.92 (d, J = 1.3 Hz, 1H), 6.83 (dd, J = 7.7, 2.6 Hz, 1H), 4.62 (s, 2H), 4.28 - 4.19 (m, (2H), 3.78 - 3.68 (m, 2H), 3.33 (s, 3H).

[00409] N-({[1,1'-biphenyl]-4-yl}methyl)-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidine4-amine (A3) of F1; branched crystals; HPLC / MS (A) 1.55 min, [M+H]+408.

[00410] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.16 (s, 1H), 7.91 (t, J = 6.2 Hz, 1H, 7.69), - m , 51 (m 7.52 - 7.40 (m, 7H), 7.40 Petition 870260069920, of 14 / 07 / 2026, p. 111 / 519 105 / 219 7.28 (m, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2.8 Hz), (3.37 s).

[00411] 6-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-(1 -methyl-1 H-pyrazol-4yl)phenyl]methyl}pyrimidine-4-amine (A4) of D1 and F2; pale yellow solid; HPLC / MS (A) 1.30 min, [M+H]+456.

[00412] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.84 (t, J = 6.3 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.82 (dd, J = 7,7, 2,6 Hz, (1H), 4.54 (d, J = 6.0 Hz, 2H), 4.29 - 4.17 (m, 2H), 3.84 (s, 3H), 3.73 - 3.67 (m, 2H), 3.32 (s, 3H).

[00413] 6-[7-(2-metoxietóxi)imidazo[1,2-a]piridin-3-il]-N-{[4-(pirid in-3il)fenil]metil}pirimidin-4-amina (A5) de F2; solid amarelo pallido; HPLC / MS (A) 1.15 min, ([M+2H]2+) / 2 227.

[00414] 1H RMN (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.87 (dd, J = 2.5, 0.9 Hz, 1H), 8.55 (dd, J = 4.8, 1.6 Hz, 1H), 8.52 (s, 1H), 8.16 (s, 1H), 8.07 - 8.01 (m, 1H), 7.93 (t, J = 6.2 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.54 - 7.44 (m, 3H), 7.09 (d, J = 2.6 Hz, 1H), 6.92 (d, J = 1.3 Hz, 1H), 6.82 (dd, J = 7.7, 2.6 Hz, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.26 - 4.12 (m, 2H), 3.80 - 3.67 (m, 2H), 3.33 (s, 3H).

[00415] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-(piridin-3-il)fen il]m eti l}pirim idin-4-amina (A6) Petition: 870260069920, on 07 / 14 / 2026, page. 112 / 519 106 / 219 deF1; Solido esbranquiçado; HPLC / MS (A) 1.06 min, [M+H]+409.

[00416] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.87 (dd, J = 2.5, 0.9 Hz, 1H), 8.55 (dd, J = 4.8, 1.6 Hz, 1H), 8.52 (s, 1H), 8.16 (s, 1H), 8.05 (ddd, J = 7.9, 2.5, 1.7 Hz, 1H), 7.93 (t, J = 6.2 Hz, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.56 - 7.43 (m, 3H), 7.08 (d, J = 2.6 Hz, 1H), 6,92 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.62 (d, J = 5.9 Hz, 2H), 3.87 (s, 3H).

[00417] 6-[7-(2-metoxietóxi)imidazo[1,2-a]piridin-3-il]-N-{[4-( 1 -metil-1 H-pirazol-3il)fenil]metil}pirimidin-4-amina (A7) (de F2); solid amarelo pallido; HPLC / MS (A) 1.06 min, [M+H]+456.

[00418] 1H RMN (500 MHz, DMSO-d6) δ 9.76 - 9.63 (m, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 7.87 (t, J = 6.1 Hz, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 2.3 Hz, 1H), 7.37 (d, J = 7.8 Hz, 2H), 7.14 - 7.08 (m, 1H), 6.90 (d, J = 1.3 Hz, 1H), 6.82 (dd, J = 7.7, 2.6 Hz, 1H), 6.64 (d, J = 2.2 Hz, 1H), 4.57 (d, J = 5.9 Hz, 2H), 4.32 - 4.16 (m, 2H), 3.86 (s, 3H), 3.77 - 3.64 (m, 2H), 3.33 (s, 3H).

[00419] (6-imidazo[1,2-a]piridin-3-il-pirimidin-4-il)-(4-im idazol-1-il-benzil)-amina (A8) Petition: 870260069920, on 07 / 14 / 2026, page. 113 / 519 107 / 219 de F3; Solido esbranquiçado; HPLC / MS [M+H]+368.

[00420] (6-imidazo[1,2-a]piridin-3-il-pirimidin-4-il)-(4-pirazol-1-il-benzil)-amina (A9) de F3; Solido esbranquiçado; mp 217-219°C; HPLC / MS [M+H]+368.

[00421] 1H RMN (400 MHz, DMSO-d6,): δ 9.86 (d, J = 7.0 Hz, 1H), 8.57 (s, 1H), 8.46 (d, J = 2.5 Hz, 1H), 8.32 (s, 1H), 8.01 (m, 1H), 7.85 - 7.77 (m, 2H), 7.75 - 7.68 (m, 2H), 7.49 (d, J = 8.1 Hz, 2H), 7.42 (m, 1H), 7.10 (m, 1H), 7.00 (d, J = 1.3 Hz, 1H), 6.53 (m, 1H), 4.62 (s, 2H).

[00422] N-{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}-6-[7-(trifluorometil)imidazo[1,2a]piridin-3-il]pinmidin-4-amina (A10) de F4 e D1; solid branco; HPLC / MS (A) 1.64 min, [M+H]+450.

[00423] 1H RMN (400 MHz, DMSO-d6) δ 10.01 (d, J = 7.4 Hz, 1H), 8.60 (s, 1H), 8.49 (s, 1H), 8.19 (s, 1H), 8.08 (s, 1H), 8.02 (t, J = 6.1 Hz, 1H), 7.81 (s, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.41 - 7.32 (m, 3H), 7.05 (d, J = 1.3 Hz, 1H), 4.60 - 4.52 (m, 2H), 3.85 (s, 3H).

[00424] 6-[7-(2-metoxietóxi)imidazo[1,2-a]piridin-3-il]-N-{[6-( 1 -metil-1 H-pirazol-4il)piridin-3-il]metil}pinmidin-4-amina (A11) Petition: 870260069920, on 07 / 14 / 2026, page. 114 / 519 108 / 219 de F2; pó esbranquiçado; HPLC / MS (A) 1.02 min, [M+H]+457.

[00425] 1H RMN (400 MHz, DMSO-d6) δ 9.71 (d, J = 7.8 Hz, 1H), 8.56 - 8.49 (m, 2H), 8.22 (s, 1H), 8.19 (s, 1H), 7.94 (d, J = 0.7 Hz, 1H), 7.88 (t, J = 6.1 Hz, 1H), 7.73 (dd, J = 8.2, 2.2 Hz, 1H), 7.59 (dd, J = 8.1,0.9 Hz, 1H), 7.10 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 1.3 Hz, 1H), 6.83 (dd, J = 7,7, 2,6 (Hz, 1H), 4.55 (d, J = 6.0 Hz, 2H), 4.28-4.16 (m, 2H), 3.87 (s, 3H), 3.78 - 3.64 (m, 2H).

[00426] 1 -(4-{[(6-{7-metoxiimidazo[1,2-a]piridin-3-il}pirim id in-4-i I)amino]metil}fenil)piperidin-2-ona (A12) deF1; pó marrom palido; HPLC / MS (A) 1.18 min, [M+H]+429.

[00427] 1H RMN (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 7.87 (t, J =6.1 Hz, 1H), 7.35 (d, J = 8.1 Hz, 2H), 7.27 - 7.16 (m, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.61 - 4.46 (m, 2H), 3.87 (s, 3H), 3.63 - 3.49 (m, 2H), 2.36 (t, J = 6.3 Hz, 2H), 1.89 -1.77 (m, 4H).

[00428] 4-{[(6-{7-metoxiimidazo[1,2-a]piridin-3-il}pirimidin-4-il)amino]metil}-N,Ndimetilbenzamida (A13) deF1; Solido esbranquiçado; HPLC / MS (A) 1.19 min, [M+H]+403.

[00429] 1H RMN (400 MHz, DMSO-d6) δ 9.79 (d, J = 7.6 Hz, 1H), 8.59 (s, 1H), 8.20 (t, J = 6.2 Hz, 1H), 7.45 - 7.31 (m, 4H), 7.26 (d, J = 2.6 Hz, 1H), 7.15 (dd, J = 7.7, 2.6 Hz, 1H), 7.00 (s, 1H), 4.63 (s, 2H), 3.98 (s, 3H), 2.96 (s, 3H), 2.90 (s, 3H).

[00430] (6-imidazo[1,2-a]piridin-3-il-pirimidin-4-il)-[4-(1-metil-1 H-pirazol-3-il)benzil]-amina (A14) Petition: 870260069920, on 07 / 14 / 2026, page. 115 / 519 109 / 219 de F3; solid branco; mp 165-166°C; HPLC / MS [M+H]+382.

[00431] 1H RMN (300 MHz, DMSO-d6) δ 9.83 (d, J = 7.0 Hz, 1H), 8.54 (s, 1H), 8.28 (s, 1H), 7.99 - 7.92 (m, 1H), 7.86 - 7.66 (m, 5H), 7.37 (dd, J = 7.5, 5.0 Hz, 2H), 7.07 (t, J = 6.8 Hz, 1H), 6.96 (d, J = 1.3 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 4.57 (s, 2H), 3.84 (s, 3H).

[00432] [4-(4,5-di-hydro-1 H-imidazol-2-il)-benzil]-(6-imidazo[1,2-a]piridin-3-ilpirimidin-4-il)-amina (A15) de F3; solid branco; HPLC / MS [M+H]+370.

[00433] 6-[7-(2-metoxietóxi)imidazo[1,2-a]piridin-3-il]-N-{[4-(1 H-1,2,3-triazol-1 il)fenil]metil}pirimidin-4-amina (A16) de F2; solid amarelo pallido; HPLC / MS (A) 1.17 min, [M+H]+443.

[00434] 1H RMN (400 MHz, DMSO-d6) δ 9.71 (d, J = 7.7 Hz, 1H), 8.79 (d, J = 1.3 Hz, 1H), 8.52 (s, 1H), 8.18 (s, 1H), 8.00 (t, J = 6.2 Hz, 1H), 7.96 (d, J = 1.1 Hz, 1H), 7.92 - 7.70 (m, 2H), 7.66 - 7.51 (m, 2H), 7.10 (d, J = 2.6 Hz, 1H), 6.93 (d, J = 1.3 Hz, 1H), 6.83 (dd, J = 7.8, 2.6 Hz, 1H), 4.64 (d, J = 5.9 Hz, 2H), 4.32 - 4.14 (m, 2H), 3.87 - 3.51 (m, 2H), 3.32 (s, 3H). Petition: 870260069920, on 07 / 14 / 2026, page. 116 / 519 110 / 219

[00435] 6-[7-(2-metoxietóxi)imidazo[1,2-a]piridin-3-il]-N-[(4-{4H,5H, 6H-pir ​​roll[1,2-b]pirazol-3-il}fenil)metil]pirimidin-4-amina (A17) de F2 e D3; solid amarelo pallido; HPLC / MS (A) 1.29 min, [M+H]+482.

[00436] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,16 (s, 1H), 7,89 (t, J = 6,2 Hz, 1H), 7,84 (s, 1H), 7,52 - 7,43 (m, 2H), 7,35 (d, J = 7,8 Hz, 2H), 7,10 (d, J = 2,6 Hz, 1H), 6,89 (d, J = 1,3 Hz, 1H), 6,83 (dd, J = 7,7, 2,6 Hz, 1H), 4,54 (s, 2H), 4,24 - 4,18 (m, 2H), 4,07 (t, J = 7,3 Hz, 2H), 3,76 - 3,61 (m, 2H), 3,32 (s, 3H), 3,04 (t, J = 7,3 Hz, 2H).

[00437] 6-{7-metoxiimidazo[1,2-a]piridin-3-i l}-N-{[4-( 1H-1,2,3-triazol-1 -il)fen i l]m etil}pirimidin-4-amina (A18) de F1; sólido marrom pálido; HPLC / MS (A) 1,18 min, [M+H]+399.

[00438] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,79 (d, J = 1,2 Hz, 1H), 8,52 (s, 1H), 8,18 (s, 1H), 8,00 (t, J = 6,3 Hz, 1H), 7,96 (d, J = 1,2 Hz, 1H), 7,87 (d, J = 8,5 Hz, 2H), 7,58 (d, J = 8,1 Hz, 2H), 7,09 (d, J = 2,6 Hz, 1H), 6,93 (d, J = 1,3 Hz, 1H), 6,81 (dd, J = 7,7, 2,7 Hz, 1H), 4,65 (s, 2H), 3,87 (s, 3H).

[00439] {4-[1-(2-metóxi-etil)-1 H-pirazol-4-il]-benzil}-[6-(7-metóxi-imidazo[1,2a]piridin-3-il)-pirimidin-4-il]-amina (A19) de F1 e D4; Solido esbranquiçado; mp 212-213°C; HPLC / MS [M+H]+456. Petition: 870260069920, on 07 / 14 / 2026, page. 117 / 519 111 / 219

[00440] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.8 Hz, 1H), 8.51 (s, 1H), 8.12 (s, 1H), 7.86 (s, 1H), 7.92-7.82 (m, 2H), 7.53 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.80 (d, J = 2.7 Hz, 1H), 4.54 (s, 2H), 4.25 (t, J = 5.3 Hz, 2H), 3.87 (s, 3H), 3.70 (t, J = 5.3 Hz, 2H), 3.24 (s, 3H).

[00441] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirimidin-4-il]-[4-(1-metil-1 Himidazol-4-il)-benzil]-amina (A20) de F1 e D5; solid amarelo pallido; mp 234-235°C; HPLC / MS [M+H]+412.

[00442] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1 H), 8,51 (s, 1 H), 8,15 (s, 1 H), 7,87 (t, J = 5,6 Hz, 1 H), 7,69 (d, J = 8,4 Hz, 2 H), 7,60 (s, 1 H), 7,55 (s, 1 H), 7,33 (d, J = 8,4 Hz, 2 H), 7,08 (d, J = 2,4 Hz, 1 H), 6,89 (s, 1 H), 6,80 (dd, J = 7,6, 2,4 Hz, 1 H), 4,55 (s, 2 H), 3,87 (s, 3 H), 3,67 (s, 3 H).

[00443] [4-(1 -ciclopropilmetil-1 H-pirazol-4-il)-benzil]-[6-(7-metóxi-imidazo[1,2a]piridin-3-il)-pirimidin-4-il]-amina (A21) de F1 e D6; sólido branco; m.p. 248-249°C; HPLC / MS [M+H]+452.

[00444] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,6 Hz, 1 H), 8,51 (s, 1 H), 8,16 (s, 2 H), 7,88 (t, J = 6,1 Hz, 1 H), 7,83 (s, 1 H), 7,53 (d, J = 8,4 Hz, 2 H), 7,35 (d, J = 7,6 Hz, 2 H), 7,08 (d, J = 2,4 Hz, 1 H), 6,90 (d, J = 0,8 Hz, 1H), 6,80 (dd, J = 6,4, 2,8 Hz, 1H), 4,54 (s, 2 H), 3,96 (d, J = 7,2 Hz, 2 H), 3,87 (s, 3 H), 1,29-1,21 (m, 1 H), 0,55-0,51 (m, 2 H), 0,37-0,34 (m, 2 H).

[00445] [6-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)-pyrim idin-4-yl]-{4-[1 -(2-morpholin-4-ylethyl)-1 H-pyrazol-4-yl]-benzyl}-amine (A22) Petition 870260069920, of 14 / 07 / 2026, p. 118 / 519 112 / 219 of F1 and D7; white solid; mp 217-218°C; HPLC / MS [M+H]+511.

[00446] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (d, J = 0.8 Hz, 1H), 7.87 (t, J = 0.8 Hz, 1H), 7.87 (t, J = 6.1 Hz, 1H), J 0.8 Hz, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 1H), 4.54 (s, 2H), 4.22 (t, J = 6.6 Hz, 2H), 3.87 (s, 3H), 3.57 - 3.50 (m, 4H), 2.72 (t, J = 6.6 Hz, 2H), 2.40 (t, J = 6.6 Hz, 4H).

[00447] [4-(1 -ethyl-1 H-pyrazol-4-yl)-benzyl]-[6-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)pyrimidin-4-yl]-amine (A23) of F1; pale yellow solid; mp 251-252°C; HPLC / MS [M+H]+426.

[00448] 1H NMR (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.15 (d, J = 0.8 Hz, 2H), 7.89 (H, J 7, =8.1), 0.8 Hz, 1H), 7.58 − 7.47 (m, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), (m 4.8 - 4.52 (m, 2H), 4.18 - 4.08 (m, 2H), 3.88 (s, 3H), 1.39 (t, J = 7.3 Hz, 3H).

[00449] [6-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)-pyrim idin-4-yl]-{4-[1 -(2-pyrrolidin-1 -ylethyl)-1 H-pyrazol-4-yl]-benzyl}-amine (A24) of F1 and D8; solid white; mp 203–205°C; HPLC / MS [M+H]+495. Petition 870260069920, dated 07 / 14 / 2026, p. 119 / 519 113 / 219

[00450] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1 H), 8,51 (s, 1H), 8,14 (d, J = 0,9 Hz, 2 H), 7,88 (t, J = 6,2 Hz, 1 H), 7,83 (d, J = 0,8 Hz, 1 H), 7,55 - 7,49 (m, 2 H), 7,35 - 7,33 (m, 2 H), 7,08 (d, J = 2,6 Hz, 1 H), 6,89 (d, J = 1,2 Hz, 1 H), 6,80 (dd, J = 7,7, 2,7 Hz, 1 H), 4,54 (s, 2 H), 4,20 (t, J = 6,6 Hz, 2 H), 3,87 (s, 3 H), 2,83 (t, J = 6,6 Hz, 2 H), 2,50 - 2,45 (m, 4 H), 1,66 -1,62 (m, 4 H).

[00451] [4-(1,3-dimetil-1 H-pirazol-4-il)-benzil]-[6-(7-metóxi-imidazo[1,2-a]piridin-3-il)pirimidin-4-il]-amina (A25) de F1; sólido branco; m.p,264-265°C; HPLC / MS [M+H]+426.

[00452] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,52 (s, 1H), 8,15 (s, 1H), 7,90 (t, J = 6,1 Hz, 1H), 7,84 (s, 1H), 7,37 (s, 4H), 7,09 (d, J = 2,7 Hz, 1H), 6,90 (d, J = 1,2 Hz, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,56 (s, 2H), 3,87 (s, 3H), 3,76 (s, 3H), 2,26 (s, 3H).

[00453] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-(5-metil-1,2,4-oxadiazol-3-il)fenil]metil}pinmidin-4-amina (A26) deF1; Solido esbranquiçado; HPLC / MS (A) 1.28 min, [M+H]+414.

[00454] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (d, J = 1.1 Hz, 1H), 8.16 (s, 1H), 8.04 - 7.90 (m, 3H), 7.53 (d, J = 7.9 Hz, 2H).

[00455] N-{[4-(1 H-1,3-benzodiazol-1 -il)fenil]metil}-6-{7-metoxiimidazo[1,2-a]piridin-3-il}pirimidin-4-amina (A27) Petition: 870260069920, on 07 / 14 / 2026, page. 120 / 519 114 / 219 deF1; Solido esbranquiçado; HPLC / MS (A) 1.21 min, [M+H]+448.

[00456] 1H RMN (500 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,54 (s, 1H), 8,52 (s, 1H), 8,18 (s, 1H), 7,99 (t, J = 6,2 Hz, 1H), 7,79-7,72 (m, 1H), 7,69-7,53 (m, 5H), 7,37 - 7,25 (m, 2H), 7,08 (d, J = 2,6 Hz, 1H), 6,95 (d, J = 1,2 Hz, 1H), 6,81 (dd, J = 7,7, 2,7 Hz, 1H), 4,68 (d, J = 5,7 Hz, 2H), 3,88 (s, 3H).

[00457] [6-(7-metóxi-imidazo[1,2-a]piridin-3-i l)-pirim idin-4-i l]-[3-( 1 -metil-1 H-pirazol-4il)-benzil]-amina (A28) de F1 e D9; sólido amarelo pálido; m.p. 258-259°C; HPLC / MS [M+H]+412.

[00458] 1H RMN (400 MHz, DMSO-d6)õ 9,70 (d, J = 7,7 Hz, 1H), 8,53 (s, 1H), 8,18 8,13 (m, 1H), 8,11 (s, 1H), 7,90 (t, J = 6,1 Hz, 1H), 7,83 (s, 1H), 7,58 (s, 1H), 7,44 (d, J = 7,6, 1,5 Hz, 1H), 7,32 (t, J = 7,6 Hz, 1H), 7,20 - 7,17 (m, 1H), 7,09 (d, J = 2,6 Hz, 1H), 6,92 (d, J = 1,2 Hz, 1H), 6,81 (dd, J = 7,7, 2,6 Hz, 1H), 4,60 - 4,52 (m, 2H), 3,89 - 3,83 (m, 6H).

[00459] N-{[3-fluoro-4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-{7-methoxyimidazo[1,2a]pyridin-3-yl}pyrimidin-4-am ina (A29) of F1 and D10; bleached powder; UPLC / MS 0.799 min, [M+H]+430. Petition 870260069920, of 14 / 07 / 2026, p. 121 / 519 115 / 219

[00460] 1H NMR (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (d, J = 1.1 Hz, 1H), 8.17 (s, 1H), 8.08 (d, J = 2.2 Hz, 1Hz, 1H), 8.08 (d, J = 7.2 Hz, 1H), t 6.2 Hz, 1H), 7.84 (dd, J = 1.5, 0.8 Hz, 1H), 7.65 (t, J = 8.2 Hz, 1H), 7.25 - 7.17 (m, 2H), 7.08 (d, J = 2.6 Hz, 1H, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.57 (d, J = 5.9 Hz, 2H), 3.88 (s, 3H), 3.30 (s, 3H).

[00461] 2-[4-(4-{[6-(7-methoxy-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl ino]-methyl}phenyl)-pyrazol-1 -yl]-ethanol (A30) of F1 and D11; solid branched; mp 257-258°C; HPLC / MS [M+H]+442.

[00462] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,17 8,12 (m, 1H), 8,10 (s, 1H), 7,91 - 7,82 (m, 2H), 7,53 (d, J = 8,4 Hz, 2H), 7,34 (d, J = 7,8 Hz, 2H), 7,08 (d, J = 2,6 Hz, 1H), 6,90 (d, J = 1,3 Hz, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,91 (t, J = 5,3 Hz, 1H), 4,54 (s, 2H), 4,14 (t, J = 5,7 Hz, 2H), 3,87 (s, 3H), 3,81 - 3,71 (m, 2H).

[00463] [6-(7-metóxi-imidazo[1,2-a]piridin-3-i l)-pirim idin-4-i l]-[4-(1 -metil-1 H[1,2,3]triazol-4-il)-benzil]-amina (Ά31) de F1 e D12; sólido branco; m.p. 254-255°C; HPLC / MS [M+H]+413.

[00464] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,52 (s, 1H), 8,47 (s, 1H), 8,16 (s, 1H), 7,92 (t, J = 6,2 Hz, 1H), 7,83 - 7,76 (m, 2H), 7,43 (d, J = 7,8 Hz, 2H), 7,08 (d, J = 2,6 Hz, 1H), 6,93 - 6,91 - 6,90 (m, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,59 (s, 2H), 4,08 (s, 3H), 3,87 (s, 3H). Petição 870260069920, de 14 / 07 / 2026, pág. 122 / 519 116 / 219

[00465] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirimidin-4-il]-[4-(2-metil-2H[1,2,3]triazol-4-il)-benzil]-amina (A32) (de F1 e D2); solid branco; mp 253-254°C; HPLC / MS [M+H]+413.

[00466] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.18 8.17 (m, 2H), 7.93 (t, J = 6.2 Hz, 1H), 7.83 - 7.76 (m, 2H), 7.44 (d, J = 7.8 Hz, 2H), 7.08 (d, J =2.6 Hz, 1H), 6.93-6.88 (m, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.60 (s, 2H), 4.18 (s, 3H), 3.87 (s, 3H).

[00467] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-({4-[ 1 -(oxetan-3-il)-1 H-pirazol-4-il]fenil}metil)pirimidin-4-amina (A33) de F1 e D13; pale pó amarelo; UPLC / MS 0.478 min, [M+H]+454.

[00468] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.31 (d, J = 0.8 Hz, 1H), 8.15 (s, 1H), 7.98 (d, J = 0.8 Hz, 1H), 7.85 (t, J = 6.1 Hz, 1H), 7.56 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 5.62 - 5.50 (m, 1H), 4.97 - 4.81 (m, 4H), 4.55 (d, J = 6.1 Hz, 2H), 3.87 (s, 3H).

[00469] 6-{7-methoximidazo[1,2-a]pyridin-3-yl}-N-{[4-(4-methoxipirim idin-2-yl)phenyl]me- Petition 870260069920, 14 / 07 / 2026, pág. 123 / 519 117 / 219 of F1 and D14; solid bitter pale; UPLC / MS 0.500 min, [M+H]+441.

[00470] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,64 (d, J = 5,2 Hz, 1H), 8,52 (d, J = 1,1 Hz, 1H), 8,16 (d, J = 8,4 Hz, 2H), 7,95 (t, J = 6,2 Hz, 1H), 7,67 (d, J = 5,3 Hz, 1H), 7,52 (d, J = 8,0 Hz, 2H), 7,08 (d, J = 2,6 Hz, 1H), 6,92 (d, J = 1,3 Hz, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,65 (d, J = 6,0 Hz, 2H), 3,98 (s, 4H), 3,87 (s, 3H).

[00471] [4-(3-amino-1 -metil-1 H-pirazol-4-il)-benzil]-[6-(7-metóxi-imidazo[1,2a]piridin-3-il)-pirimidin-4-il]-amina (A35) de F1 e D15; sólido branco; m.p. 271-272°C; HPLC / MS [M+H]+427.

[00472] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,50 (s, 1H), 8,17 8,13 (m, 1H), 7,88 (t, J = 6,2 Hz, 1H), 7,65 (s, 1H), 7,42 (d, J = 8,0 Hz, 2H), 7,34 - 7,28 (m, 2H), 7,07 (d, J = 2,6 Hz, 1H), 6,91 - 6,86 (m, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,59 (s, 2H), 4,52 (s, 2H), 3,87 (s, 3H), 3,60 (s, 3H).

[00473] 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[5-(1 -methyl-1 H-pyrazol-4-yl)thiophen-2yl]methyl}pyrimidine-4-amine (A36) of F1 and D16; pale yellow solid; HPLC / MS (A)1.24 min, [M+H]+418.

[00474] 1H NMR (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.56 (s, 1H), 8.16 (s, 1H), 7.93 (d, J = 0.7 Hz, 1H, 88), t 7.62 (d, J = 0.8 Hz, 1H), 7.08 (d, J = 2.6 Hz, 1H), 7.01 - 6.94 (m, 4H), 6.91 (s, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, 1H, J 2H), 3.88 (s, 3H), 3.81 (s, 3H).

[00475] 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-2H-1,2,3,4-tetrazol-5yl)phenyl]methyl}pyrimidine-4-amine (A37) Petition 870260069920, of 14 / 07 / 2026, p. 124 / 519 118 / 219 of F1 and D17; yellow powder; UPLC / MS 0.476 min, [M+H]+414.

[00476] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (d, J = 1.2 Hz, 1H), 8.16 (s, 1H), 8.02 (d, J = 8.2 Hz, 2H), 7.93 (t, J = 6.2 Hz, 1H), 7.54 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.92 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.65 (d, J = 6.1 Hz, 2H), 4.41(s, 3H), 3.88 (s, 3H).

[00477] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirim idin-4-il]-[4-(8-oxa-3-azabiciclo[3,2,1]oct-3-il)-benzil]-amina (A38) de F1 e D18; solid amarelo; mp 201-202°C; HPLC / MS [M+H]+443.

[00478] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.8 Hz, 1H), 8.49 (s, 1H), 8.23 ​​8.02 (m, 1H), 7.77 (t, J = 6.2 Hz, 1H), 7.29 - 7.16 (m, 2H), 7.08 (s, 1H), 6.92 - 6.66 (m, 4H), 4.51 - 4.27 (m, 4H), 3.87 (s, 3H), 3.43 - 3.35 (m, 1H), 3.32 - 3.26 (m, 1H), 2.79 - 2.69 (m, 2H), 1.93-1.71(m, 4H).

[00479] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-( 1 -metil-1 H-imidazol-5-il)fenil]metil}pirimidin-4-amina (A39)

[00480] of F1 and D19; you can love him; UPLC / MS 0.342 min, ([M+2H]2+) / 2 206.5. [00481 ]1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 9.14 (s, 1H), 8.60 (s, 1H), 8.28 Petition 870260069920, 14 / 07 / 2026, pág. 125 / 519 119 / 219 (s, 1 Η), 7.83 (d, J = 1.5 Hz, 1 Η), 7.67 - 7.43 (m, 5H), 7.28 (d, J = 2.6 Hz, 1H), 7.26 - 7.12 (m, 1H), 7.03 (s, 1H), 4.68 (s, 2H), 3.98 (s, 3H), 3.82 (s, 3H).

[00482] 6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}-N-{[4-(6-methylpyridazin-3-yl)phenyl]methyl}pyrimidin-4-amine (A40) de F1 and D20; branquiçada resin; UPLC / MS 0.452 min, [M+H]+424.

[00483] 1H NMR (400 MHz, DMSO-d6) δ 8.73 (s, 1H), 8.63 (s, 1H), 8.37 (t, J = 6.2 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 8.11 (d, J = 8.3 Hz, 2H), 7.69 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 2H), 7.32 (d, J = 2.6 Hz, 1H), 7.26 (dd, J = 7.7, 2.6 Hz, 1H), 7.05 (s, 1H), 4.70 (bs, 2H), 4.02 (s, 3H), 2.66 (s, 3H).

[00484] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-(2-metilpirim idin-5-il)fenil]metil}pirimidin-4-amina (A41) de F1 e D21; pó amarelo pallido; UPLC / MS 0.456 min, [M+H]+424.

[00485] 1H RMN (400 MHz, DMSO-d6) δ 9.73 (s, 1H), 9.00 (s, 2H), 8.52 (s, 1H), 8.23 ​​(s, 1H), 7.98 (t, J = 6.2 Hz, 1H), 7.82 - 7.69 (m, 2H), 7.51 (d, J = 7.8 Hz, 2H), 7.09 (s, 1H), 6.92 (s, 1H), 6.81 (d, J = 7.7 Hz, 1H), 4.62 (s, 2H), 3.87 (s, 3H), 2.65 (s, 3H).

[00486] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-(2-metil-1,3-oxazol-4-il)fenil]metil}pirimidin-4-amina (A42) Petition: 870260069920, on 07 / 14 / 2026, page. 126 / 519 120 / 219 de F1 e D22; pó esbranquiçado; UPLC / MS 0.495 min, [M+H]+495.

[00487] 1H RMN (500 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.40 (s, 1H), 8.14 (s, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.70 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.90 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 3.87 (s, 2H), 2.45 (s, 3H).

[00488] 5-(4-{[(6-{7-metoxiimidazo[1,2-a]piridin-3-il}pirimidin-4-il)amino]metil}fenil)-2metilpirimidin-4-amina (A43) de F1 e D23; Solido esbranquiçado; HPLC / MS(A) 0.95 min, [M+H]+439.

[00489] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (d, J = 1.1 Hz, 1H), 8.16 (s, 1H), 7.91 (t, J = 6.5 Hz, 1H), 7.89 (s, 1H), 7.45 (d, J = 7.9 Hz, 2H), 7.38 (s, 1H), 7.36 (d, J = 4.8 Hz, 1H), 7.09 - 7.06 (m, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 6.42 (s, (3H), 4.61 (d, J = 5.9 Hz, 2H), 3.88 (s, 3H), 2.35 (s, 3H).

[00490] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirimidin-4-il]-[5-(2-metil-2H) [1,2,3]triazol-4-yl)-pyridin-2-ylmethyl]-amine (A44) de F1 and D24; solid pack; mp 254-256°C; HPLC / MS [M+H]+414. [00491 ]1H NMR (300 MHz, DMSO-d6) δ 9.70 (d, J = 7.8 Hz, 1H), 8.99 (d, J = 2.1 Hz, 1H), 8.51 (s, 1H), 8.31 (s, 1H), 8.15 (d, J = 7.9 Hz, 2H), 7.96 (s, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.09 (d, J = 2.6 Hz, 1H), 6.99 (s, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, 1H), 4.70 (d, J = 6.0 Hz, 2H), 4.21 (s, 3H), 3.87 (s, 3H).

[00492] [6-(7-metóxi-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-4-yl]-[6-(2-methyl-2HPetição 870260069920, de 14 / 07 / 2026, pág. 127 / 519 121 / 219 [1,2,3]triazol-4-yl)-pyridin-3-ylmethyl]-amine (A45) de F1 and D25; solid love it; mp 260-261 °C; HPLC / MS [M+H]+414.

[00493] 1H RMN (300 MHz, DMSO-d6) δ 9.27 (s, 1H), 8.86 (s, 1H), 8.79 (s, 3H), 8.59 (s, 1H), 8.40 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 2.6 Hz, 2H), 7.28 (dd, J = 7.7, 2.7 Hz, 1H), 4.94 (s, 2H), 4.27 (s, 3H), 3.98 (s, 3H).

[00494] N-({4-[2-(2-metoxietil)-2H-1,2,3-triazol-4-il]fenil}metil)-6-{7-metoxiimidazo[1,2-a]piridin-3-il}pirimidin-4-amina (A46) de F1 e D26; solid marrom pallido; UPLC / MS 0.491 min, [M+H]+457.

[00495] 1H RMN (500 MHz, DMSO-d6) δ 9.74 - 9.68 (m, 1H), 8.52 (d, J = 1.2 Hz, 1H), 8.19 (s, 1H), 8.16 (s, 1H), 7.95 - 7.86 (m, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.46 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.92 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.67 - 4.53 (m, 5H), 3.88 (s, (3H), 3.85 (t, J = 5.3 Hz, 2H), 3.23 (s, 3H).

[00496] 6-{7-metoxiimidazo[1,2-a]piridin-3-il}-N-{[4-(3-metil-1,2,4-oxadiazol-5-il)fenil]metil}pirimidin-4-amina (A47) de F1; pó bege; UPLC / MS 0,488 min, [M+H]+414. Petição 870260069920, de 14 / 07 / 2026, pág. 128 / 519 122 / 219

[00497] 1H RMN (500 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,51 (d, J = 1,1 Hz, 1H), 8,16 (s, 1H), 8,06 (d, J = 8,3 Hz, 2H), 7,98 (t, J = 6,2 Hz, 1H), 7,59 (d, J = 8,0 Hz, 2H), 7,08 (d, J = 2,6 Hz, 1H), 6,93 (s, 1H), 6,80 (dd, J = 7,7, 2,7 Hz, 1H), 4,68 (d, J = 6,1 Hz, 2H), 3,88 (s, 3H), 2,40 (s, 3H).

[00498] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirim idin-4-il]-[4-(2-metil-oxazol-5-il)benzil]-amina (A48) de F1; sólido branco;m.p. 225-226°C; HPLC / MS [M+H]+413.

[00499] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,25 8,13 (m, 1H), 7,91 (t, J = 6,3 Hz, 1H), 7,66 - 7,60 (m, 2H), 7,49 - 7,40 (m, 3H), 7,08 (d, J = 2,6 Hz, 1H), 6,90 (s, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,63 - 4,54 (m, 2H), 3,87 (s, 3H), 2,46 (s, 3H).

[00500] [4-(1-ciclopropil-1 H-pirazol-4-il)-benzil]-[6-(7-metóxi-imidazo [1,2-a]piridin-3il)-pirimidin-4-il]-amina (A49) de F1 e D27; solid branco; mp 261-262°C; HPLC / MS [M+H]+438.

[00501] 1H RMN (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.8 Hz, 1H), 8.51 (s, 1H), 8.20 8.09 (m, 2H), 7.89 - 7.78 (m, 2H), 7.56 - 7.50 (m, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.61 - 4.51 (m, 2H), 3.87 (s, 3H), 3,72 (tt, J = 7.3, 3.8 Hz, 1H), 1.10-1.00 (m, 2H), 0.96 (ddd, J = 7.7, 6.4, 4.4 Hz, 2H).

[00502] N-{[4-(3-metóxi-1-metil-1 H-pirazol-4-il)fenil]metil}-6-{7-metoxiimidazo[1,2a]piridin-3-il}pirimidin-4-amina (A50) Petition: 870260069920, on 07 / 14 / 2026, page. 129 / 519 123 / 219 de F1 e D28; Solido esbranquiçado; HPLC / MS (B) 0.753 min, [M+H]+442.

[00503] 1H RMN (400 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,13 (s, 1H), 7,92 (s, 1H), 7,81 (t, J = 6,1 Hz, 1H), 7,54 (d, J = 8,3 Hz, 2H), 7,31 (d, J = 7,9 Hz, 2H), 7,07 (d, J = 2,6 Hz, 1H), 6,88 (d, J = 1,2 Hz, 1H), 6,79 (dd, J = 7,7, 2,6 Hz, 1H), 4,52 (d, J = 6,0 Hz, 2H), 3,87 (s, 6H), 3,70 (s, 3H).

[00504] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirim idin-4-il]-(4-oxazol-4-il-benzil)amina (A51) de F1 e D29; sólido amarelo pálido; m.p. 268 -269°C; HPLC / MS [M+H]+399.

[00505] 1H RMN (300 MHz, DMSO-d6) δ 9,68 (d, J = 7,7 Hz, 1H), 8,57 (d, J = 1,0 Hz, 1H), 8,50 (d, J = 1,1 Hz, 1H), 8,42 (d, J = 1,0 Hz, 1H), 8,14 (s, 1H), 7,90 (t, J = 6,1 Hz, 1H), 7,79 - 7,70 (m, 2H), 7,41 (d, J = 7,9 Hz, 2H), 7,06 (d, J = 2,6 Hz, 1H), 6,89 (d, J = 1,3 Hz, 1H), 6,78 (dd, J = 7,7, 2,7 Hz, 1H), 4,57 (d, J = 5,9 Hz, 2H), 3,85 (s, 3H).

[00506] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirim idin-4-il]-[4-(3-metil-isoxazol-5-il)benzil]-amina (A52) de F1 e D30; solid amarelo pallido; mp 198 - 199°C; HPLC / MS [M+H]+413.

[00507] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.20 8.14 (m, 1H), 7.95 (t, J = 6.2 Hz, 1H), 7.79 (d, J = 8.1 Hz, 2H). Petition: 870260069920, on 07 / 14 / 2026, page. 130 / 519 124 / 219

[00508] [6-(7-metóxi-imidazo[1,2-a]piridin-3-il)-pirim idin-4-il]-[4-(5-metil-oxazol-2-il)benzil]-amina (A53) de F1 e D31; solid amarelo; mp 281 - 282°C; HPLC / MS [M+H]+413.

[00509] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (d, J = 1.1 Hz, 1H), 8.19 - 8.14 (m, 1H), 7.95 (t, J = 6.2 Hz, 1H), 7.92 - 7.86 (m, 2H), 7.48 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 2.7 Hz, 1H), 6.99 - 6.89 (m, 2H), 6.80 (dd, J = 7.7, 2.7 Hz, 1H), 4.69 4.55 (m, 2H), 3.87 (s, 3H), 2.37 (s, 3H). Example 2 Síntese of 6-{7-fluoroimidazoí 1,2-a]piridin-3-il}-N-{[4-( 1 -metil-1 H-pirazol-4-il)fenillmetil}pirimidin-4-amina (H1)

[00510] A suspension of 6-[(E)-2-ethoxythenyl]-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine (G1) (335 mg, 1.00 mmol) in a mixture of 1,4-dioxane (4.5 mL) and water (1.5 mL) is cooled to 0°C and N-bromosuccinimide (196 mg, 1.10 mmol) is added in portions over a period of 15 minutes. After the last addition, the reaction mixture is stirred for 20 minutes at 0°C. 2-Amino-4-fluoropyridine (118 mg, 1.00 mmol) is added. The reaction solution is heated to 60°C and stirred at this temperature for 2 hours. The reaction mixture is allowed to reach temperature and poured into a 1 N aqueous NaOH solution (25 mL). The resulting mixture is stirred for Petition 870260069920, dated 07 / 14 / 2026, page 131 / 519 125 / 219 several hours. The resulting solid material is filtered, washed with water, dried and chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine as a pale yellow crystalline solid; HPLC / MS(B) 0.794 min, [M+H]+400.

[00511] 1H NMR (500 MHz, DMSO-d6) δ 9.94 - 9.85 (m, 1H), 8.55 (s, 1H), 8.28 (s, 1H), 8.07 (s, 1H), 7.91 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.9 Hz, 1H), 7.57 (dd, J = 9.8, 2.7 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.15 (td, J = 7.6, 2.8 Hz, 1H), 6.96 (d, J = 1.2 Hz, 1H), 4.55 (d, J = 5.8 Hz, 2H), 3.84 (s, 3H).

[00512] The following compounds are prepared analogously:

[00513] {6-[7-(2-methoxy-1-methoxymethyl-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-i I}[4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-amine (A54) de G1 e E2; sólido amarelo; m.p. 52 - 53°C; HPLC / MS [M+H]+452.

[00514] 1H RMN (300 MHz, DMSO-d6) δ 9,80 (s, 1H), 8,71 (s, 1H), 8,60 (s, 1H), 8,31 (s, 1H), 8,08 (s, 1H), 7,82 (s, 1H), 7,55 - 7,44 (m, 3H), 7,38 - 7,23 (m, 3H), 7,02 (s, 1H), 5,02 (t, J = 4,9 Hz, 1H), 4,63 - 4,48 (m, 2H), 3,85 (s, 3H), 3,73 - 3,51 (m, 4H), 3,27 (s, 6H).

[00515] [4-(1 -metil-1 H-pirazol-4-il)-benzil]-{6-[7-(tetra-hidro-piran-4-ilóxi)imidazo[1,2-a]piridin-3-il]-pinmidin-4-il}-amina (A55) de G1 e E3; sólido branco; m.p. 215 - 216°C; HPLC / MS [M+H]+482.

[00516] 1H RMN (300 MHz, DMSO-d6) δ 9,69 (d, J = 7,8 Hz, 1H), 8,59 - 8,41 (m, 1H), 8,41 - 8,02 (m, 2H), 7,95 -7,85 (m, 1H), 7,80 (s, 1H), 7,50 (d, J = 7,9 Hz, 2H), 7,30 (m, 2H), 7,20 (s, 1H), 6,97 - 6,71 (m, 2H), 4,79 - 4,77 (m, 1H), 4,62 - 4,48 (m, 2H), 3,94 - 3,80 (m, 5H), 3,52 (t, J = 10,4 Hz, 2H), 2,15-1,92 (m, 2H), 1,71 -1,51 (m, 2H). Petição 870260069920, de 14 / 07 / 2026, pág. 132 / 519 126 / 219

[00517] [4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-morpholin-4-yl-ethoxy)-imidazo[1,2a]pyridin-3-yl]-pyrimidine-4-yl}-amine (A56) of G1 and E4; debranched solid; mp 220 - 221 °C; HPLC / MS [M+H]+511.

[00518] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.6 Hz, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.7,806 (t, J = Hz 1H), 7.50 (d, J = 7.9 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.87 (s, 1H), 6.84 - 6.2, t, 4, 4 (m, 1H). J = 5.5 Hz, 2H), 3.83 (s, 3H), 3.57 (t, J = 4.7 Hz, 4H), 2.72 (t, J = 5.5 Hz, 2H), 2,512.42 (s, 4H).

[00519] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(tetra-hydro-furan-3-yloxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-amine (A57) of G1 and E5; debranched solid; mp 283 −294°C; HPLC / MS [M+H]+468.

[00520] 1H NMR (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.15 (s, 1H), 8.07 (s, 1H), 7.87 (t, J = 6.0 Hz, 1H), 7.80 (s, 1H), 7.50 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.88 (s, 1H), 6.85 - 6.67 (m, 1H), 5.22 - 5.15 (m, 1H), 4.62 - 4.51 (m, 2H), 3.96 - 3.72 (m, 7H), 2.39 - 2.21 (m, 1H), 2.06 -1.96 (m, 1H).

[00521] 6-[7-(cyclopropylmethoxy)imidazo[1,2-a]pyridin-3-yl]-N-{[4-(1-methyl-1H-pyrazol-4yl)phenyl]methyl}pyrimidin-4-amine (A58) Petition 870260069920, dated 07 / 14 / 2026, p. 133 / 519 127 / 219 of G1 and E6; pale yellow solid; mp 236 - 237°C; HPLC / MS [M+H]+452.

[00522] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.80 (s, 1H), 7.54 - 7.46 (m, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.00 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, 1H), 4.52 (d, 2H), 3.92 (d, J = 7.1 Hz, 2H), 3.83 (s, 3H), 1.31 - 1.19 (m, 1H), 0.65 - 0.50 (m, 2H), 0.42-0.28 (m, 2H).

[00523] 6-{7-[2-(dimetilamino)etóxi]imidazo[1,2-a]piridin-3-il}-N-{[4-(1 -metil-1 H-pira zol-4-il)fenil]metil}pirimidin-4-amina (A59) de G1 and E7; Solido esbranquiçado; mp 235 -236°C; HPLC / MS [M+H]+469.

[00524] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), J, 806 (t, J = Hz) 0.8 Hz, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, J = 1H, 6 1H), 4.57 − 4.49 (m, 2H), 4.14 (t, J = 5.7 Hz, 2H), 3.83 (s, 3H), 2.65 (t, J = 5.6 Hz, 2H), 2.21 (s, 6H).

[00525] [4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(2-pyrrolidin-1 -yl-ethoxy)-imidazo[1,2a]pyridine-3-yl]-pyrimidine-4-yl}-amine (A60) of G1 and E8; debranched solid; UPLC / MS 0.376 min, [M+H]+495.

[00526] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.71, 81,2, J = Hz 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 1H, J = 6.81 (dd, Hz 4.54 (d, J = 4.8 Hz, 2H), 4.19 (t, J = 5.5 Hz, 2H), 3.84 (s, 3H), 2.87 (bs, 2H), Petition: 870260069920, on 07 / 14 / 2026, page. 134 / 519 128 / 219 2.57 (bs, 4H), 1.71 (bs, 4H).

[00527] (6-{7-[2-(4-metil-piperazin-1-il)-etóxi]-imidazo[1,2-a]piridin-3-il}-pirim idin-4-il)[4-(1-metil-1 H-pirazol-4-il)-benzil]-amina (A61) de G1 e E9; solid branco; mp 200 - 201 °C; HPLC / MS [M+H]+524.

[00528] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.79 (dd, J = 7.7, 2.6 Hz, 1H), 4.59 - 4.47 (m, 2H), 4.16 (t, J = 5.6 Hz, 2H), 3.83 (s, 3H), 2.71 (t, J = 5.6 Hz, 2H), 2.57 (s, 2H), 2.44 (s, 2H), 2.30 (s, 4H), 2.13 (s, 3H).

[00529] {6-[7-(1 -metil-piperidin-4-ilmetóxi)-imidazo[1,2-a]pirid in-3-il]-pirim idin-4-il}-[4(1 -metil-1 H-pirazol-4-il)-benzil]-amina (A62) of G1 and E10; solid white; mp 238 −239°C; HPLC / MS [M+H]+509.

[00530] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 8.07 (s, 1H), J, 806 (t, J = Hz) 0.8 Hz, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 2.5 Hz, 1H), 6.87 (d, J = 1.2 Hz, J = 18 (dd), 6 1H), 4.55 − 4.49 (m, 2H), 3.93 (d, J = 5.9 Hz, 2H), 3.83 (s, 3H), 2.77 (d, J = 11.0 Hz, 2H), 2.14 (s, 3H), 1.5 J = 1.86 (t (d, J = 11.7 Hz, 3H), 1.40 1.25 (m, 2H).

[00531] {6-[7-(1 -methyl-piperidin-4-yloxy)-imidazo[1,2-a]pyridin-3-yl]-pinmidine-4-yl}-[4-(1 methyl-1 H-pyrazol-4-yl)-benzyl]-amine (A63) Petition 870260069920, dated 07 / 14 / 2026, p. 135 / 519 129 / 219 of G1 and E11; debranched solid; mp 224 - 225°C; HPLC / MS [M+H]+495.

[00532] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 8.07 (s, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.50 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.12 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.77 (dd, J = 7.7, 2.6 Hz, 1H), 4,70 - 4.46 (m, 3H), 3.83 (s, 3H), 2.65 - 2.54 (m, 2H), 2.31 - 2.12 (m, 5H), 2.08 - 1.88 (m, 2H), 1.83 - 1.59 (m, 2H).

[00533] 2-meti 1-1 -(3-{6-[4-(1 -metil-1 H-pirazol-4-il)-benzilam ino]-pirim idin-4-il}-im idazo[1,2-a]piridin-7-ilóxi)-propan-2-ol (A64) de G1 e E12; Solido esbranquiçado; mp 229 - 230°C; HPLC / MS [M+H]+480.

[00534] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.19 8.03 (m, 2H), 7.91 - 7.77 (m, 2H), 7.50 (d, J = 7.8 Hz, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.07 - 7.01 (m, 1H), 6.88 (s, 1H), 6.85 - 6.76 (m, 1H), 4.71 (s, 1H), 4.60 - 4.42 (m, 2H), 3.83 (s, 5H), 1.21 (s, 6H).

[00535] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(4-oxetan-3-yl-piperazin-1 -yl) ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pinmidin-4-yl)-amine (A65) of G1 and E13; yellow solid; mp 209-210°C; HPLC / MS [M+H]+566. Petition 870260069920, of 14 / 07 / 2026, p. 136 / 519 130 / 219

[00536] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.6 Hz, 1H), 8.49 (s, 1H), 8.16 8.05 (m, 2H), 7.93 - 7.85 (m, 1H, 7.8 Hz), J 1H), 7.50 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.87 (s, 1H), 6.79 (dd, J = 7.8, 2.6 Hz, 1H), t 6.5 Hz, 4H)

[00537] [6-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrim idin-4-yl]-[4-( 1 -methyl-1 H-pyrazol-4yl)-benzyl]-amine (A66) ofG1; solid branched; mp 229-230°C; HPLC / MS [M+H]+396.

[00538] 1H NMR (300 MHz, DMSO-d6) δ 9.71 (d, J = 7.2 Hz, 1H), 8.52 (s, 1H), 8.20 (s, 1H), 8.07 (s, 1H), 7.70, 81,H1), J = 1H), 7.55 - 7.44 (m, 3H), 7.33 (d, J = 7.8 Hz, 2H), 6.98 - 6.88 (m, 2H), 4.59 - 4.46 (m, 2H), 3.83 (s, 38H).

[00539] (6-{7-[2-(4-methyl-piperazine-1-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrim idin-4-yl)(4-[1,2,3]triazol-1 -yl-benzyl)-amine (A67) of G2 and E9) solid white; mp 233 - 234°C; HPLC / MS [M+H]+511.

[00540] 1H NMR (400 MHz, methanol-d4) δ 9.72 (d, J = 7.7 Hz, 1H), 8.53 (d, J = 8.0, 1.2 Hz, 2H), 8.07 (s, 1H), 7.820 (s, 7), 7.82H (s, 7 2H), 7.62 (d, J = 8.3 Hz, 2H), 7.00 (d, J = 2.6 Hz, 1H), 6.90 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.74 (s, 4, 2H), 4.74 (J, 2 = 2H), 2.90 (t, J = 5.4 Hz, 2H), 2.72 − 2.67 (m, 4H), 2.57 − 2.53 (m, 4H), 2.31 (s, 3H).

[00541] {6-[7-(2-morpholin-4-yl-ethoxy)-imidazo[1,2-a]pyridine-3-yl]-pyrimidine-4-yl}-(4[1,2,3]triazol-1-yl-benzyl)-amine (A68) Petition 870260069920, dated 07 / 14 / 2026, p. 137 / 519 131 / 219 of G2 and E4; solid white; mp 234 - 235°C; HPLC / MS [M+H]+498.

[00542] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.77 (s, 1H), 8.52 (s, 1H), 8.18 (s, 1H), 8.02 (d, J = 7,29), 8.2 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.10 (d, J =2.6 Hz, 1H), 6.92 (s, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, J, 1H, 4.67 (m), 4.67-4 5.6 Hz, 2H), 3.58 (t, J = 4.6 Hz, 4H), 2.73 (t, J = 5.5 Hz, 2H), 2.50 − 2.45 (m, 4H).

[00543] [6-(6-fluoro-7-methoxy-imidazo[1,2-a]pyrid in-3-yl)-pyrim idin-4-yl]-[4-(1 -methyl-1 Hpyrazol-4-yl)-benzyl]-amine (A69) (from G1; yellow solid; mp 299 - 300°C; HPLC / MS [M+H]+430.

[00544] 1H RMN (400 MHz, DMSO-d6) δ 8,58 (d, J = 2,8 Hz, 1H), 8,44 (s, 1H), 8,27 (s, 1H), 8,23-8,13 (m, 1H), 8,08 (s, 1H), 7,81 (s, 1H), 7,74-7,65 (m, 2H), 7,51 (d, J = 7,8 Hz, 2H), 7,37 - 7,26 (m, 2H), 4,60 - 4,48 (m, 2H), 3,95 (s, 3H), 3,84 (s, 3H).

[00545] {6-[7-(2-pirrol idin-1 -il-etóxi)-imidazo[1,2-a]piridin-3-il]-pirim id in-4-il}-(4[1,2,3]triazol-1-il-benzil)-amina (A70) de G2 e E8; sólido branco; m.p. 250 - 251 °C; HPLC / MS [M+H]+482. Petição 870260069920, de 14 / 07 / 2026, pág. 138 / 519 132 / 219

[00546] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,78 (s, 1H), 8,52 (s, 1H), 8,18 (s, 1H), 8,02 - 7,93 (m, 2H), 7,90 - 7,83 (m, 2H), 7,57 (d, J = 8,1 Hz, 2H), 7,09 (d, J = 2,6 Hz, 1H), 6,92 (s, 1H), 6,81 (dd, J = 7,7, 2,6 Hz, 1H), 4,64 (d, J = 5,3 Hz, 2H), 4,18 (t, J = 5,7 Hz, 2H), 2,83 (t, J = 5,7 Hz, 2H), 2,57-2,51 (m, 4H), 1,75 - 1,65 (m, 4H).

[00547] {6-[7-(2-metóxi-etóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-[4-(2-metil-2H[1,2,3]triazol-4-il)-benzil]-amina (A71) de G3 e E1; solid branco; mp 240 - 241 °C; HPLC / MS [M+H]+457.

[00548] 1H RMN (400 MHz, DMSO-d6) δ 9.71 (d, J = 7.8 Hz, 1H), 8.52 (s, 1H), 8.24 8.12 (m, 2H), 7.94 (t, J = 6.2 Hz, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.49 - 7.40 (m, 2H), 7.10 (d, J = 2.6 Hz, 1H), 6.91 (s, 1H), 6.83 (dd, J = 7.8, 2.7 Hz, 1H), 4.66 - 4.55 (m, 2H), 4.26 - 4.20 (m, 2H), 4,18 (s, 3H), 3.74 - 3.68 (m, 2H), 3.31 (s, 3H).

[00549] 6-[7-(benzilóxi)imidazo[1,2-a]piridin-3-il]-N-{[4-( 1 -metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A72) deG1; solid branco; HPLC / MS (A)1,43 min, [M+H]+488.

[00550] 1H RMN (500 MHz, DMSO-d6) δ 9,71 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,15 (s, 1H), 8,07 (s, 1H), 7,84 (t, J = 6,1 Hz, 1H), 7,81 (s, 1H), 7,54 - 7,46 (m, 4H), 7,46-7,38 (m, 2H), 7,40 - 7,31 (m, 3H), 7,17 (d, J = 2,6 Hz, 1H), 6,89 (s, 1H), 6,87 (dd, J = 7,7, 2,7 Hz, 1H), 5,23 (s, 2H), 4,54 (bs, 2H), 3,84 (s, 3H). [00551 ] [4-(2-metil-2H-[1,2,3]triazol-4-il)-benzi l]-{6-[7-(2-pirrol id in-1 -il-etóxi)imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-amina (A73) Petição 870260069920, de 14 / 07 / 2026, pág. 139 / 519 133 / 219 de G3 e E8; sólido branco; m.p. 235 - 236°C; HPLC / MS [M+H]+496.

[00552] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,52 (s, 1H), 8,21 8,16 (m, 1H), 7,94 (t, 1H), 7,85 - 7,75 (m, 2H), 7,45 (d, J = 7,8 Hz, 2H), 7,10 (d, J = 2,6 Hz, 1H), 6,94 - 6,89 (m, 1H), 6,82 (dd, J = 7,7, 2,6 Hz, 1H), 4,68 - 4,55 (m, 2H), 4,35 4,06 (m, 5H), 2,83 (t, J = 5,7 Hz, 2H), 2,56 - 2,52 (m, 4H), 1,81-1,59 (m, 4H).

[00553] [4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-morpholin-4-yl-propoxy)-imidazo[1,2a]pyridin-3-yl]-pyrimidine-4-yl}-amine (A74) of G1 and E14; solid white; mp 213 −214°C; HPLC / MS [M+H]+496.

[00554] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.17 8.12 (m, 1H), 8.08 (s, 1H, 1H), J = 7 (7, Hz (s, 1H), 7.55 - 7.48 (m, 2H), 7.37 - 7.31 (m, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.86 (s, 1H), 6.80 (dd, J = 7-1H 4, 2.6 (m, 2H), 4.13 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 3.58 (t, J = 4.6 Hz, 4H), 2.44 (t, J = 7.2 Hz, 2H), 2.40 - J = 2.35 (m, 2H).

[00555] [4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1 -yl-propoxy)-im idazo[1,2a]pyridine-3-yl]-pyrimidine-4-yl}-amine (A75) of G1 and E15: debranched solid; mp 213°C; UPLC / MS 0.377 min [M+H]+509.

[00556] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.14 (s, 1H), 8.08 (s, 1H), J, 81, 61,2 = J = Hz 0.8 Hz, 1H), 7.52 (d, J = 8.2 Hz, Petition 870260069920, dated 07 / 14 / 2026, p. 140 / 519 134 / 219 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.06 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 4, 1H), H = 4, 4.14 (t, J = 6.3 Hz, 2H), 3.85 (s, 3H), 2.55 (t, J = 7.2 Hz, 2H), 2.49 - 2.41 (m, 4H), 1.93 (p, J = 6.7 Hz, 1.75 H).

[00557] [4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-( 1 -oxetan-3-yl-piperidine-4ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine-amine (A7-yl} of G3 and E17): yellow solid; mp 181 - 182°C; HPLC / MS [M+H]+552.

[00558] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.20 8.07 (m, 2H), 7.92 (t, J = 6.1 Hz, 1H), 7.82 - 7.73 (m, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (s, 1H), 6.79 (dd, J = 7.7, 2.6 Hz, 1H), 4.70 - 4.47 (m, 4H), 4.40 (t, J = 6.0 Hz, 2H), 4.16 (s, (3H), 3.94 (d, J = 5.8 Hz, 2H), 3.40 - 3.33 (m, 1H), 2.78 - 2.62 (m, 2H), 1.87- 1.62 (m, 5H), 1.43 - 1.22 (m, 2H).

[00559] 6-{7-[2-(3,3-d if luoropirrol id in-1-il)etóxi]imidazo[1,2-a]pirid in-3-il}-N-{[4-( 1-metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A77) de G1 and E18; Solid laranja pallido; UPLC / MS 0.439 min, [M+H]+531.

[00560] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.73 (t, 81,2), J = Hz 0.8 Hz, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.10 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, J = 1H (dd), 6 1H), 4.54 (d, J = 5.3 Hz, 2H), 4.20 (t, J = 5.5 Hz, 2H), 3.84 (s, 3H), 3.00 (t, J = 13.5 Hz, 2H), 2.88 (t, J = 2, 7 Hz, H0, Hz), 2.2. 2H), 2.24 (tt, J = 15.3, 7.0 Hz, 2H). [00561 ] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-( 1 -oxetan-3-yl-piperidine-4-ylmethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl})amine (A Petition 870260069920, dated 07 / 14 / 2026, p. 141 / 519 135 / 219 of G1 and E17; solid white; mp 241 - 242°C; HPLC / MS [M+H]+551.

[00562] 1H RMN (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.22 8.06 (m, 2H), 7.91 - 7.80 (m, 2H), 7.55 - 7.48 (m, 2H), 7.37 - 7.27 (m, 2H), 7.09 - 7.04 (m, 1H), 6.89 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.59 - 4.37 (m, 6H), 3.96 (d, J = 5.9 Hz, 2H), 3.84 (s, 3H), 3,42 - 3.36 (m, 1H), 2.75 - 2.68 (m, 2H), 1.84 -1.68 (m, 5H), 1.41-1.27 (m, 2H).

[00563] {6-[7-(1 -metil-piperidin-4-ilmetóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-[4(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A79) de G3 and E19; solid branco; mp 240 - 241 °C; HPLC / MS [M+H]+510.

[00564] 1H RMN (400 MHz, DMSO-d6) 9.70 (d, J = 7.8 Hz, 1H), 8.51 (s, 1H), 8.24 8.09 (m, 2H), 7.93 (t, J = 6.2 Hz, 1H), 7.79 (d, J = 8.2 Hz, 2H), 7.51 - 7.39 (m, 2H), 7.09 7.04 (m, 1H), 6.90 (s, 1H), 6.80 (dd, J = 7.8, 2.6 Hz, 1H), 4.66 - 4.51 (m, 2H), 4.18 (s, 3H), 3.94 (d, J = 5.8 Hz, 2H), 2.78 (d, J = 11.0 Hz, 2H), 2.15 (s, 3H), 1.85 (t, 2H), 1.78 - 1.67 (m, 3H), 1.39 - 1.25 (m, 2H).

[00565] {6-[7-(1 -metil-piperidin-4-ilmetóxi)-imidazo[1,2-a]pirid in-3-il]-pirim id in-4-il}-(4[1,2,3]triazol-1-il-benzil)-amina (A80) de G2 and E19; solid branco; mp 221 -222°C; HPLC / MS [M+H]+496.

[00566] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.79 (s, 1H), 8.52 (s, 1H), 8.23 ​​- 8.11 (m, 1H), 8.03 - 7.93 (m, 2H), 7.91 - 7.83 (m, 2H), 7.57 (d, J = 8.1 Hz, Petition: 870260069920, on 07 / 14 / 2026, page. 142 / 519 136 / 219 2H), 7.07 (d, J = 2.6 Hz, 1 Η), 6.92 (d, J = 1.3 Hz, 1 Η), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.69 - 4.59 (m, 2H), 3.95 (d, J = 5.9 Hz, 2H), 2.80 (d, J = 11.0 Hz, 2H), 2.17 (s, 3H), 1.98 -1.70 (m, 2H), 1.75 (d, J = 11.5 Hz, 3H), 1.39- 1.22 (m, 2H).

[00567] N-{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}-6-{7-nitroimidazo[1,2-a]pirid in-3-il}pyrimidin-4-amina (A81) deG1; pó amarelo; UPLC / MS 0.740 min, [M+H]+427.

[00568] 1H RMN (400 MHz, DMSO-d6) δ 9.99 (d, J = 7.8 Hz, 1H), 8.73 - 8.53 (m, 3H), 8.08 (d, J = 5.0 Hz, 2H), 7.85 (dd, J = 7.7, 2.5 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.66 7.47 (m, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.10 (d, J = 1.2 Hz, 1H), 4.58 (s, 2H), 3.84 (s, 3H).

[00569] 6-{7-chloroimidazo[1,2-a]piridi n-3-il}-N-{[4-( 1 -metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A82) deG1; Solido esbranquiçado; UPLC / MS 0.645 min, [M+H]+416.

[00570] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (d, J = 7.5 Hz, 1H), 8.56 (s, 1H), 8.32 (s, 1H), 8.07 (s, 1H), J, 8, 81 (t, J = Hz 2.2, 0.8 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.7 Hz, 2H), 7.18 (dd, J = 1.5 Hz, J, = 9 1.2 Hz, 1H), 4.55 (s, 2H), 3.84 (s, 3H).

[00571] {6-[7-(1-oxetan-3-yl-piperidine-4-ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine4-yl}-(4-[1,2,3]triazol-1 -yl-benzyl)-amine (A83) of G2 and E17; debranched solid; mp 272 - 273°C; HPLC / MS [M+H]+538. Petition 870260069920, dated 07 / 14 / 2026, p. 143 / 519 137 / 219

[00572] 1H NMR (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.81 − 8.76 (m, 1H), 8.52 (s, 1H), 8.18 (s, 7.73 (m), − 8,8 (d, J = 8.5 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.95 − 6.90 (m, 1H), 6.81 (dd, J = 7.7, 2H, 2.6), 4.52 (t, J = 6.4 Hz, 2H), 4.42 (t, J = 6.1 Hz, 2H), 3.96 (d, J = 5.8 Hz, 2H), 2.75 2.68 (m, 2H), 2.72(d, J = 72.2 (Ht), 1 Hz, 5H), 1.35 (t, J = 12.2 Hz, 2H).

[00573] [4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzi l]-{6-[7-(3-pyrrol id in-1 -yl-propoxy) imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-amine of G3e E15; solid yellow; mp 251 −242°C; HPLC / MS [M+H]+510.

[00574] 1H RMN (300 MHz, DMSO-d6) δ 9,69 (d, J = 7,8 Hz, 1H), 8,51 (s, 1H), 8,22 8,11 (m, 2H), 7,93 (t, J = 6,1 Hz, 1H), 7,79 (d, J = 8,2 Hz, 2H), 7,44 (d, J = 7,8 Hz, 2H), 7,06 (d, J = 2,6 Hz, 1H), 6,90 (s, 1H), 6,80 (dd, J = 7,8, 2,6 Hz, 1H), 4,68 - 4,52 (m, 2H), 4,17 (s, 3H), 4,12 (t, J =6,3 Hz, 2H), 2,60-2,53 (m, 2H), 2,47-2,41 (m, 3H), 1,92 (p, J = 6,7 Hz, 2H), 1,77- 1,60 (m, 4H).

[00575] 2-meti 1-1 -(3-{6-[4-(2-metil-2H-[1,2,3]triazol-4-i l)-benzi lam ino]-pirim idin-4-i I}imidazo[1,2-a]piridin-7-ilóxi)-propan-2-ol (A85) de G3 e E12; sólido branco; m.p. 195 - 196°C; HPLC / MS [M+H]+471.

[00576] 1H RMN (400 MHz, DMSO-d6) δ 8,53 (s, 1H), 8,22-8,10 (m, 2H), 7,94 (t, J = 6,2 Hz, 1H), 7,80 (d, J = 8,2 Hz, 2H), 7,45 (d, J = 7,8 Hz, 2H), 7,06 (d, J = 2,6 Hz, 1H), 6,91 (d, J = 1,2 Hz, 1H), 6,83 (dd, J = 7,7, 2,6 Hz, 1H), 4,73 (s, 1H), 4,60 (s, 2H), 4,18 (s, 3H), 3,84 (s, 2H), 1,23 (s, 6H).

[00577] 7-[2-(4-methyl-piperazin-1 -yl)-ethoxy]-3-{6-[4-( 1 -methyl-1 H-pyrazol-4-yl)-benzyloxy]pyrimidin-4-yl}-imidazo[1,2-a]pyridine (A86) Petition 870260069920, of 14 / 07 / 2026, p. 144 / 519 138 / 219 of G4 and E9; pale brown solid; mp 210–211 °C; HPLC / MS [M+H]+525.

[00578] 1H NMR (300 MHz, DMSO-d6) δ 9.75 (d, J = 7.7 Hz, 1H), 8.83 (d, J = 1.1 Hz, 1H), 8.48 (s, 1H), 8.13 (s, 1H, 1H, 7.8), J = 0, Hz, 7.63 -7.52 (m, 2H), 7.47 (d, J = 1.2 Hz, 1H), 7.45 (d, J = 8.1 Hz, 2H), 7.15 (d, J= 2.6 Hz, 1H), 6.87 (dd, J = 7.7, 2.6 Hz, 2.2Hz), (s 4.18 (t, J = 5.6 Hz, 2H), 3.84 (s, 4H), 2.71 (t, J = 5.5 Hz, 2H), 2.55 - 2.23 (m, 8H), 2.14 (s, 3H).

[00579] 3-{6-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzy loxy]-pyrim id in-4-yl}-7-(2-pyrrole id in-1 -ylethoxy)-imidazo[1,2-a]pyridine (A87) of G4 and E8; white solid; mp 177-178° C; HPLC / MS [M+H]+496.

[00580] 1H NMR (300 MHz, DMSO-d6) δ 9.75 (d, J = 7.7 Hz, 1H), 8.83 (d, J = 1.0 Hz, 1H), 8.48 (s, 1H), 8.13 (s, 5, 185H), 8.13 (s, 7, 185H), 8.2 Hz, 2H), 7.49 - 7.42 (m, 3H), 7.14 (d, J = 2.6 Hz, 1H), 6.87 (dd, J = 7.7, 2.6 Hz, 1H), 5.42 (s, 2H), 4,3, 8.6 (t 3H), 2.81 (t, J = 5.7 Hz, 2H), 2.55 − 2.46 (m,4H), 1.67 (p, J = 3.0 Hz, 4H).

[00581] 4-[3-({3-[6-({[[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidine-4-yl]imidazo[1,2-a]pyridin-7-yl}oxy)propyl]morpholin-3-one (A88) of G1 and E20; debranched solid; UPLC / MS 0.478 min, [M+H]+539.

[00582] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2), Petition 870260069920, dated 07 / 14 / 2026, p. 145 / 519 139 / 219 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.9 Hz, 2H), 4.11 (t, J = 6.2 Hz, 2H), 4.01 (s, 2H), 3.84 (s, 3H), 3.84 - 3.81 (m, 3H), 3.50 (t, J = 7.1 Hz, 2H), 3.38 (dd, J = 5.9, 4.4 Hz, 2H), 2.02 (p, J = 6.5 Hz, 2H). (A89) de G1 e E21; Solido esbranquiçado; UPLC / MS 0.382 min, [M+H]+513.

[00584] 1H RMN (500 MHz, DMSO-d6) δ 9.75 (d, J = 7.7 Hz, 1H), 8.53 (s, 1H), 8.24 (s, 1H), 8.07 (d, J = 0.9 Hz, 1H), 7.92 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.22 (d, J = 2.6 Hz, 1H), 5.46 (d, J = 53.8 Hz, 1H), 4.55 (d, J = 5.9 Hz, 2H), 4.49 (t, J = 5.0 Hz, 2H), 3.84 (s, 3H), 3.9 - 3.1 (m, 6H), 2.22 (bs, 2H).

[00585] 7-[2-(3,3-d if luoro-pirrol id in-1 -il)-etóxi]-3-{6-[4-( 1 -metil-1 H-pirazol-4-i I)benzilóxi]-pirimidin-4-il}-imidazo[1,2-a]piridina (A90) de G4 and E18; solid branco; mp 178-179°C; HPLC / MS [M+H]+532.

[00586] 1H RMN (300 MHz, DMSO-d6) δ 9.76 (d, J = 7.7 Hz, 1H), 8.84 (d, J = 1.1 Hz, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 7.86 (s, 1H), 7.57 (d, J = 8.2 Hz, 2H), 7.47 (d, J = 1.1 Hz, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.16 (d, J = 2.7 Hz, 1H), 6.89 (dd, J = 7.7, 2.6 Hz, 1H), 5.42 (s, 2H), 4.20 (t, J = 5.5 Hz, (2H), 3.84 (s, 3H), 2.99 (t, J = 13.5 Hz, 2H), 2.87 (t, J = 5.4 Hz, 2H), 2.80 (t, J = 7.0 Hz, 2H), 2.23 (tt, J = 15.0, 7.0 Hz, 2H).

[00587] {6-[7-(2,2-dimetil-3-pirrolidin-1 -il-propóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin4-il}-[4-(1 -metil-1 H-pirazol-4-il)-benzil]-amina (A91) Petition: 870260069920, on 07 / 14 / 2026, page. 146 / 519 140 / 219 of G1 and E22; solid white; mp 251–252°C; HPLC / MS [M+H]+537.

[00588] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.08 (d, J = 0.8 Hz, J = 1, 7), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (Hdd, J = 6, 8, 1.1). 7.7, 2.6 Hz, 1H), 4.54 (s, 2H), 3.84 (s, 3H), 3.82 (s, 2H), 2.57 - 2.51 (m, 4H), 2.45 (s, 2H), 1.63 (H, J 0, 3.4).

[00589] 4-[2-({3-[6-({[[4-(1 -methyl-1 H-pyrazol-4-yl)pheni l]methyl}am ino)pyrim id in-4-yl] and idazo[1,2-a]pyridin-7-yl}oxy)ethyl]morpholin-9)-ona (A of G1 and E24; debranched solid; HPLC / MS(A) 1.19 min, [M+H]+525.

[00590] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.83 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7,7, 2,6 Hz, 1H), 4.54 (d, J = 5.7 Hz, 2H), 4.27 (t, J = 5.6 Hz, 2H), 4.05 (s, 2H), 3.84 (s, 3H), 3.84 - 3.81 (m, 2H), 3.75 (t, J = 5.6 Hz, 2H), 3.54 - 3.48 (m, 2H).

[00591] 1-metil-4-[2-({3-[6-({[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}am ino)pirim idin-4il]imidazo[1,2-a]piridin-7-il}óxi)etil]piperazin-2-ona (A93) de G1 e E26; resina amarela pallida; UPLC / MS0,424 min, [M+H]+538.

[00592] 1H RMN (500 MHz, DMSO-d6) δ 9.83 (s, 1H), 8.60 (s, 1H), 8.17 (t, J = 6.2 Hz, Petition: 870260069920, on 07 / 14 / 2026, page. 147 / 519 141 / 219 Η), 8.07 (s, 1 Η), 7.81 (d, J = 0.8 Hz, 1H), 7.58 - 7.47 (m, 2H), 7.37 - 7.30 (m, 3H), 7.24 7.14 (m, 1H), 7.01 (s, 1H), 4.57 (s, 2H), 4.50 (t, J = 5.0 Hz, 2H), 3.85 (s, 3H), 3.64 (s, 2H), 3.52 - 3.41 (m, 4H), 3.42 - 3.19 (m, 4H), 2.87 (s, 3H).

[00593] N-{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}-6-{7-[3-(4-metilpiperazin-1 -il)propóxi]imidazo[1,2-a]piridin-3-il}pirimidin-4-amina (A94) de G1 e E27; resina amarela; UPLC / MS0,376 min, [M+H]+538.

[00594] 1 -[2-({3-[6-({[4-(1 -metil-1 H-pirazol-4-il)feni l]metil}am ino)pirim id in-4il]imidazo[1,2-a]piridin-7-il}óxi)etil]-4-(oxetan-3-il)piperazin-2-ona (A95) de G1 e E28; Agulhas esbranquiçadas; HPLC / MS(A) 1.16 min, [M+H]+580.

[00595] 1H RMN (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.83 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7,7, 2,6 Hz, 1H), 4.54 (t, J = 6.6 Hz, 2H), 4.44 (t, J = 6.1 Hz, 2H), 4.25 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 3.72 (t, J = 5.6 Hz, 2H), 3.52 (p, J = 6.2 Hz, 1H), 3.47 (dd, J = 6.1,4.8 Hz, 2H), 2.97 (s, 2H), 2.58 (dd, J = 6.2, 4.7 Hz, 2H). (A96) de G3 e E27; solid amarelo pallido; UPLC / MS0,367 min, [M+H]+539. Petition: 870260069920, on 07 / 14 / 2026, page. 148 / 519 142 / 219

[00597] 5-fluoro-6-{7-metoxiimidazo[1,2-a]piridin-3-i Ι}-Ν-{[4-( 1 -metil-1 H-pirazol-4il)fenil]metil}pirimidin-4-amina (A97) of G5; pó peeled; UPLC / MS0,519 min, [M+H]+430.

[00598] 1H NMR (500 MHz, DMSO-d6) δ 9.77 (d, J = 7.8 Hz, 1H), 8.37 (d, J = 2.2 Hz, 1H), 8.28 (t, J = 6.2 Hz, 1H, 3), J = 8.4 8.07 (s, 1H), 7.81 (d, J = 0.6 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 2.6 Hz, J, 85 ( 85), 1H), 4.65 (d, J = 6.1 Hz, 2H), 3.91 (s, 3H).

[00599] (6-{7-[2-(1 -methyl-1 H-imidazol-2-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}-pyrim id in4-yl)-[4-(2-methyl-2H-[1,2,3]amine-benzyl-4-8-yl) of G3 and E30; white solid, mp 240–241 °C; HPLC / MS [M+H]+507.

[00600] 1H NMR (300 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.78 (d, J = 19.4 Hz, 2H), 8.18 (s, 1H), 8.12 (s, 2H), 7.79 J 67 (d, J = = 17.3, 1.9 Hz, 2H), 7.48 (d, J = 2.5 Hz, 3H), 7.40 − 7.26 (m, 2H), 4.75 (s, 2H), 4.66 (t, J = 5.6 Hz, 2H), s 3,8.14 (s 3.58 (s, 2H). [00601 ] 6-{7-[2-(azetidine-1 -yl)ethoxy] im idazo[ 1,2-a]pyride in-3-yl}-N-{[4-( 1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine (A99) of G1 and E31; white powder; UPLC / MSO, 362 min, [M+H]+481.

[00602] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.14 Petition 870260069920, of 14 / 07 / 2026, p. 149 / 519 143 / 219 (s, 1 Η), 8.08 (s, 1 Η), 7.83 (t, J = 6.2 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.5 (d, J = 8.3 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.78 (dd, J = 7.7, 2.6 Hz, 1H), 4.55 (d, J = 6.0 Hz, 2H), 4.03 (t, J = 5.5 Hz, 3.8Hz), 3H), 3.20 (t, J = 6.9 Hz, 4H), 2.74 (t, J = 5.5 Hz, 2H), 1.98 (p, J = 6.9 Hz, 2H).

[00603] 6-{7-[2-(azetidine-1 -yl)ethoxy] im idazo[1,2-a]pyridin-3-yl}-N-{[4-(2-methyl-2H-1,2,3triazol-4-yl)phenyl]methyl}pyrimidine-4-amine (A100) of G3 and E31; bleached powder; UPLC / MS0.364 min, [M+H]+482.

[00604] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.17 (s, 1H), 8.15 (s, 1H), J, 81, 60 (t, J = Hz) 8.3 Hz, 2H), 7.45 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.78 (dd, J = 7.7, 2.6 (J0, Hz), J = 7.6, 1.6, 4, Hz 2H), 4.03 (t, J = 5.5 Hz, 2H), 3.20 (t, J = 6.9 Hz, 4H), 2.75 (t, J = 5.5 Hz, 2H), 1.98 (p, J = 6.9 Hz, 2H).

[00605] Trifluoroacetate of 6-{7-[3-(3,3-difluoropyrrolidin-1 -yl)propoxy]imidase[1,2-a]pyridin-3-yl}-N-{[4-( 1 -methyl-1 H-pyrazol-4-yl-ylpyrimidine)methyl of G1 and E32; pó peeled; UPLC / MS0,408 min, [M+H]+545.

[00606] 1H RMN (500 MHz, DMSO-d6) δ 9.83 (s, 1H), 8.60 (s, 1H), 8.16 (t, J = 6.1 Hz, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.28 (d, J = 2.6 Hz, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.00 (s, 1H), 4.57 (s, 2H), 4.28 (t, J = 6.0 Hz, 2H), 3.85 (s, 3H), 2.15 (p, J = 5.9 Hz, 3H), 4.0 - 3.0 (sinais amplos). Example 3 (A102) Petition: 870260069920, on 07 / 14 / 2026, page. 150 / 519 144 / 219

[00608] To a suspension of 6-{7-fluoroimidazo[1,2-a]pyridin-3-yl}-N-{[4-(1-methyl-1-Hpyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine (H1) in dioxane (48 mL) is added 3-(azetidin-1-yl)propan-1-ol (415 mg, 3.60 mmol) and the mixture is flooded with argon. Potassium tert-butanolate (1.01 g, 9.01 mmol) is added in portions. The mixture is heated to 100°C and stirred at this temperature for 18 hours. The reaction mixture is allowed to reach room temperature, treated with methanol, and evaporated. The residue is captured in water. The solids are filtered, washed with water, and dried. The residue is chromatographed on a silica gel column with dichloromethane / methanol as eluent to give 6-{7-[3-(azetidin-1-yl)propoxy]imidazo[1,2-a]pyridin-3-yl}-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine}pinmidin-4-amine as a whitish solid; HPLC / MS(B) 0.639 min, [M+H]+495.

[00609] 1H NMR (500 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.13 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.82 (t, J = 6.1 Hz, 1H, 80), 7.82 (d, J = 6.1 Hz, 1H, 80), J 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.03 (d, J = 2.5 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.78 (dd, J = 7.7 Hz, 14 Hz), J = 6.0 Hz, 2H), 4.09 (t, J = 6.4 Hz, 2H), 3.84 (s, 3H), 3.17 (s, 1H), 3.09 (t, J = 6.9 Hz, 4H), 2.46 (t, J = 6.9 Hz, 4H), 2H), 1.73 (p, J = 6.6 Hz, 2H).

[00610] The following compounds are similarly prepared: [00611 ] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(6-oxa-3-aza-bicyclo[3,1,1 ]hept-3yl)-ethoxy]-im idazo[1,2-a]pyridin-3-yl}-pyrimidine-4-1-3) (Al Petition 870260069920, of 14 / 07 / 2026, p. 151 / 519 145 / 219 of H1; white solid; mp 185 - 187°C; HPLC / MS [M+H]+523.

[00612] 1H RMN (400 MHz, DMSO-d6)õ 9,70 (d, J = 7,6 Hz, 1H), 8,52 (s, 1H), 8,22 8,14 (m, 1H), 8,10 (s, 1H), 7,89 (t, J = 6,1 Hz, 1H), 7,82 (s, 1H), 7,52 (d, J = 8,1 Hz, 2H), 7,39 - 7,28 (m, 2H), 7,14 (d, J = 2,6 Hz, 1H), 6,90 (s, 1H), 6,83 (dd, J = 7,7, 2,6 Hz, 1H), 4,58 - 4,49 (m, 2H), 4,44 (d, J = 6,2 Hz, 2H), 4,26 (t, J = 5,7 Hz, 2H), 3,85 (s, 3H), 3,17 3,09 (m, 2H), 3,05 - 2,96 (m, 2H), 2,88 - 2,82 (m, 1H), 2,81 - 2,74 (m, 2H), 2,22 - 2,16 (m, 1H).

[00613] {6-[7-(2-amino-2-metil-propóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-[4-(1 meti 1-1 H-pirazol-4-il)-benzil]-amina (A104) de H1; sólido branco; m.p. 224 - 225°C; HPLC / MS [M+H]+469.

[00614] 1H NMR (300 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 7.72, 81 (t, J = Hz 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 1H, 6.83 (dd, 7 4.54 (s, 2H), 3.84 (s, 3H), 3.77 (s, 2H), 1.23 (s, 2H), 1.12 (s, 6H).

[00615] (6-{7-[2-(3,3-difluoro-pyrrolidin-1 -yl)-ethoxy]-im idazo[1,2-a]pyridine-3-yl}-pyrimidine4-yl)-[4-(2-methyl-2H-[1,2,3]triazol-5)benzyl-4-4 of H2; solid white; mp 257–258° C; HPLC / MS [M+H]+532.

[00616] 1H NMR (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.8 Hz, 1H), 8.50 (s, 1H), 8.17 (s, 1H), 7.93 (t, J = 6.1 Hz, J = 18H (2), 7.42 (d, J = 7.9 Hz, 2H), 7.10 (s, 1H), 6.89 (s, 1H), 6.81 (dd, J = 7.7, 2.3 Hz, 1H), 4.58 (s, 2H), 4.28 , J = 3.91 (m Hz, 2H), 2.86 (t, J = 5.3 Hz, 2H), 2.79 (t, J = 7.0 Hz, 2H), 2.23 (tt, J = 15.2, 6.9 Hz, 2H). Petition: 870260069920, on 07 / 14 / 2026, page. 152 / 519 146 / 219

[00617] [4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-{6-[7-(pirid in-2-ilm etóxi)-im idazo[ 1,2a]piridin-3-il]-pirimidin-4-il}-amina (A106) de H2; solid branco; mp 240 - 241 °C; HPLC / MS [M+H]+490.

[00618] 1H RMN (300 MHz, DMSO-d6) δ 9.72 (d, J = 7.7 Hz, 1H), 8.59 (dt, J = 4.7, 1.5 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 1H), 7.92 (t, J = 6.1 Hz, 1H), 7.85 (td, J = 7.7, 1.8 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.0 Hz, 2H), 7.36 (ddd, J = 7.6, 4.8, 1.2 Hz, 1H), 7.16 (d, J = 2.6 Hz, 1H), 6.93-6.88 (m, 2H), 5.28 (s, 2H), 4.58 (d, J = 5.8 Hz, 2H), 4.16 (s, 3H).

[00619] {6-[7-(2-metil-2-morfolin-4-il-propóxi)-imidazo[1,2-a]pirid in-3-il]-pirim id in-4-i I}[4-(1 -metil-1 H-pirazol-4-il)-benzil]-amina (A107) de H1; solid branco; mp 233 -234°C; HPLC / MS [M+H]+539.

[00620] 1H NMR (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.15 (s, 1H), 8.08 (s, 1H), J, 81 (t = Hz), J = Hz 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.13 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, J = 1H (dd), 6 1H), 4.53 (d, J = 5.9 Hz, 2H), 3.96 (s, 2H), 3.84 (s, 3H), 3.55 (t, J = 4.5 Hz, 4H), 2.61 (t, J = 4.5 Hz, 4H), 1.6H (s, 1.12). [00621 ] [4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-(6-{7-[2-(2-oxa-6-azaespiro[3,3]hept-6-yl)-ethoxy]-imidazo[1,2-a]-pyridine-1-pyridin-1-yl-mine Petition 870260069920, dated 07 / 14 / 2026, p. 153 / 519 147 / 219 of H2; solid white; mp 245 −246°C; HPLC / MS [M+H]+524.

[00622] 1H NMR (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 1H), 8.14 (s, 1H), J, 671 (t = Hz), J = 8.2 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.76 (dd, J = 7.7, 2.6, -m4, 6H), 4.16 (s, 3H), 4.00 (t, J = 5.4 Hz, 2H), 3.30 (s, 4H), 2.70 (t, J = 5.3 Hz, 2H).

[00623] {6-[7-(2-methyl-2-morpholin-4-yl-propoxy)-imidazo[1,2-a]pyridine-3-yl]-pinmidine-4-yl}[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-ina (A1]0-am of H2; solid white; mp 220 - 221 °C; HPLC / MS [M+H]+540.

[00624] 1H NMR (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.15 (d, J = 6.9 Hz, 2H), 7.91 (H, J 7, =7.2), 8.2 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.12 (d, J = 2.6 Hz, 1H), 6.92 - 6.78 (m, 2H), 4.58 (s, 2H), 4.16 (s, 2H), 4.16 (s, 2, 3H), 4.5 Hz, 4H), 2.60 (d, J = 4.9 Hz, 4H), 1.11 (s, 6H). (A110) de H3; solid branco; mp 255 - 256°C; HPLC / MS [M+H]+493.

[00626] 1H RMN (300 MHz, DMSO-d6) δ 9.70 (d, J = 7.4 Hz, 1H), 8.48 (d, J = 15.2 Hz, 2H), 7.78 (d, J = 7.8 Hz, 2H), 7.43 (s, 2H), 7.34 (s, 1H), 7,20 (s, 1H), 6,86 (d, J = 21,4 Hz, 3H), 5,25 (s, 2H), 4,06 (s, 3H), 3,68 (s, 3H).

[00627] (6-{7-[2-(1 -metil-1 H-imidazol-2-il)-etóxi]-imidazo[1,2-a]pirid in-3-il}-pirim idin4-il)-[4-(1 -metil-1 H-imidazol-4-il)-benzil]-amina (A111) Petition: 870260069920, on 07 / 14 / 2026, page. 154 / 519 148 / 219 de H1; solid branco; mp 215-216°C; HPLC / MS [M+H]+506.

[00628] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.8 Hz, 1H), 8.51 (s, 1H), 8.21 8.12 (m, 1H), 8.08 (s, 1H), 7.87 (t, J = 6.1 Hz, 1H), 7.81 (s, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 7.07 (dd, J = 12.6, 1.9 Hz, 2H), 6.89 (d, J = 1.3 Hz, 1H), 6.83 6.74 (m, 2H), 4.53 (s, 2H), 4.42 (t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.63 (s, 3H), 3.15 (t, J = 6.5 Hz, 2H).

[00629] [4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-{6-[7-(pindin-3-ilmetóxi)-imidazo[1,2a]piridin-3-il]-pirimidin-4-il}-amina (A112) de H2; solid branco; mp 280 - 281 °C; HPLC / MS [M+H]+490.

[00630] 1H RMN (300 MHz, DMSO-d6) δ 9.71 (d, J = 7.7 Hz, 1H), 8.71 (d, J = 2.2 Hz, 1H), 8.60 - 8.47 (m, 2H), 8.16 (s, 2H), 7.98 - 7.85 (m, 2H), 7.78 (d, J = 8.2 Hz, 2H), 7.52 7.36 (m, 3H), 7.22 (d, J = 2.6 Hz, 1H), 6.93 - 6.82 (m, 2H), 5.27 (s, 2H), 4.58 (s, 2H), 4.16 (s, 3H).

[00631] {6-[7-(1 -metil-1 H-imidazol-2-ilmetóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4il}-[4-(1 -metil-1 H-pirazol-4-il)-benzil]-amina (A113) de H1; solid branco; mp 271 - 272°C; HPLC / MS [M+H]+492.

[00632] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.23 ​​8.12 (m, 1H), 8.07 (s, 1H), 7.87 (t, J =6.1 Hz, 1H), 7.80 (s, 1H), 7.54-7.46 (m, 2H), 7.42 Petition: 870260069920, on 07 / 14 / 2026, page. 155 / 519 149 / 219 - 7.28 (m, 3H), 7.20 (s, 1H), 6.92 - 6.75 (m, 3H), 5.25 (s, 2H), 4.55 - 4.49 (m, 2H), 3.83 (s, 3H), 3.68 (s, 3H).

[00633] [4-(1 -metil-1 H-pirazol-4-il)-benzil]-(6-{7-[2-(2-oxa-6-aza-espiro[3,3]hept-6-il)etóxi]-imidazo[1,2-a]piridin-3-il}-pirimidin-4-il)-amina (A114) de H1; solid amarelo; mp 234-235°C; HPLC / MS [M+H]+523.

[00634] 1H NMR (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.19 8.10 (m, 1H), 8.07 (s, 1H), J =1, 7.86 ( (s, 1H), 7.54–7.45 (m, 2H), 7.36 – 7.25 (m, 2H), 7.03 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.76 (dd, 4, J = 187 (s, 4H), 4.55 − 4.45 (m, 2H), 4.00 (t, J = 5.3 Hz, 2H), 3.34 (s, 4H), 2.70 (t, J = 5.3 Hz, 2H).

[00635] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(1 -m eti l-pyrrol id in-3-yl)-ethoxy]imidazo[1,2-a]pyridin-3-yl}-pyrimidine-a)mine (A11-yl) of H1; solid white; mp 219 - 220°C; HPLC / MS [M+H]+509.

[00636] 1H RMN (400 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,52 (s, 1H), 8,25 8,05 (m, 2H), 7,88 (t, J = 6,2 Hz, 1H), 7,82 (s, 1H), 7,57 - 7,49 (m, 2H), 7,35 (d, J = 7,8 Hz, 2H), 7,07 (d, J = 2,6 Hz, 1H), 6,89 (s, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,62 - 4,45 (m, 2H), 4,08 (t, J = 6,6 Hz, 2H), 3,85 (s, 3H), 3,49 - 3,31 (m, 1H), 2,68 (t, J = 8,9, 7,3 Hz, 1H), 2,45-2,34 (m, 1H), 2,34 - 2,21 (m, 4H), 2,18 - 2,09 (m, 1H), 2,04 -1,91 (m, 1H), 1,91 -1,75(m, 2H), 1,44 (ddt, J = 12,3, 8,3, 6,1 Hz).

[00637] (6-{7-[2-(1 -metil-pirrolidin-3-il)-etóxi]-imidazo[1,2-a]piridin-3-il}-pirim idin-4-il)[4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A116) Petição 870260069920, de 14 / 07 / 2026, pág. 156 / 519 150 / 219 de H2; sólido branco; m.p. 220 - 221 °C; HPLC / MS [M+H]+510.

[00638] 1H RMN (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.15 (d, J = 7.5 Hz, 2H), 7.90 (t, J = 6.2 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.77 (dd, J = 7.7, 2.6 Hz, 1H), 4.58 (d, J = 6.0 Hz, 2H), 4,16 (s, 3H), 4.06 (t, J = 6.6 Hz, 2H), 2.64 (dd, J = 8.7, 7.3 Hz, 1H), 2.45 - 2.29 (m, 2H), 2.20 (s, 4H), 2.09 (dd, J = 8.8, 6.6 Hz, 1H), 2.01 -1.89 (m, 1H), 1.85 -1.73 (m, 2H), 1.46-1.34 (m, 1H).

[00639] {6-[7-((R)-4-metil-morfolin-2-ilmetóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4il}-[4-( 1 -metil-1 H-pirazol-4-il)-benzil]-amina (A117) de H1; solid branco; mp 221 - 222°C; HPLC / MS [M+H]+511.

[00640] 1H RMN (300 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,25 8,12 (m, 1H), 8,08 (s, 1H), 7,87 (t, J = 6,1 Hz, 1H), 7,81 (s, 1H), 7,56 - 7,47 (m, 2H), 7,38 - 7,29 (m, 2H), 7,09 (d, J = 2,6 Hz, 1H), 6,89 (s, 1H), 6,82 (dd, J = 7,7, 2,6 Hz, 1H), 4,64 - 4,49 (m, 2H), 4,09 (d, J = 5,0 Hz, 2H), 3,84 (s, 4H), 3,83 - 3,78 (m, 1H), 3,60 - 3,48 (m, 1H), 2,82 (d, J = 10,5 Hz, 1H), 2,64 (d, J = 11,1 Hz, 1H), 2,29-2,20 (m, 3H), 2,09-1,89 (m, 2H).

[00641] {6-[7-((S)-4-metil-morfolin-2-ilmetóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4il}-[4-( 1 -metil-1 H-pirazol-4-il)-benzil]-amina (A118) Petição 870260069920, de 14 / 07 / 2026, pág. 157 / 519 151 / 219 de H1; sólido branco; m.p. 224 - 225°C; HPLC / MS [M+H]+511.

[00642] 1H RMN (300 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,22 8,12 (m, 1H), 8,08 (s, 1H), 7,87 (t, J = 6,2 Hz, 1H), 7,81 (s, 1H), 7,56 - 7,47 (m, 2H), 7,38 - 7,29 (m, 2H), 7,09 (d, J = 2,6 Hz, 1H), 6,89 (d, J = 1,2 Hz, 1H), 6,82 (dd, J = 7,7, 2,6 Hz, 1H), 4,60 - 4,46 (m, 2H), 4,09 (d, J = 5,0 Hz, 2H), 3,84 (s, 4H), 3,82 - 3,78 (m, 1H), 3,62 3,49 (m, 1H), 2,81 (d, J = 11,2 Hz, 1H), 2,63 (d, J = 11,3 Hz, 1H), 2,29 - 2,17 (m, 3H), 2,06- 1,87 (m, 2H).

[00643] [4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-(6-{7-[2-(1-oxetan-3-il-pirrolidin-3-il)etóxi]-imidazo[1,2-a]piridin-3-il}-pirim idin-4-il)-am ina (A119) de H2; sólido branco; m.p. 224 -225°C; HPLC / MS [M+H]+552.

[00644] 1H RMN (300 MHz, DMSO-d6) δ 9,67 (d, J = 7,7 Hz, 1H), 8,50 (s, 1H), 8,15 (d, J = 7,5 Hz, 2H), 7,91 (t, J = 6,1 Hz, 1H), 7,82 - 7,71 (m, 2H), 7,42 (d, J = 7,8 Hz, 2H), 7,06 (d, J = 2,6 Hz, 1H), 6,89 (d, J = 1,2 Hz, 1H), 6,77 (dd, J = 7,7, 2,6 Hz, 1H), 4,53 (td, J = 6,5, 1,8 Hz, 4H), 4,42 (td, J = 6,0, 1,5 Hz, 2H), 4,16 (s, 3H), 4,07 (t, J = 6,5 Hz, 2H), 3,53 (t, J = 6,2 Hz, 1H), 2,70 (t, J = 7,9 Hz, 1H), 2,39 (q, J = 8,2 Hz, 1H), 2,25 (q, J = 7,8 Hz, 1H), 2,15-2,04 (m, 1H), 2,03- 1,08 (m, 1H), 1,81 (q, J = 6,7 Hz, 2H), 1,51 -1,36 (m, 1H).

[00645] {6-[7-(3-azetidin-1 -il-propóxi)-imidazo[1,2-a]piridin-3-i l]-pirim id in-4-i l}-[4-(2metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A120) de H2; sólido branco; UPLC / MS 0,372 min, [M+H]+496.

[00646] 1H RMN (500 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,52 (s, 1H), 8,17 (s, 1H), 8,15 (s, 1H), 7,89 (t, J = 6,2 Hz, 1H), 7,80 (d, J = 8,3 Hz, 2H), 7,45 (d, J = 7,8 Hz, Petition 870260069920, dated 07 / 14 / 2026, p. 158 / 519 152 / 219 2H), 7.05 (d, J = 2.6 Hz, 1 Η), 6.91 (d, J = 1.3 Hz, 1 Η), 6.79 (dd, J = 7.7, 2.6 Hz, 1H), 4.61 (d, J = 5.9 Hz (4, 2H8), J = 6.4 Hz, 2H), 3.10 (t, J = 6.9 Hz, 4H), 2.47 (t, J = 7.0 Hz, 2H), 1.95 (p, J = 6.9 Hz, 2H), 1.74 (p, J = 6.7 Hz, 2H).

[00647] {6-[7-((R)-4-methyl-morpholin-2-ylmethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4yl}-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-(Anzyl1]2-amine of H2; solid white; mp 225–226°C; HPLC / MS [M+H]+512.

[00648] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.50 (d, J = 1.1 Hz, 1H), 8.16 (s, 2H), 7.91 (t, J = 6.1 Hz, 1H), 7.82 - 7.73 (m, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 4,16 (s, 3H), 4.07 (d, J = 5.0 Hz, 2H), 3.85 - 3.75 (m, 2H), 3.53 (td, J = 11.2, 2.4 Hz, 1H), 2.77 (d, J = 11.2 Hz, 1H), 2.59 (d, J = 11.8 Hz, 1H), 2.18 (s, 3H), 2.04 -1.81 (m, 2H).

[00649] {6-[7-((S)-4-metil-morfolin-2-ilmetóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4il}-[4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A122) de H2; solid branco; mp 200-201°C; HPLC / MS [M+H]+512.

[00650] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 2H), 7.91 (t, J = 6.1 Hz, 73H), ( 72H), 7.42 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.81 (dd, J = 7.7, 2.6 Hz, 1H), s J 4,2 = 1.6 (d, d 3H), 4.07 (d, J = 5.0 Hz, 2H), 3.85 − 3.75 (m, 2H), 3.59 − 3.47 (m, 1H), 2.77 (d, J = 11.0 Hz, 1H), 2.19 (d, J = Hz = 1H), 2.19 (d, J = 1 3H), 1.99 (td, J = 11.4, 3.4 Hz, 1H), 1.88 (t, J = 10.6 Hz, 1H). [00651 ] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(1 -oxetan-3-i l-pyrrolide in-3-yl)-ethoxy] Petition 870260069920, dated 07 / 14 / 2026, p. 159 / 519 153 / 219 imidazo[1,2-a]pyridine-3-yl}-pyrimidine-4-yl)-amine (A123) of H1; solid white; mp 231 −232°C; HPLC / MS [M+H]+551.

[00652] 1H NMR (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.23 ​​8.13 (m, 1H), 8.09 (s, 12, 6), J =7.88 ( (s, 1H), 7.56–7.49 (m, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.6, 17.80 (dd, J = 4 (td, J = 6.4, 2.4 Hz, 4H), 4.45 (td, J = 5.9, 1.9 Hz, 2H), 4.10 (t, J = 6.6 Hz, 2H), 3.85 (s, 3H), 3.61 - 3.78H (m, 2H 1H), 2.57 - 2.52 (m, 1H), 2.41 (td, J = 8.6, 5.5 Hz, 1H), 2.34 - 2.21 (m, 1H), 2.12 (dd, J = 8.8, 7.0 Hz, 1, 1H 2), ( 1.84 (q, J = 6.9 Hz, 2H), 1.45 (ddt, J = 12.6, 8.3, 6.3 Hz, 1H).

[00653] N-{[[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-(7-{[(3R)-4-methylmorpholin-3-yl]methoxy}imidazo[1,2-a]pyridine-3-yl)pyrimidine-4-amine (A124) of H1; pó peeled; HPLC / MS(A) 1,034 min, [M+H]+511.

[00654] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H, 83), t 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.8 Hz, 2H), 4.22 (dd, J = 10.4, 4.2 Hz, 1H), 4.02 (dd, J = 10.4, 6.0 Hz, 1H), J = 11.0, 3.1 Hz, 1H), 3.56 3.48 (m, 1H), 3.38 (dd, J = 11.2, 9.3 Hz, 1H), 2.69 (dt, J = 11.8, 2.7 Hz, 1H), J = 11.8, 10.3, 3.3 Hz, 1H).

[00655] N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-(7-{[(3S)-4-methylmorpholin-3-yl]methoxy}imidazo[1,2-a]pyridin-3-yl)pyrimidine-4-amine (A125) Petition 870260069920, of 14 / 07 / 2026, p. 160 / 519 154 / 219 (from H1); bleached powder; HPLC / MS(A) 1.034 min, [M+H]+511.

[00656] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.13 (d, J = 2.6 Hz, 1H), 6.89 (Hdd, J = 6, 8, 1.1). 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.8 Hz, 2H), 4.22 (dd, J = 10.4, 4.2 Hz, 1H), 4.02 (dd, J = 10.4, 6.0 Hz, 1H), ( 3.89), ( 3.89 (dt, J = 11.0, 3.1 Hz, 1H), 3.56 3.48 (m, 1H), 3.38 (dd, J = 11.2, 9.3 Hz, 1H), 2.69 (dt, J = 11.8, 2.7 Hz, 13H), ( 2.25 (ddd, J = 11.8, 10.3, 3.3 Hz, 1H).

[00657] [4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-{6-[7-(2-pyridin-3-yl-ethoxy)imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-amine (A126) of H2; HPLC / MS [M+H]+504.

[00658] (6-{7-[2-(3-aza-bicyclo[3,1,0]hex-3-yl)-ethoxy]-imidazo[1,2-a]pyridine-3-yl}pyrimidine-4-yl)-[4-(1 -methyl-1 H-pyrazol-41-27)(A)-benzyl de H1; sólido branco; m.p. 219 - 220°C; HPLC / MS [M+H]+507.

[00659] 1H RMN (300 MHz, DMSO-d6) δ 9,69 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,22 8,12 (m, 1H), 8,08 (s, 1H), 7,87 (t, J = 6,1 Hz, 1H), 7,81 (s, 1H), 7,56 - 7,47 (m, 2H), 7,38 -7,29 (m,2H), 7,11 -7,05 (m, 1H), 6,89 (d, J = 1,3 Hz, 1H), 6,79 (dd, J = 7,7, 2,6 Hz, 1H), 4,58 - 4,49 (m, 2H), 4,21 - 4,07 (m, 2H), 3,84 (s, 3H), 3,01 (d, J = 8,6 Hz, 2H), 2,91 - 2,76 Petição 870260069920, de 14 / 07 / 2026, pág. 161 / 519 155 / 219 (m, 2H), 2,42 - 2,33 (m, 2H), 1,42 -1,31 (m, 2H), 0,58 (d, J = 3,9 Hz, 1H), 0,37 - 0,24 (m, 1H).

[00660] (6-{7-[2-(3-aza-biciclo[3,1,0]hex-3-il)-etóxi]-imidazo[1,2-a]piridin-3-il}pirimidin-4-il)-[4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A128) de H2; sólido branco; m.p. 220 - 221 °C; HPLC / MS [M+H]+508.

[00661] 1H RMN (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 2H), 7.94 - 7.75 (m, 3H), 7.43 (d, J = 8.0 Hz, 2H), 7.06 1.34 (s, 2H), 0.57 (s, 1H), 0.28 (s, 1H).

[00662] (6-{7-[2-(1 -metil-piperidin-4-il)-etóxi]-im idazo[1,2-a]piridin-3-il}-pirim idin-4-il)[4-(1-metil-1 H-pirazol-4-il)-benzil]-amina (A129) de H1; solid branco; mp 261 -262°C; HPLC / MS [M+H]+523.

[00663] (6-{7-[2-(1-metil-piperidin-4-il)-etóxi]-imidazo[1,2-a]piridin-3-il}-pirim idin-4-il)[4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A130) de H2; solid branco; mp 230 - 231 °C; HPLC / MS [M+H]+524.

[00664] 1H NMR (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.15 (d, J = 8.0 Hz, 2H), 7.91 (d, J = 6, =7.1), 8.0 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.89 (s, 1H), 6.77 (dd, J = 7.7, 2.6 Hz, 1H), 4.6 (d, J = 6). (s, 3H), 4.10 (t, J = 6.6 Hz, 2H), 2.71 (d, J = 11.1 Hz, 2H), 2.11 (s, 3H), 1.80 Petition 870260069920, dated 07 / 14 / 2026, p. 162 / 519 156 / 219 (t, J = 11.3 Hz, 2H), 1.72–1.61 (m, 4H), 1.40 (s, 1H), 1.22 (t, J = 12.3 Hz, 2H)

[00665] 3-(3-{6-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzylamino]-pyrimidine-4-yl}-imidazo[1,2a]pyridin-7-yloxy)-propan-1 -ol (A131)M_ / =H=N v / / H ' # N' solid yellow; mp 216 - 217°C; HPLC / MS [M+H]+456.

[00666] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.08 (s, 1H), 7.86, 81 (t, J = Hz 1H), 7.51 (d, J = 7.8 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.06 (d, J = 2.7 Hz, 1H), 6.89 (s, 1H), 6.79 (dd, J = 1,6 Hz, 2, = 2.5 5.2 Hz, 1H), 4.56 − 4.45 (m, 2H), 4.15 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 3.58 (q, J = 5.9 Hz, 2H), 1.91 (H, J = 6 = 6).

[00667] {6-[7-(3-dimethylamino-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pinm id in-4-yl}-[4-( 1 methyl-1 H-pyrazol-4-yl)-benzyl]-amine (A132 [ / v-nh I of H1; solid white; mp 232 - 233°C; HPLC / MS [M+H]+483.

[00668] 1H NMR (400 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.19 8.10 (m, 1H), 8.08 (s, 1H, 1), J = 7.86 ( (s, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H, 7), 6, J =79 ( 4.60 − 4.48 (m, 2H), 4.11 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 2.37 (t, J = 7.1 Hz, 2H), 2.15 (s, 6H), 1.89 (H, J = 6).

[00669] (6-{7-[2-(1 -methyl-pyrrolidin-3-yl)-ethoxy]-imidazo[1,2-a]pyridin-3-yl}-pyrim idin-4-yl)[4-(2-methyl-2H-[1,2,3]triazol-41-yl-3)-benzyl M — / ==N ΓΝ / ·——X / · V-NHfí VA n == / 'v / N C) J Petition 870260069920, dated 07 / 14 / 2026, p. 163 / 519 157 / 219 of H2; solid white; HPLC / MS [M+H]+526.

[00670] 3-(3-{6-[4-(2-methyl-2H-[1,2,3]triazol-4-yl)-benzylamino]-pinmidine-4-yl}imidazo[1,2-a]pyridin-7-yloxy)-propan-1 -ol (A134) of H2; solid white; mp 240 - 241 °C; HPLC / MS [M+H]+457.

[00671] 1H NMR (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.8 Hz, 1H), 8.53 − 8.47 (m, 1H), 8.16 (s, 2H), 7.90 (t, J7, 82H Hz), 7.90 (t, J7, 72H Hz 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.04 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.78 (dd, J = 7.7, 2.6 Hz, 1H), H = 4, 4.15 (d, J = 7.7 Hz, 5H), 3.56 (q, J = 5.9 Hz, 2H), 1.89 (p, J = 6.1 Hz, 2H).

[00672] {6-[7-(3-dimethylamino-propoxy)-imidazo[1,2-a]pyridine-3-yl]-pinmidine-4-yl}-[4-(2methyl-2H-[1,2,3]triazol-4-yl)-benzyl]-amine (A135) of H2; pale yellow solid; mp 250 - 251 °C; HPLC / MS [M+H]+484.

[00673] 1H RMN (300 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.15 (d, J = 7.2 Hz, 2H), 7.90 (t, J = 6.2 Hz, 1H), 7.82 - 7.73 (m, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.03 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.78 (dd, J = 7.7, 2.6 Hz, 1H), 4.58 (d, J = 6.1 Hz, 2H), 4,16 (s, 3H), 4.09 (t, J = 6.4 Hz, 2H), 2.35 (t, J = 7.2 Hz, 2H), 2.14 (s, 6H), 1.87 (p, J =6.6 Hz, 2H).

[00674] 6-{7-[2-(3,3-d if luoropiperid in-1-il)etóxi] im idazo[ 1,2-a]pirid in-3-il}-N-{[4-( 1-metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A136) Petition: 870260069920, on 07 / 14 / 2026, page. 164 / 519 158 / 219 de H1; Solido esbranquiçado; HPLC / MS(B) 0.695 min, [M+H]+545.

[00675] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.13 - 7.08 (m, 1H), 6.89 (d, 7, J, 8, =1.2), 2.6 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.21 (t, J = 5.6 Hz, 2H), 3.84 (s, 3H), 2.86 (t, J = 5.6 Hz), 2H), 2.79 (t, J = 5.7 Hz, 2H), 2.79 (t, J = Hz 5.4 Hz, 2H), 1.87 (tt, J = 13.9, 6.4 Hz, 2H), 1.71 −1.57 (m, 2H).

[00676] 6-{7-[3-(diethylamino)propoxy]imidazo[1,2-a]pyridine-3-yl}-N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine (A137) of H1; debranched solid; UPLC / MS 0.395 min, [M+H]+511.

[00677] 1H NMR (500 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.52 − 8.46 (m, 1H), 8.13 (s, 1H), t 2,07 (d, J7, = 0.8 (H6), δ Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.04 (d, J = 2.7 Hz, 1H), 1H, 3, J =89 ( (dd, J = 7.7, 2.6 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.12 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 2.53 (t, J = 7.0 Hz, J = 2H), 4.54 (q 1.85 (p, J = 6.6 Hz, 2H), 0.95 (t, J = 7.1 Hz, 6H).

[00678] 4-[2-({3-[6-({[4-(1 -methyl-1 H-pyrazol-4-yl)pheni l]methyl}am ino)pyrim id in-4-yl] and idazo[1,2-a]pyridin-7-yl}oxy)ethyl]-1 Iamlibdana)1-thiomorne of H1; debranched solid; UPLC / MS 0.467 min, [M+H]+559.

[00679] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.83 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.79 (dd, J = 7,7, 2,6 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.21 (t, J = 5.5 Hz, 2H), 3.84 (s, 3H), 3.16 - 3.02 (m, 8H), 2.97 (t, J = 5.5 Hz, 2H). Petition: 870260069920, on 07 / 14 / 2026, page. 165 / 519 159 / 219

[00680] 6-{7-[2-(3,3-d ifluoroazetid in-1 -il)etóxi]im idazo[1,2-a]piridin-3-il}-N-{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A139) de H1; Solido esbranquiçado; UPLC / MS 0.443 min, [M+H]+517.

[00681] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.89 (Hdd, J = 6, 8, 1.1). 7.7, 2.6 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.12 (t, J = 5.3 Hz, 2H), 3.84 (s, 3H), 3.69 (t, J = 12.4 Hz, 2H).

[00682] 6-{7-[2-(3-fluoroazetidin-1 -yl)ethoxy] and idazo[ 1,2-a]pyridin-3-yl}-N-{[4-( 1 -methyl1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-40)amine (A of H1; debranched solid; UPLC / MS 0.372 min, [M+H]+499.

[00683] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.07 (d, J = 0.8 Hz, 1H), 7.83 (t, J = 6.2 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.78 (dd, J = 7,7, 2,6 Hz, 1H), 5.15 (dddd, J = 57.9, 10.2, 5.6, 4.6 Hz, 1H), 4.69-4.45 (m, 2H), 4.07 (t, J = 5.3 Hz, 2H), 3.84 (s, 3H), 3.64 (dddd, J = 15.3, 7.6, 5.6, 2.0 Hz, 2H), 3.21 (dddd, J = 23.9, 7.5, 4.6, 2.1 Hz, 2H), 2.86 (t, J = 5.3 Hz, 2H).

[00684] 4-metil-1-[2-({3-[6-({[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}amino)pirim idin-4il]imidazo[1,2-a]piridin-7-il}óxi)etil]piperazin-2-ona (A141) Petition: 870260069920, on 07 / 14 / 2026, page. 166 / 519 160 / 219 de H1; Solido esbranquiçado; UPLC / MS 0.380 min, [M+H]+538.

[00685] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.7 Hz, 1H), 7.83 (t, J = 6.1 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.12 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.3 Hz, 1H), 6.79 (dd, J = 7,7, 2,6 Hz, (1H), 4.54 (d, J = 6.0 Hz, 2H), 4.24 (t, J = 5.7 Hz, 2H), 3.84 (s, 3H), 3.70 (t, J = 5.6 Hz, 2H), 3.44 (dd, J = 6.1,4.9 Hz, 2H), 2.94 (s, 2H), 2.68 - 2.54 (m, 2H), 2.20 (s, 3H).

[00686] 6-{7-[3-(3,3-difluoroazetidin-1-il)propóxi]imidazo[1,2-a]piridin-3-il}-N-{[4-(1 metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A142) de H1; Solido esbranquiçado; UPLC / MS 0.413 min, [M+2H] / 2266.

[00687] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.89 (Hdd, J = 1, 7 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.9 Hz, 2H), 4.11 (t, J = 6.3 Hz, 2H), 3.84 (s, 3H), 3.58 (t, J = 12.5 Hz, 4H), ( m 1, 2.62), ( 2.62 (p, J = 6.6 Hz, 2H).

[00688] {6-[7-(3-methanosulfonyl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pinm idin-4-yl}-[4(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-amine (A143) of H1; solid white; mp 300°C; HPLC / MS [M+H]+518.

[00689] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.10 (d, J = 23.3 Hz, 2H), 7.91 - 7.75 (m, 2H), 7.54 - 7.45 (m, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.88 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.52 (d, J = 5.8 Hz, 2H), 4,20 (t, J = 6,2 (Hz, 2H), 3.83 (s, 3H), 3.30 - 3.19 (m, 2H), 3.02 (s, 3H), Petition: 870260069920, on 07 / 14 / 2026, page. 167 / 519 161 / 219 2.26-2.10 (m, 2H).

[00690] N-{[4-(1 -metil-1 H-pirazol-4-il)feni l]meti l}-6-{7-[( 1 -metilazetidin-3-il)metóxi]imidazo[1,2-a]piridin-3-il}pirimidin-4-amina (A144) de H1; Solido esbranquiçado; UPLC / MS 0.365 min, [M+2H] / 2241.

[00691] 1H RMN (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.14 (s, 1H), 8.08 (s, 1H), 7.83 (t, J = 6.2 Hz, 1H), 7.81 (s, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.8 Hz, (2H), 4.21 (d, J = 6.9 Hz, 2H), 3.85 (s, 3H), 3.32 - 3.27 (m, 2H), 2.98 (dd, J = 7.0, 5.6 Hz, 2H), 2.79 (tt, J = 7.4, 5.8 Hz, 1H), 2.22 (s, 3H). (A145) de H1; Solido esbranquiçado; HPLC / MS(B) 0.734 min, [M+H]+518.

[00693] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.73 (t, 61,2), J = Hz 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.04 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, J = 1H (dd), 6 1H), 4.54 (d, J = 5.5 Hz, 2H), 4.08 (t, J = 6.2 Hz, 2H), 3.84 (s, 3H), 3.36 (dt, J = 9.2, 7.0 Hz, 4H), 2.241 (H-271), J = 1 = 8 (m, 4H).

[00694] {6-[7-(3-amino-3-methyl-butoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrim id in-4-yl}-[4-( 1 methyl-1 H-pyrazol-4-yl)-benzyl]-amine (A223) Petition 870260069920, dated 07 / 14 / 2026, p. 168 / 519 162 / 219 of H1; solid white; mp 252 - 253°C; HPLC / MS [M+H]+483.

[00695] 1H NMR (300 MHz, DMSO-d6) δ 9.67 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.82 (d, J = Hz 7.45 (m, 2H), 7.32 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.75 (dd, J = 7.7, 2, H6 (2.6), Hz 2H), 4.18 (t, J = 7.2 Hz, 2H), 3.83 (s, 3H), 1.80 (t, J = 7.2 Hz, 2H), 1.09 (s, 6H)

[00696] {6-[7-(2-methanosulfonyl-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidine-4-yl}-[4-(1 methyl-1 H-pyrazol-4-yl)-benzyl]-amine (A224) of H1; solid white; HPLC / MS [M+H]+504.

[00697] 1H NMR (300 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 1H), 8.07 (s, 1H), J, 807 (t, J = Hz 0.8 Hz, 1H), 7.54 – 7.45 (m, 2H), 7.32 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 2.6 Hz, 1H), 6.88 (d, J = 22 Hz, J, 17), dd , 6, 6, 1H), 4.49 (dt, J = 11.4, 5.6 Hz, 4H), 3.82 (s, 3H), 3.67 (t, J = 5.6 Hz, 2H), 3.08 (s, 3H).

[00698] {6-[7-(3-metanossulfonil-propóxi)-imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-[4(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A231) de H2; solid branco; mp 300°C; HPLC / MS [M+H]+519. Petition: 870260069920, on 07 / 14 / 2026, page. 169 / 519 163 / 219

[00699] 1H RMN (300 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.50 (s, 1H), 8.16 (s, 2H), 7.91 (t, J = 6.2 Hz, 1H), 7.77 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 2.6 Hz, 1H), 6.90 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.58 (s, 2H), 4.21 (d, J = 6.1 Hz, 2H), 4.16 (s, 3H), 3,26 (s, 2H), 3.02 (s, 3H), 2.18 (t, J = 7.9 Hz, 2H).

[00700] (6-{7-[2-(3-amino-oxetan-3-il)-etóxi]-imidazo[1,2-a]piridin-3-il}-pirimidin-4-il)[4-(2-metil-2H-[1,2,3]triazol-4-il)-benzil]-amina (A233) de H1; solid branco; mp 240 - 241 °C;HPLC / MS [M+H]+497.

[00701] 1H RMN (300 MHz, DMSO-d6) δ 9,73 - 9,63 (m, 1H), 8,49 (s, 1H), 8,10 (d, J = 19,3 Hz, 2H), 7,92-7,82 (m, 1H), 7,80 (s, 1H), 7,50 (d, J = 8,0 Hz, 2H), 7,32 (d, J = 7,9 Hz, 2H), 7,10 - 7,02 (m, 1H), 6,91 - 6,74 (m, 2H), 4,52 (s, 2H), 4,42 (d, J = 5,7 Hz, 1H), 4,31 (d, J = 5,8 Hz, 1H), 4,21 (t, J = 6,6 Hz, 1H), 3,98 (s, 1H), 3,82 (s, 4H), 3,55 (dd, J = 79,3, 8,5 Hz, 1H), 2,17 (t, J = 6,7 Hz, 2H), 2,00 -1,88 (m, 1H), 1,72 (dt, J = 11,7, 5,7 Hz, 1H)

[00702] 2-[2-(3-{6-[4-(1 -metil-1 H-pirazol-4-il)-benzilamino]-pirimidin-4-il}-imidazo[1,2a]piridin-7-ilóxi)-etóxi]-etanol (A234) de H1; sólido branco; m.p. 240 - 241 °C; HPLC / MS [M+H]+486.

[00703] 1H RMN (300 MHz, DMSO-d6) 9.68 (d, J = 7.7 Hz, 1H), 8.49 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.86 (t, J = 6.2 Hz, 1H), 7.80 (s, 1H), - 4,60 (m, 1H), 4.52 (s, 2H), 4.19 (dd, J = 5.9, 3.2 Hz, 2H), 3.82 (s, 3H), 3.77 Petition: 870260069920, on 07 / 14 / 2026, page. 170 / 519 164 / 219 (dd, J = 5.5, 3.4 Hz, 2H), 3.50 (dt, J = 8.1,3.9 Hz, 4H).

[00704] 2-(3-{6-[4-(2-metil-oxazol-4-il)-benzilamino]-pirimidin-4-il}-imidazo[1,2] a]piridin-7-ilóxi)-etanol (A236) de H4; solid branco; mp 266 - 267°C; HPLC / MS [M+H]+443.

[00705] 1H RMN (400 MHz, DMSO-d6) δ 9.71 (d, J = 7.6 Hz, 1H), 8.51 (s, 1H), 8.42 (s, 1H), 8.17-8.13 (m, 1H), 7.93-7.87 (m, 1H), 7.71 (d, J = - 4.52 (m, (2H), 4.10 (t, J = 4.7 Hz, 2H), 3.80 - 3.72 (m, 2H), 2.45 (s, 3H).

[00706] N-{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}-6-{7-[3-(piperidin-1 -il)propóxi]imidazo[1,2-a]piridin-3-il}pirimidin-4-amina (A237) de H1; solid branco; UPLC / MS 0.396 min, [M+H]+523.

[00707] 1H NMR (500 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.07 (d, J = 0.7 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 2.6 Hz, 1H), 6.88 (Hdd, J = 6, = 1.7 7.7, 2.6 Hz, 1H), 4.54 (d, J = 5.9 Hz, 2H), 4.11 (t, J = 6.4 Hz, 2H), 3.84 (s, 3H), 2.39 (t, J = 7.2 Hz, 2H), 2.9 ( m 1, 2.37 J = 6.7 Hz, 2H), 1.50 (p, J = 5.5 Hz, 4H), 1.42- 1.33 (m, 2H).

[00708] 2-{3-[6-(4-oxazol-4-yl-benzylamino)-pyrimidine-4-yl]-imidazo[1,2-a]pyridin-7yloxy-ethanol (A251) Petition 870260069920, dated 07 / 14 / 2026, p. 171 / 519 165 / 219 of H6; debranched solid; mp 244 −245°C; HPLC / MS [M+H]+429.

[00709] 1H RMN (300 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 8.43 (s, 1H), 8.14 (s, 1H), 7.91 (t, J = 6.1 Hz, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 2.6 Hz, 1H), 6.88 (s, 1H), 6.80 (dd, J = 7.8, 2.6 Hz, 1H), 4.94 (t, J = 5.4 Hz, 1H), 4,57 (s, 2H), 4.09 (t, J = 4.7 Hz, 2H), 3.80 - 3.71 (m, 2H).

[00710] (4-oxazol-4-il-benzil)-{6-[7-(3-pirrolidin-1-il-propóxi)-imidazo[1,2-a]piridin-3il]-pirimidin-4-il}-amina (A252) solid branco; HPLC / MS [M+H]+496. (A254) de H1) solido cristalino branco; HPLC / MS(B) 0.717 min, [M+H]+549.

[00712] 1H NMR (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 2H), 6.89 (Hdd, J = 6, 8, 1.1). 7.7, 2.6 Hz, 1H), 4.54 (d, J = 6.1 Hz, 2H), 4.23 (d, J = 6.8 Hz, 2H), 3.84 (s, 3H), 3.53 (t, J = 7.4 Hz), 2H), 3.17 ( 3.16 (hept, J = 6.9 Hz, 1H).

[00713] N-{[[4-(1 -methyl-1 H-pyrazol-4-yl)pheni l]meti l}-6-{7-[2-( 1 H-pyrazol-1 -yl)ethoxy] im idazo[1,2-a]pyridin-3-yl}pinmidin-45-amine (A2 Petition 870260069920, dated 07 / 14 / 2026, p. 172 / 519 166 / 219 of H1) white crystalline solid; HPLC / MS(B) 1,345 min, [M+H]+492.

[00714] 1H NMR (400 MHz, DMSO-d6) δ 9.68 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.15 (s, 1H), 8.08 (d, J = 0.8 Hz, J = 1, 7), 7.81 (dd, J = 3.0, 0.8 Hz, 2H), 7.51 (d, J = 8.2 Hz, 2H), 7.47 (dd, J = 1.9, 0.7 Hz, 1H), 7.34 (d, J = 7.8 Hz, J 2H (H = 2H), 7 6.89 (d, J = 1.3 Hz, 1H), 6.75 (dd, J = 7.8, 2.7 Hz, 1H), 6.25 (t, J = 2.1 Hz, 1H), 4.64 - 4.50 (m, 4H), 4.3.47 (t, J = 3H).

[00715] 6-{7-[(3-fluoro-1-methylazetidine-3-yl)methoxy]imidazo[1,2-a]pyridine-3-yl}-N-{[4-(1 methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine (A256) (from H1); pó peeled; UPLC / MS 0.379 min, [M+H]+499.

[00716] 1H NMR (500 MHz, DMSO-d6) δ 9.71 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.15 (s, 1H), 8.07 (d, J = 0.8 Hz, J = 1, 7), 7.80 (d, J = 0.8 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.17 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 1.2 Hz, 1H), 6.85 (dd, J = 7.7, 2.7 Hz, 1H), 4.54 (d, J = 6.0 Hz, 2H), 4.42 (d, J = 24.4 Hz, 2H), 3.84 (s, 3H), 3.58 − 3.51 (m, 2H), 3.17 (dd, J = 21.7, 9.5 Hz, 2H), 2.34 (s, 3H).

[00717] N-{[[4-(1 -methyl-1 H-pyrazol-4-yl)phene l]methi l}-6-{7-[3-( 1 H-pyrazol-1 -yl)propoxi]im idazo[1,2-a]pyridine-3-yl}pinmidin-45-amine (A of H1; pó peeled; UPLC / MS 0.511 min, [M+H]+506.

[00718] 1H NMR (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.07 (d, J = 0.8 Hz), J , = 1H (t 7.80 (d, J = 0.8 Hz, 1H), 7.74 (dd, J = 2.2, 0.7 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.44 (dd, J = 1.8, 0.7 Hz, J, 2 4H = 1H), 7, 7 7.02 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 6.23 (t, J = 2.0 Hz, 1H), J 4, 3 = 6.4 (d J = 6.9 Hz, 2H), 4.06 (t, J = 6.1 Hz, 2H), 3.84 (s, 3H), 2.26 (p, J = 6.5 Hz, 2H). Petition 870260069920, dated 07 / 14 / 2026, p. 173 / 519 167 / 219

[00719] N-{[4-( 1 -metil-1 H-pirazol-4-il)fenil]metil}-6-(7-{3-[(oxetan-3-il) amino]pro póxi}imidazo[1,2-a]piridin-3-il)pirimidin-4-amina (A258) de H1; solid branco; HPLC / MS [M+H]+511.

[00720] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.15 (s, 1H), 8.08 (d, J = 0.8 Hz, 1H), 7.86 (t, J = 6.2 Hz, 1H), 7.82 (d, J = 0.8 Hz, 1H), 7.55 - 7.49 (m, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 2.7 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.67 - 4.61 (m, 2H), 4.54 (s, 2H), 4.33 (t, J = 6.1 Hz, 2H), 4.14 (t, J = 6.4 Hz, 2H), 3.91 - 3.82 (m, 1H), 3.85 (s, 3H), 2.60 (t, J = 6.8 Hz, 2H), 1.85 (p, J = 6.6 Hz, 2H).

[00721] The price tag will refer to [4-(1-metil-1 H-pirazol-4il)-benzil]-(6-{7-[3-(oxetan-3-ilamino)-propóxi]-imidazo[1,2167iridinadin-3-il}-pinm idin4-il)-amina.

[00722] N-{[[4-(2-methyl-2H-1,2,3-triazol-4-yl)phenyl]methyl}-6-(7-{3-[(oxetan-3yl)amino]propoxy}imidazo[1,2-a]pyridin-3-yl)pyrimidine-459)amine (A2 of H2; solid white; HPLC / MS [M+H]+512.

[00723] 1H NMR (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 7.72, 81 (t, - Hz), J = (m, 2H), 7.44 (d, J = 7.5 Hz, 2H), 7.07 (d, J = 2.8 Hz, 1H), 6.91 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.4.63 (t, J = 2H), 4.33 (t, J = 6.2 Hz, 2H), 4.18 (s, 3H), 4.14 (t, J = 6.4 Hz, 2H), 3.86 (p, J = 6.7 Hz, 1H), 2.60 (t, J = 6.6 Hz, Jp = 6, 2H), 1H 2H).

[00724] N-{[[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}-6-[7-(3-{[(3R)-oxolan -3yl]amino}propoxy)imidazo[1,2-a]pyridin-3-yl]pyrimidine-460-amine (A Petition 870260069920, dated 07 / 14 / 2026, p. 174 / 519 168 / 219 of H1; solid white; HPLC / MS [M+H]+524.

[00725] 1H NMR (500 MHz, DMSO-d6) δ 9.72 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.16 (s, 1H), 8.09 (d, J = 0.8 Hz, J = 1, 7), 7.82 (d, J = 0.8 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.35 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 2.6 Hz, 1H), 6.91 (d, 7, J = 1, 8, = 1.2), 2.6 Hz, 1H), 4.54 (s, 2H), 4.21 (t, J = 6.2 Hz, 2H), 3.96 3.81 (m, 5H), 3.78 (dd, J = 9.6, 5.8 Hz, 1H), 3, 6, 1 = 8.2 (td), 3.07 (q, J = 8.6, 6.9 Hz, 2H), 2.21 (dtd, J = 13.9, 8.0, 6.0 Hz, 1H), 2.14 (q, J = 6.9 Hz, 2H), 2.05 1.96 (m, 1H).

[00726] The compound may also be referred to as [4-(1 -methyl-1 H-pyrazol-4-yl)benzyl]-[6-(7-{3-[(R)-(tetra-hydro-furan-3-yl)amino]-propoxy}-imidazo)yl-pyrime1,2168 idin-4-yl]-amine.

[00727] 4-methyl-1 -[2-({3-[6-({[[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}amino)pyrimidine4-yl]imidazo[1,2-a]pyridin-7-yl}oxy)etiI]-A2,51-onazepan-1,51-onazepan of H4; solid white; HPLC / MS [M+H]+553.

[00728] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.40 (s, 1H), 8.14 (s, 1H), 7.86 (t, J = 6.2 Hz, 1H), 7.70 (d, J = 7.9 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.89 (s, 1H), 6.79 (dd, J = 7.6, 2.6 Hz, 1H), 4.57 (d, J = 6.1 Hz, 2H), 4.20 (t, J = 5.6 Hz, (2H), 3.45 - 3.40 (m, 2H), 2.86 (d, J = 13.7 Hz, 5H), 2.71 - 2.61 (m, 4H), 2.56 - 2.50 (m, 2H), 2.44 (s, 3H).

[00729] 6-{7-[3-(4-f luoro-4-meti Ipiperidin-1 -il)propóxi]imidazo[1,2-a] piridin-3-il}-N{[4-(1 -metil-1 H-pirazol-4-il)fenil]metil}pirimidin-4-amina (A262) Petition: 870260069920, on 07 / 14 / 2026, page. 175 / 519 169 / 219 de H1; solid branco; HPLC / MS [M+H]+555.

[00730] 1H RMN (500 MHz, DMSO-de) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.08 (d, J = 0.8 Hz, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.34 (d, J = 7.7 Hz, 2H), 7.07 (s, 1H), 6.89 (d, J = 1.2 Hz, 1H), 6.79 (dd, J = 7.7, 2.6 Hz, 1H), 4,54 (s, 2H), 4.13 (s, 2H), 3.84 (s, 3H), 2.60 (s, 1H), 2.49 (s, 2H), 2.23 (s, 2H), 1.93 (s, 2H), 1.73 (s, 4H), 1.32 (d, J = 21.5 Hz, 3H). 00731 H-pirazol-4-il)-benzil]-amina.

[00732] 6-{7-[3-(4-f luoro-4-meti Ipiperidin-1 -il)propóxi]imidazo[1,2-a]pirid in-3-il}-N{[4-(1,3-oxazol-4-il)fenil]metil}pirimidin-4-amina (A263) de H6; solid branco; HPLC / MS [M+H]+543.

[00733] 1H NMR (500 MHz, DMSO-de) δ 9.69 (d, J = 7.7 Hz, 1H), 8.58 (d, J = 1.0 Hz, 1H), 8.51 (s, 1H), 8.41 (s, J= 1.5), H 7.89 (t, J = 6.2 Hz, 1H), 7.79 - 7.72 (m, 2H), 7.43 (d, J = 7.9 Hz, 2H), 7.06 (d, J = 2.6 Hz, 1H), 6.90 (d, 7, J = 1, 1.7 (H 2.7 Hz, 1H), 4.58 (s, 2H), 4.12 (t, J = 6.3 Hz, 2H), 3.28 (s, 3H), 2.63-2.57 (m, 1H), 2.46 (t, J = 7.1 Hz, = 2,2H), 2,6 1.92 (p, J = 6.6 Hz, 2H), 1.71 (dd, J = 13.5, 9.3 Hz, 2H), 1.69 − 1.57 (m, 1H), 1.30 (d, J = 21.5 Hz, 3H).

[00734] N-{[[4-(2-methyl-1,3-oxazol-4-yl)phenyl]methyl}-6-[7-(2-{4H,5H,6H, 7H[1,2,3]triazolo[1,5-a]pyrazine-5-yl}ethoxy inaina-imidine-pyridazo][1 (A264) Petition 870260069920, dated 07 / 14 / 2026, p. 176 / 519 170 / 219 of H4; solid white; HPLC / MS [M+H]+543.

[00735] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.41 (s, 1H), 8.15 (s, 1H), 7.88 (t, J = 6.1 Hz, 1H), 7.74 - 7.67 (m, 2H), 7.53 (s, 1H), 7.40 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 2.6 Hz, 1H), 6.90 (d, J = 1.3 Hz, 1H), 6.82 (dd, J = 7.7, 2.6 Hz, 1H), 4.59 - 4,54 (m, 1H), 4.37 (t, J = 5.6 Hz, 2H), 4.30 (t, J = 5.5 Hz, 2H), 3.88 (s, 2H), 3.09 (t, J = 5.6 Hz, 2H), 3.03 (t, J = 5.4 Hz, 2H), 2.45 (s, 3H).

[00736] 6-[7-(2-{4H,5H,6H,7H-[1,2,3]triazolo[1,5-a]pirazin-5-il}etóxi)imidazo[1,2a]piridin-3-il]-N-{[4-(trifluorometóxi)fenil]methyl}pirimidin-4-amina (A265) de H7; solid branco; HPLC / MS [M+H]+552.

[00737] 1H NMR (500 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 - 8.51 (m, 1H), 8.19-8.14 (m, 1H), 7.91 (t, J = 6.2 Hz, 1H), 7.54-7.53 (m, 1H), 7.50 - 7.46 (m, 2H), 7.35 - 7.31 (m, 2H), 7.15 - 7.13 (m, 1H), 6.90 (d, J = 1.2 Hz, 1H), 6.82 (dd, J = 7.7, 2.6 Hz, 1H), 4.62 - 4.57 (m, 2H), 4.39 - 4.35 (m, 2H), 4.30 (t, J = 5.5 Hz, 2H), 3.89 - 3.88 (m, 2H), 3.11 - 3.08 (m, 2H), 3.03 (t, J = 5.5 Hz, 2H). Example 4 Synthesis of 6-{imidazo[1 ^-alpyridin-S-ill-N-í / e-ÍORÍ-S-methoxipyrrolidin-l-illpyridin-SilImethylÍpyrimidin^-amine (A146) Petition 870260069920, 14 / 07 / 2026, pág. 177 / 519 171 / 219 solid stripped; mp 161 - 163°C; HPLC / MS [M+H]+402.

[00738] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,1 Hz, 1H), 8,56 (s, 1H), 8,29 (s, 1H), 8,11 (s, 1H), 7,82 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 8,9, 1,2 Hz, 1H), 7,56 - 7,48 (m, 1H), 7,41 (ddd, J = 9,2, 6,7, 1,3 Hz, 1H), 7,10 (td, J = 6,9, 1,3 Hz, 1H), 6,94 (s, 1H), 6,43 (d, J = 8,6 Hz, 1H), 4,40 (s, 2H), 4,08 - 4,01 (m, 1H), 3,44 (d, J = 3,7 Hz, 3H), 3,33 - 3,29 (m, 1H), 3,24 (s, 3H), 2,03 (td, J = 8,1,4,4 Hz, 2H).

[00739] Os seguintes compostos são preparados analogamente:

[00740] (6-imidazo[1,2-a]piridin-3-i l-pirim id in-4-i l)-(6-pirrol id in-1 -il-piridin-3ilmetil)-amina (A147) sólido amarelo; m.p. 176 - 177°C; HPLC / MS [M+H]+372.

[00741] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (d, J = 7.2 Hz, 1H), 8.56 (s, 1H), 8.31 (s, 1H), 8.10 (s, 1H), 7.80 (t, J = 6.0 Hz, 1H), 7.71 (dt, J). = 9.1, 1.2 Hz, 1H), 7.51 (dd, J = 8.7, 2.4 Hz, 1H), 7.41 (m, J = 9.0, 6.7, 1.3 Hz, 1H), 7.10 (td, J = 6.9, 1.3 Hz, 1H), 6.94 (s, 1H), 6.42 (d, J = 8.7 Hz, 1H), 4.40 (s, 2H), 3.35–3.32 (m, 4H), 1.94–1.90 (m, 4H). Petition 870260069920, 7 / 14 / 2026, p. 178 / 5 172 / 2

[00742] N-({6-[(3S)-3-fluoropyrrolidin-1 -yl]pyridin-3-yl}methyl)-6-{im idazo[1,2-a]pyridin-3-yl}pyrimidin-4-amine (A148); solid branched; mp 190 - 192°C; HPLC / MS [M+H]+390.

[00743] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,1 Hz, 1H), 8,57 (s, 1H), 8,30 (s, 1H), 8,13 (s, 1H), 7,84 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 9,0, 1,2 Hz, 1H), 7,59 - 7,52 (m, 1H), 7,42 (ddd, J = 9,0, 6,8, 1,3 Hz, 1H), 7,10 (td, J = 6,9, 1,3 Hz, 1H), 6,95 (s, 1H), 6,49 (dd, J = 8,6, 0,8 Hz, 1H), 5,43 (d, J = 53,6 Hz, 1H), 4,42 (s, 2H), 3,74 3,48 (m, 3H), 3,44 - 3,37 (m, 1H), 2,28 - 2,07 (m, 2H).

[00744] [6-(3-aza-biciclo[3,1,0]hex-3-il)-piridin-3-ilmetil]-(6-imidazo [1,2-a]piridin3-il-pirimidin-4-il)-amina (A149) sólido branco; m.p. 185 - 187°C; HPLC / MS [M+H]+384.

[00745] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 6,9 Hz, 1H), 8,56 (s, 1H), 8,09 (s, 1H), 7,82 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 9,0, 1,2 Hz, 1H), 7,50 (d, J = 8,6 Hz, 1H), 7,41 (ddd, J = 9,1, 6,8, 1,4 Hz, 1H), 7,10 (td, J = 6,9, 1,3 Hz, 1H), 6,93 (s, 1H), 6,42 (d, J = 8,6 Hz, 1H), 4,39 (s, 2H), 3,60 (d, J = 10,1 Hz, 2H), 3,29 (dt, J = 10,1, 1,9 Hz, 2H), 1,69-1,61 (m, 2H), 0,70 (td, J = 7,8, 4,4 Hz, 1H), 0,15 (q, J = 4,1 Hz, 1H).

[00746] [6-(3,3-d ifluoro-pirrol id in-1 -il)-piridin-3-i Imeti l]-(6-im idazo[1,2-a]pirid in-3-ilpirimidin-4-il)-amina (A150) sólido branco; m.p. 192 - 194°C; HPLC / MS [M+H]+408. Petição 870260069920, de 14 / 07 / 2026, pág. 179 / 519 173 / 219

[00747] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,0 Hz, 1H), 8,56 (s, 1H), 8,30 (s, 1H), 8,16 (s, 1H), 7,86 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 9,0, 1,2 Hz, 1H), 7,60 (d, J = 8,5 Hz, 1H), 7,42 (ddd, J = 9,0, 6,8, 1,3 Hz, 1H), 7,10 (td, J = 6,9, 1,3 Hz, 1H), 6,95 (s, 1H), 6,54 (dd, J = 8,6, 0,8 Hz, 1H), 4,44 (s, 2H), 3,80 (t, J = 13,4 Hz, 2H), 3,58 (t, J = 7,3 Hz, 2H), 2,58 - 2,52 (m, 1H), 2,47 (d, J = 7,3 Hz, 1H).

[00748] 6-{imidazo[1,2-a]piridi n-3-i l}-N-({6-[(3S)-3-metoxipirrolid in-1 -il]piridin-3il}metil)pirimidin-4-amina (A151) sólido branco; m.p. 159-161 °C; HPLC / MS [M+H]+402.

[00749] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,0 Hz, 1H), 8,56 (s, 1H), 8,28 (s, 1H), 8,11 (s, 1H), 7,83 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 9,0, 1,2 Hz, 1H), 7,56 - 7,48 (m, 1H), 7,41 (ddd, J = 9,0, 6,8, 1,3 Hz, 1H), 7,09 (td, J = 6,9, 1,3 Hz, 1H), 6,94 (s, 1H), 6,47 - 6,38 (m, 1H), 4,40 (s, 2H), 4,04 (p, J = 3,6 Hz, 1H), 3,47 - 3,38 (m, 3H), 3,36 (s, 3H), 3,31 (td, J = 9,9, 9,4, 7,6 Hz, 1H), 2,02 (td, J = 8,6, 8,2, 4,5 Hz, 2H).

[00750] (4-f luoro-6-pirrol idi n-1 -i l-piridin-3-i Imeti l)-(6-i m idazo[ 1,2-a]pirid in-3-i Ipirimidin-4-il)-amina (A152) sólido esbranquiçado; m.p. 239 - 241 °C; HPLC / MS [M+H]+390.

[00751] 1H NMR (400 MHz, DMSO-d6) δ 9.85 (d, J = 7.1 Hz, 1H), 8.58 (s, 1H), 8.28 (s, 1H), 8.13 (d, J = 11.3 Hz, 1H), 7.77 (s, 1H), 7.71 (dt J = 9.0, 1.2 Hz, 1H), 7.42 (ddd, J = 9.0, 6.8, 1.3 Hz, 1H), 7.10 (td, J = 6.9, 1.3 Hz, 1H), 6.96 (s, 1H), 6.27 (d, J = 13.1 Hz, 1H), 4.45 (d, J = 5.6 Hz, 2H), 3.35 (d, J = 2.7 Hz, 4H), 1.98 - 1.88 (m, 4H).

[00752] N-({6-[(3R)-3-fluoropyrrolidin-1 -yl]pyridin-3-yl}methyl)-6-{im idazo[1,2-a]pyridin3-yl}pyrimidin-4-amine (A153); Petition 870260069920, 7 / 14 / 2026, p. 180 / 5 174 / 2 solid white; mp 188 - 190°C; HPLC / MS [M+H]+390.

[00753] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,0 Hz, 1H), 8,56 (s, 1H), 8,29 (s, 1H), 8,13 (s, 1H), 7,84 (t, J = 6,0 Hz, 1H), 7,71 (dt, J = 9,0, 1,2 Hz, 1H), 7,62 - 7,51 (m, 1H), 7,41 (ddd, J = 9,0, 6,7, 1,3 Hz, 1H), 7,10 (td, J = 6,9, 1,3 Hz, 1H), 6,94 (s, 1H), 6,48 (d, J = 8,5 Hz, 1H), 5,52 - 5,31 (m, 1H), 4,42 (s, 2H), 3,75 - 3,46 (m, 3H), 3,39 (dd, J = 10,4, 6,9 Hz, 1H), 2,28 - 2,05 (m, 2H). Exemplo 5 Síntese de (6-imidazo[1,2-alpiridin-3-il-pirimidin-4-il)-(4-metil-6-pirrolidin-1-il-piridin-3ilmetiD-amina (A154)

[00754] Sólido esbranquiçado; m.p. 195 - 197°C.

[00755] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,0 Hz, 1H), 8,58 (s, 1H), 7,98 (s, 1H), 7,71 (dd, J = 9,0, 1,2 Hz, 1H), 7,63 (t, J = 5,4 Hz, 1H), 7,46-7,37 (m, 1H), Petição 870260069920, de 14 / 07 / 2026, pág. 181 / 519 175 / 219 7.10 (td, J = 6.9, 1.3 Hz, 1H), 6.94 (s, 1H), 6.29 (s, 1H), 4.41 (s, 2H), 3.38-3.35 (m, 4H), 2.27 (s, 3H), 1.97-1.87 (m, 4H).

[00756] Our components are similar to analogues:

[00757] [6-((S)-3-fluoro-pirrolidin-1-il)-4-methyl-piridin-3-ilmetil]-(6-imidazo[1,2a]piridin-3-il-pirimidin-4-il)-amina (A155) solid branco; mp 187 - 190°C; HPLC / MS [M+H]+404.

[00758] 1H RMN (400 MHz, DMSO-d6) δ 9.85 (d, J = 6.9 Hz, 1H), 8.58 (s, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.01 (s, 1H), 7.75-7.67 (m, 1H), 7.65 (t, J = 5.5 Hz, 1H), 7,467.37 (m, 1H), 7.15-7.06 (m, 1H), 6.95 (s, 1H), 6.37 (s, 1H), 5.42 (d, J = 53.8 Hz, 1H), 4.49-4.38 (m, 2H), 3.75-3.47 (m, 4H), 2.29 (s, 3H), 2.24- 2.04 (m, 2H).

[00759] [6-((R)-3-fluoro-pirrolidin-1-il)-4-methyl-piridin-3-ilmetil]-(6-imidazo[1,2a]piridin-3-il-pirimidin-4-il)-amina (A156)

[00760] solid branco; mp 184 - 197°C; HPLC / MS [M+H]+404.

[00761] 1H RMN (400 MHz, DMSO-d6) δ 9,85 (d, J = 7,0 Hz, 1H), 8,58 (s, 1H), 8,35-8,13 (m, 1H), 8,01 (s, 1H), 7,71 (dd, J = 9,0, 1,2 Hz, 1H), 7,65 (t, J = 5,5 Hz, 1H), 7,45-7,38 (m, 1H), 7,15-7,06 (m, 1H), 6,95 (s, 1H), 6,37 (s, 1H), 5,52-5,32 (m, 1H), 4,44 (s, 2H), 3,75-3,40 (m, 4H), 2,29 (s, 3H), 2,25-2,06 (m, 2H). Exemplo 6 Síntese de (6-imidazo[1,2-alpiridin-3-il-pirimidin-4-il)-[4-(1 H-imidazol-2-il)-benzillamina (A157) Petição 870260069920, de 14 / 07 / 2026, pág. 182 / 519 176 / 219

[00762] Sólido branco; m.p. 300°C; HPLC / MS[M+H]+368.

[00763] 1H RMN (400 MHz, DMSO-d6) δ 12,44 (s, 1H), 9,85 (d, J = 7,0 Hz, 1H), 8,57 (s, 1H), 8,30 (s, 1H), 7,97 (t, J = 6,1 Hz, 1H), 7,92-7,86 (m, 2H), 7,71 (m, 1H), 7,46-7,37 (m, 3H), 7,21 (s, 1H), 7,09 (m, 1H), 6,99 (d, J = 1,6 Hz, 2H), 4,61 (s, 2H). Exemplo 7 Synthesis of 7-methoxy-3-{6-[4-(1-methyl-1 H-pyrazol-4-yl)-benzyloxyl-pyrimidin-4-yl}-imidazoyl^-alpyridine (A158) K,CO3 Pd(PPh3)4 YOUR dioxane / H2O 100“ c

[00764] White solid; mp 216 - 218° C; HPLC / MS [M+H]+413.

[00765] 1H NMR (400 MHz, DMSO-d6) δ 9.77 (d, J = 8 Hz, 1H), 8.85 (d, J = 1.1 Hz, 1H), 8.50 (s, 1H), 8.15 (s, 1H), 7.8 (d, 0.8 Hz), 7.63 - 7.55 (m, 2H), 7.51 - 7.43 (m, 3H), 7.15 (d, J = 2.4 Hz, 1H), 6.88 (dd, J = 7.7, 2.7 Hz, 1H), 5.44 (s, 2.9-m), 3.8 (m, 6H). Petition 870260069920, of 14 / 07 / 2026, p. 183 / 519 177 / 219 Example 8

[00766] Synthesis of N-[(4-{1-[(azetidin-3-yl)methyl]-1 H-pyrazol-4yl}phenyl)methyl]-6-{7-methoxyimidazo[1,2-a]pyridin-3-yl}pyrimidine-4-amine (A159)

[00767] Yellow resin; HPLC / MS(B) 1.017 min, [M+H]+467. Example 9 Synthesis of 3-[6-({[4-(1-methyl-1 H-pyrazol-4-yl)phenyl1methyl}amino)pyrimidine-4-yl1imidazoM ,2-alpyridin-7-ol (A160) Petition 870260069920, of 14 / 07 / 2026, p. 184 / 519 178 / 219 of A72; pale brown powder; UPLC / MS0,450 min, [M+H]+398.

[00768] 1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, 1H), 9.68 (d, J = 7.6 Hz, 1H), 8.50 (s, 1H), 8.25 - 8.02 (m, 3H), 7.8 t (J, 1Hz, 6.3), 7.82 (s, 1H), 7.52 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 7.9 Hz, 2H), 6.86 (d, J = 1.3 Hz, 1H), 1H), 4.53 (s, 2H), 3.84 (s, 3H). Example 10 Synthesis of [4-(4-{[6-(7-methoxy-imidazo[1,2-alpyridin-3-yl)-pyrimidin-4-ylamino1-methyl}-phenyl)-2-methyl-2H-pyrazol-3-yl]-methanol (Ά161) Petition 870260069920, of 14 / 07 / 2026, p. 185 / 519 179 / 219

[00769] Bleached solid; mp 263 - 264°C; HPLC / MS[M+H]+442.

[00770] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.17 (s, 1H), 7.92 (t, J = 6.1 Hz, 1H), 7.56 (s, 1H), 7.49 - 7.33 (m, 5H), 7.09 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.82 (dd, J = 7.9, 2.6 Hz, 1H), 5.36 (t, J = 5.2 Hz, 1H), 4.57 (s, 2H), 4.52 (d, J = 5.2 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 3H). Example 11 Síntese of 6-{7-aminoimidazo[1,2-a]piridin-3-il}-N-{[4-(1-metil-1 H-pirazol-4-il)fenil1metil}pirimidin-4-amina (A162) de A81; pó marrom palido; UPLC / MS0,446 min, [M+H]+397.

[00771] 1H RMN (400 MHz, DMSO-d6) δ 9.49 (d, J = 7.5 Hz, 1H), 8.45 (s, 1H), 8.09 (s, 1H), 7.96 (s, 1H), 7.82 (s, 1H), 7.74 (t, J = 6.1 Hz, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 6.78 (d, J = 1.2 Hz, 1H), 6.52 (dd, J = 7.6, 2.3 Hz, 1H), 6.46 (d, J = 2.2 Hz, 1H), 5.94 (s, 2H), 4,55 - 4.48 (m, 2H), 3.84 (s, 3H). Example 12 Synthesis of 2-methyl-2-(3-{6-[4-(1 -methyl-1 H-pyrazol-4-yl)-benzylamino1-pyrimidin-4-yl}-imidazo[1l2-alpyridin-7-ylamino)-propan-1-ol (A163) Petition 870260069920, of 14 / 07 / 2026, p. 186 / 519 180 / 219

[00772] White solid; mp 228 - 229° C; HPLC / MS [M+H]+469.

[00773] 1H NMR (300 MHz, DMSO-d6) δ 9.42 (d, J = 7.7 Hz, 1H), 8.45 (s, 1H), 8.09 (s, 1H), 7.96 (s, 1H), 7.81 (s, 1H), 7.74 (t, J = 6.0 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), (dd, J = 7.8, 2.2 Hz, 1H), 6.51 (d, J = 2.3 Hz, 1H), 5.94 (s, 1H), 4.91 (t, J = 5.7 Hz, 1H), 5.7 Hz, 2H), 1.29 (s, 6H). Example 13 Synthesis of N-{[4-(1-methyl-1 H-pyrazol-4-yl)phenylmethyl}-6-[7-(piperidin-4-yloxy)imidazo[1,2alpyridin-3-illpyrimidin-4-amine (A164)

[00774] A suspension of 6-[(E)-2-ethoxythenyl]-N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}pyrimidin-4-amine (G1) (168 mg, 0.50 mmol) in a mixture of 1,4-dioxane (1.5 mL) and water (0.5 mL) is cooled to 0°C and N-bromosuccinimide (98 mg, 0.55 mmol) is added and the reaction mixture is stirred for 20 minutes at 0°C. tert-Butyl 4-[(2-aminopyridin-4-yl)oxy]pipendin-1-carboxylate (E23) (147 mg, 0.50 mmol) is added. The reaction solution is heated to 60°C and stirred at this temperature for 5 hours. The reaction mixture is allowed to reach temperature and poured into a 1 N aqueous NaOH solution (13 mL). The resulting precipitate is filtered, washed with water, dried, and chromatographed on a silica gel column with dichloromethane / methanol as eluent to give tert-butyl 4-({3-[6-({[4-(1-methyl-1H-pyrazol-4yl)phenyl]methyl}amino)pyrimidin-4-yl]imidazo[1,2-α]pyridin-7-yl}oxy)pipendin-1-carboxylate Petition 870260069920, dated 07 / 14 / 2026, page 187 / 519 181 / 219 como sólido bege pálido; HPLC / MS(A) 1,50 min, [M+H]+581.

[00775] 1H RMN (500 MHz, DMSO-d6) δ 9,70 (d, J = 7,7 Hz, 1H), 8,51 (s, 1H), 8,14 (s, 1H), 8,07 (d, J = 0,8 Hz, 1H), 7,83 (t, J = 6,2 Hz, 1H), 7,80 (d, J = 0,8 Hz, 1H), 7,51 (d, J = 8,2 Hz, 2H), 7,34 (d, J = 7,8 Hz, 2H), 7,19 (d, J = 2,6 Hz, 1H), 6,88 (d, J = 1,2 Hz, 1H), 6,80 (dd, J = 7,7, 2,6 Hz, 1H), 4,75 (tt, J = 8,0, 3,7 Hz, 1H), 4,54 (d, J = 6,0 Hz, 2H), 3,84 (s, 3H), 3,69 (dt, J = 13,1, 4,8 Hz, 2H), 3,25 - 3,18 (m, 2H), 2,04 1,92 (m, 2H), 1,57 (dtd, J = 12,9, 8,8, 3,7 Hz, 2H), 1,41 (s, 9H).

[00776] A suspension of tert-butyl 4-({3-[6-({[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}amino)pyrimidin-4-yl]imidazo[1,2-a]pyridin-7-yl}oxy)piperidine-1-carboxylate in a 4 N hydrochloric acid solution in dioxane is stirred at room temperature for 1.5 hours. The reaction mixture is evaporated under reduced pressure and the residue is triturated with tert-butyl methyl ether to give N-{[4-(1-methyl-1H-pyrazol-4-yl)phenyl]methyl}-6-[7-(piperidin-4-yloxy)imidazo[1,2-a]pyridin-3-yl]pinm-idin-4-amine hydrochloride as a beige solid; HPLC / MS(A) 1.06 min, [M+H]+481.

[00777] 1H NMR (500 MHz, DMSO-d6) δ 9.83 (s, 1H), 9.02 (s, 2H), 8.70 (s, 1H), 8.61 (s, 1H), 8.28 (s, 1H), 8.08 (d, J = 0.8 Hz, 1H), 7.81 (d, J = 0.9 Hz, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 2.6 Hz, 1H), 7.34 (d, J = 7.8 Hz, 2H), 7.27 (dd, J = 7.7, 2.5 Hz, 1H), 7.05 (s, 1H), 5.03 (p, J = 3.8 Hz, 1H), 4.58 (s, 2H), 3.85 (s, 3H), 3.40 - 3.22 (m, 2H), 3.21 - 3.09 (m, 2H), 2.32 - 2.08 (m, 2H), 2.04 - 1.85 (m, 2H).

[00778] Used similar options:

[00779] [4-(1 -metil-1 H-pirazol-4-il)-benzil]-{6-[7-(piperidin-4-ilmetóxi)imidazo[1,2-a]piridin-3-il]-pinmidin-4-il}-amina (A165) solid amarelo; mp 224 - 225°C; HPLC / MS [M+H]+496.

[00780] 1H RMN (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.19 (s, 1H), 8.16 (s, 1H), 7.94 (t, J = 6.2 Hz, 1H), 7.80 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.60 (s, 2H), 4.18 (s, 3H), 3,93 (d, J = 6.4 Hz, 2H), 2.99 (d, J = 11.9 Hz, 2H), Petition: 870260069920, on 07 / 14 / 2026, page. 188 / 519 182 / 219 2.01 -1.82 (m, 1H), 1.72 (d, J = 11.9 Hz, 2H), 1.32 -1.11 (m, 2H). [00781 ] [4-(1 -metil-1 H-pirazol-4-il)-benzi l]-{6-[7-(piperid in-4-i Imetóxi)imidazo[1,2-a]piridin-3-il]-pirimidin-4-il}-amina (A166) (of G1 and E16); solid white; mp 211 −212°C; HPLC / MS [M+H]+495.

[00782] 1H NMR (400 MHz, DMSO-d6) δ 9.70 (d, J = 7.7 Hz, 1H), 8.52 (s, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 7.72, 81, H, J = Hz 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.07 (d, J = 2.6 Hz, 1H), 6.89 (d, J = 1.2 Hz, 1H), 1H, 6.80 (dd, 7 4.54 (s, 2H), 3.93 (d, J = 6.3 Hz, 2H), 3.85 (s, 3H), 3.00 (d, J = 11.9 Hz, 2H), 1.95- 1.83 (m, 1H), 1.73 (d, 1.7 J = 1, (m, 2H).

[00783] 6-{7-[(azetidine-3-yl)methoxy]imidazo[1,2-a]pyridine-3-yl}-N-{[4-(1 -methyl-1 H-pyrazol-4-yl)phenyl]methyl}pyrimidine-4-amine (A167) (from G1 and E29); pó peeled; UPLC / MS 0.358 min, [M+H]+467.

[00784] 1H RMN (500 MHz, DMSO-d6) δ 9.69 (d, J = 7.7 Hz, 1H), 8.51 (s, 1H), 8.14 (s, 1H), 8.07 (s, 1H), 7.86 (t, J = 6.1 Hz, 1H), 7.80 (s, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.09 (d, J = 2.6 Hz, 1H), 6.90 (s, 1H), 6.80 (dd, J = 7.7, 2.6 Hz, 1H), 4.54 (d, J = 6.1 Hz, 2H), 4.32 - 4.12 (m, 2H), 3.84 (s, 3H), 3.69 (t, J = 7.7 Hz, 1H), 3.64 - 3.51 (m, 1H), 3.46 - 3.30 (m, 2H), 3.09 - 2.92 (m, 1H), 2.75 - 2.66 (m, 1H). Example 14 Síntese de [4-(1-metil-1 H-pirazol-4-il)-benzil1-{6-[7-(2-pirrolidin-1-il-etil)-imidazo[1,2alpiridin-3-ill-pirimidin-4-il}-amina (A168) Petition: 870260069920, on 07 / 14 / 2026, page. 189 / 519 183 / 219

[00785] Solido branco; mp 214 - 215°C; HPLC / MS [M+H]+479.

[00786] 1H RMN (400 MHz, CD3OD) δ 9.77 (d, J = 7.2 Hz, 1H), 8.56 (d, J = 1.2 Hz, 1H), 8.15 (s, 1H), 7.95 (s, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.59 - 7.49 (m, 3H), 7.43 - 7.36 (m, 2H), 7.03 (dd, J = 7.2, 1.7 Hz, 1H), 6.91 (s, 1H), 4.66 - 4.57 (m, 2H), 3.93 (s, 3H), 3.03 - 2.96 (m, 2H), 2.92 - 2.85 (m, 2H), 2.76 - 2.66 (m, 4H), 1.94- 1.80 (m, 4H).

[00787] Used similar options: (A169) solid amarelo; mp 205-206°C; HPLC / MS [M+H]+515.

[00789] 1H RMN (400 MHz, DMSO-d6) δ 9.73 (d, J = 7.2 Hz, 1H), 8.55 (s, 1H), Petition: 870260069920, on 07 / 14 / 2026, page. 190 / 519 184 / 219 8.24 (s, 1H), 8.09 (s, 1H), 7.91 (t, J = 6.2 Hz, 1H), 7.82 (d, J = 0.8 Hz, 1H), 7.57 (s, 1H), 7.53 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 7.9 Hz, 2H), 7.03 (dd, J = 7.2, 1.8 Hz, 1H), 6.94 (d, J = 1.2 Hz, 1H), 4.56 (s, 2H), 3.85 (s, 3H), 2.96 (t, J = 13.5 Hz, 2H), 2.85 (t, J = 7.0 Hz, 2H), 2.431, (m 2, 2H), 2.431 − 14.9, 6.9 Hz, 2H).

[00790] [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-(6-{7-[2-(4-oxetan-3-yl-piperazine-1 -yl)ethyl]-imidazo[1,2-a]pyridin-3-yl}-pyrimidine-4-yl)-amine solid white; mp 220 - 221 °C; HPLC / MS [M+H]+550.

[00791] 1H NMR (400 MHz, DMSO-d6) δ 9.72 (d, J = 7.2 Hz, 1H), 8.55 (s, 1H), 8.24 (s, 1H), 8.09 (s, 1H), 7.72, 81 (t, J = Hz 1H), 7.63 − 7.46 (m, 3H), 7.35 (d, J = 7.9 Hz, 2H), 7.02 (dd, J = 7.3, 1.7 Hz, 1H), 6.94 (d, J = 1.2 Hz, 1H), 4,47 (m J = 6.1 Hz, 2H), 3.85 (s, 3H), 2.84 (t, J = 7.4 Hz, 2H), 2.62 (t, J = 7.4 Hz, 2H), 2.26 (bs, 4H). Example 15 Synthesis of 7-methoxy-3-(6-{1-[4-(1-methyl-1 H-pyrazol-4-yl)-phenyl]-ethoxy}-pyrimidin-4-yl)-imidazoyl^-alpyridine (A171)

[00792] White solid; mp 195 - 196°C; HPLC / MS [M+H]+427. Petition 870260069920, of 14 / 07 / 2026, p. 191 / 519 185 / 219

[00793] 1H NMR (300 MHz, DMSO-d6) δ 9.73 (d, J = 7.7 Hz, 1H), 8.77 (d, J = 1.1 Hz, 1H), 8.49 ...

Claims

1. A medicament, characterized in that it comprises a compound of Formula I, wherein R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh or O[C(R3)2]nCyc, R2 denotes H or CH3, R3 denotes H or A, V denotes H or Hal, X denotes O or N(R3), Y denotes phenylene, pyridin-di-yl, thiophendiyl, 1,3-thiazoldiyl or pyrazoldiyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and / or A, Z denotes CON(R3)2, phenyl, Het4 or -OA, Het1 denotes a saturated or unsaturated, monocyclic aromatic heterocycle of 4 to 7 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =O, and wherein one N atom may be oxidized, or denotes a saturated or unsaturated, bicyclic or spirocyclic aromatic heterocycle,6 to 10 members containing 1 to 4 atoms of N, O and / or S, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, Petition 870260069920, dated 14 / 07 / 2026, p. 227 / 519 2 / 7 [C(R3)2]nN(R3)2,[C(R3)2]nSO2R3, Het2, oxetanyl, = NR3 and / or = O, and wherein one N atom may be oxidized, Het2 denotes an aromatic or unsaturated, monocyclic heterocycle of 5 to 6 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal, or denotes an unsaturated or bicyclic aromatic heterocycle of 7 to 10 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal, Het3 denotes a saturated, monocyclic heterocycle of 4 to 7 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono- or disubstituted where A, Hal, OR3 and / or =0, Het4 denotes a saturated or unsaturated heterocycle.aromatic monocyclic compound of 4 to 7 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3,-N(R3)2 and / or =0, or denotes a saturated or unsaturated heterocycle, aromatic bicyclic compound of 6 to 10 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3 and / or =0, A denotes branched or unbranched alkyl with 1 to 10 C atoms, with 1 to 3 non-adjacent CH- and / or CH2- atoms which may be substituted by O or NH atoms and with 1 to 7 H atoms which may be substituted by R5, or denoting (CH2)nCyc, Cyc denotes cyclic alkyl having 3 to 7 C atoms, R5 denotes F, Cl, CN or OH, Ph denotes phenyl, which may be unsubstituted or mono-, di- or trisubstituted by A, OR3 and / or Hal Petition 870260069920, of 14 / 07 / 2026, p. 228 / 519 3 / 7 Hal denotes F, Cl, Br or I, m denotes 0, 1 or 2, n denotes 0, 1, 2, 3 or 4, and / or salt,a pharmaceutically acceptable tautomer and / or stereoisomer thereof; wherein the medicinal product is in the form of a unit dosage form comprising 0.5 mg to 1 g, or wherein the medicinal product is suitable for oral administration.

2. A medicament according to claim 1, characterized in that the unit dosage form comprises from 1 mg to 700 mg of a compound of Formula I or of a pharmaceutically acceptable salt, tautomer and / or stereoisomer thereof.

3. A medicament according to claim 1, characterized in that the unit dosage form comprises from 5 mg to 100 mg of a compound of Formula I or a pharmacologically acceptable salt, tautomer and / or stereoisomer thereof.

4. A medicament according to any one of claims 1 to 3, characterized in that the unit dosage form comprises a daily dose or a fraction of a dose of a compound of Formula I or of a pharmacologically acceptable salt, tautomer and / or stereoisomer thereof.

5. A medicament according to claim 1, characterized in that it is adapted for oral administration and is presented in the form of a tablet or capsule.

6. A medicament, according to any one of claims 1 to 5, characterized in that the compound of Formula I is [4-(1-methyl-1H-pyrazol-4-yl)benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine of the following formula: Petition 870260069920, dated 14 / 07 / 2026, page 229 / 519 4 / 7 or a pharmacologically acceptable salt, tautomer and / or stereoisomer thereof.

7. Process for the preparation of the compound [4-(1 -methyl-1 H-pirazol-4-yl)benzyl]-{6-[7-(3-pirrolidin-1-yl-propoxy)-imidazo[1,2-a]piridin-3-yl]-pirimidin-4-yl}-amine, characterized by the fact that 6-[(E)-2-etoxietilenil]-N-{[4-(1 -methyl-1 H-pirazol-4-yl)phenyl]methyl}pirimidin-4-amine (G1) reacted with 4-[3-(pirrolidin-1-yl)propoxy]piridin-2amine (E15).

8. Salt, characterized by the fact that it is a pharmaceutically acceptable salt of [4-(1 -methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1 -yl-propoxy)-imidazo[1,2a]pyridin-3-yl]-pyrimidine-4-pyridine-following formulation: of the group consisting of: maleate of [4-(1 -methyl-1 H-pi razol-4-yl)-benzy l]-{6-[7-(3-pyrrol id in-1 -ylpropoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine; hydrochloride of [4-(1 -methyl-1 H-pi razol-4-yl)-benzy l]-{6-[7-(3-pyrrol id in-1 -ylpropoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine; and phosphate of [4-(1 -methyl-1 H-pi razol-4-yl)-benzy l]-{6-[7-(3-pyrrol id in-1 -ylpropoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine.

9. Salt according to claim 8, characterized in that the pharmacologically acceptable salt of [4-(1-methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine is [4-(1methyl-1 H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]pyrimidin-4-yl}-amine.

10. Salt according to claim 8, characterized in that the pharmacologically acceptable salt of [4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine is the hydrochloride of [4(1-methyl-1H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}-amine. Petition 870260069920, dated 14 / 07 / 2026, page 230 / 519 5 / 7 11. Sal, de acordo com a reivindicação 8, caracterizado pelo fato de que o sal farmacologicamente aceitável de [4-(1 -metil-1 H-pirazol-4-il)-benzil]-{6-[7-(3-pirrolidin-1 -il-propoxi)-imidazo[1,2-a]piridin-3 -il]-pirimidin-4-il}-amina é o fosfato de [4-(1metil-1 H-pirazol-4-il)-benzil]-{6-[7-(3-pirrolidin-1 -il-propoxi)-imidazo[1,2-a]piridin-3-il]pirimidin-4-il}-amina.

12. Compound, characterized by the fact that it has Formula I, in which R1 denotes H, Hal, CF3, NO2, A, [C(R3)2]nN(R3)2, [C(R3)2]nHet1, OR3, O[C(R3)2]nN(R3)2, O[C(R3)2]nS(O)mR3, O[C(R3)2]nCOOR3, O[C(R3)2]nCOON(R3)2, O[C(R3)2]nHet1, O[C(R3)2]nN(R3)Het1, O[C(R3)2]nPh or O[C(R3)2]nCyc, R2 denotes H or CH3, R3 denotes H or A, V denotes H or Hal, X denotes O or N(R3), Y denotes phenylene, pyridin-di-yl, thiophen-di-yl, 1,3-thiazol-di-yl or pyrazoldi-yl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal and / or A, Z denotes CON(R3)2, phenyl, Het4 or -OA, Het1 denotes a saturated or unsaturated, monocyclic aromatic heterocycle of 4 to 7 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, =NR3 and / or =0, and wherein one N atom may be oxidized, or Petition 870260069920, of 14 / 07 / 2026, page. 231 / 519 6 / 7 denotes a saturated or unsaturated heterocycle.aromatic bicyclic or spirocyclic, 6 to 10 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR3, [C(R3)2]nN(R3)2, [C(R3)2]nSO2R3, Het2, oxetanyl, = NR3 and / or =0, and wherein one N atom may be oxidized, Het2 denotes an aromatic or unsaturated heterocycle, monocyclic of 5 to 6 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal, or denotes an unsaturated or bicyclic aromatic heterocycle of 7 to 10 members having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono- or disubstituted by A and / or Hal, Het3 denotes a saturated, monocyclic heterocycle of 4 to 7 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono- or disubstituted by A, Hal, OR3 and / or =0, Het4 denotes a saturated or unsaturated, monocyclic aromatic heterocycle of 4 to 7 members having 1 to 4 N and / or O atoms,which may be unsubstituted or mono-, di-, or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3,-N(R3)2 and / or =0, or denotes a saturated or unsaturated, bicyclic aromatic heterocycle of 6 to 10 members having 1 to 4 N and / or O atoms, which may be unsubstituted or mono-, di-, or trisubstituted by A, Hal, OR3, [C(R3)2]nHet3 and / or =0, A denotes branched or unbranched alkyl with 1 to 10 C atoms, wherein 1 to 3 non-adjacent CH- and / or CH2- groups may be substituted by O or NH atoms and wherein 1 to 7 H atoms may be substituted by R5, or denotes (CH2)nCyc, Cyc denotes cyclic alkyl having 3 to 7 C atoms, R5 denotes F, Cl, CN or OH, Petition 870260069920, dated 07 / 14 / 2026, p. 232 / 519 7 / 7 Ph denotes phenyl, which may be unsubstituted or mono-, di- or trisubstituted by A, OR3 and / or Hal Hal denotes F, Cl, Br or I, m denotes O, I or 2, n denotes O, I, 2, 3 or 4, and / or salt,tautomer and / or pharmaceutically acceptable stereoisomer thereof; wherein the compound is a labeled isotope form of the compound of Formula I, 13. Compound according to claim 12, characterized in that the compound of Formula I is a labeled form with an isotope of [4-(1-methyl-1H-pyrazol-4-yl)-benzyl]-{6-[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl}amine or a pharmacologically acceptable salt, tautomer and / or stereoisomer thereof.